image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
3331b77de82e9386451c6e11ee8c194f30734b2eb2244eae28ecf4b4365ab86f.png | simple | <table><tr><td>Self-report risk assessment</td><td><i>Positive ADHD screen % (n)</i></td><td><i>Negative ADHD screen % (n)</i></td><td><i>Χ</i><sup><i>2 </i></sup><i>(df = 1)</i></td><td><i>Odds ratio (95% confidence interval)</i></td></tr><tr><td>Any illness or injury, or any other medical condition?</td><td>51.3 (20)</td><td>31.7 (45)</td><td>5.10*</td><td>2.27 (1.10 to 4.66)</td></tr><tr><td>Taking, supposed to be taking, or need any tablets/medication?</td><td>19.5 (8)</td><td>15.6 (22)</td><td>0.35</td><td>1.31 (0.54 to 3.21)</td></tr><tr><td>Consumed alcohol in the last 24 hours?</td><td>28.2 (11)</td><td>26.8 (38)</td><td>0.03</td><td>1.08 (0.49 to 2.37)</td></tr><tr><td>Dependent on drugs or any other substances?</td><td>25.6 (10)</td><td>9.2 (13)</td><td>7.50**</td><td>3.42 (1.37 to 8.57)</td></tr><tr><td>Ever tried to harm yourself?</td><td>23.1 (9)</td><td>7.7 (11)</td><td>7.32**</td><td>3.57 (1.36 to 9.39)</td></tr><tr><td>Experiencing any mental health problems or depression?</td><td>23.1 (9)</td><td>6.4 (9)</td><td>9.35**</td><td>4.37 (1.60 to 11.94)</td></tr><tr><td>Require any help with reading/writing?</td><td>10.3 (4)</td><td>2.8 (4)</td><td>3.96</td><td>3.91 (0.93 to 16.44)</td></tr><tr><td>Custody officer risk assessment</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Detainee appears to be injured or unwell?</td><td>20.5 (8)</td><td>11.3 (16)</td><td>2.22</td><td>2.02 (0.79 to 5.14)</td></tr><tr><td>Detainee is in need of a Doctor or other Health Care Professional?</td><td>20.0 (6)</td><td>11.3 (13)</td><td>1.58</td><td>1.96 (0.68 to 5.69)</td></tr><tr><td>Appears to have taken/be under the influence of alcohol/drugs/any other substance?</td><td>23.1 (9)</td><td>12.8 (18)</td><td>2.55</td><td>2.05 (0.84 to 5.01)</td></tr><tr><td>Detainee has indications of self harm?</td><td>17.9 (7)</td><td>5.7 (8)</td><td>6.03*</td><td>3.64 (1.23 to 10.77)</td></tr></table> |
74d129fa13b2b1f2da94f258bd7f1fd32d342722dd231f40b2087a1951912731.png | simple | <table><tr><td>Cancer site</td><td>Mediastinal-both</td><td>Mediastinal-both & Supra-both</td><td>Mediastinal-both & Supra-left</td><td>Mediastinal-left</td></tr><tr><td>Breast</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>3DCRT</td><td>0.86</td><td>0.84</td><td>0.85</td><td>0.91</td></tr><tr><td>VMAT</td><td>2.05</td><td>1.82</td><td>1.89</td><td>1.93</td></tr><tr><td>Lung</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>3DCRT</td><td>0.76</td><td>0.80</td><td>0.78</td><td>0.74</td></tr><tr><td>VMAT</td><td>1.29</td><td>1.11</td><td>1.17</td><td>1.55</td></tr><tr><td>Esophagus</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>3DCRT</td><td>0.94</td><td>0.98</td><td>1.06</td><td>0.90</td></tr><tr><td>VMAT</td><td>1.01</td><td>1.12</td><td>1.15</td><td>1.00</td></tr><tr><td>Stomach</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>3DCRT</td><td>0.92</td><td>0.91</td><td>0.92</td><td>0.93</td></tr><tr><td>VMAT</td><td>0.93</td><td>0.93</td><td>0.93</td><td>0.92</td></tr><tr><td>Thyroid</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>3DCRT</td><td>0.89</td><td>0.61</td><td>0.62</td><td>0.93</td></tr><tr><td>VMAT</td><td>0.88</td><td>0.67</td><td>0.79</td><td>0.93</td></tr><tr><td>Bone sarcoma</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>3DCRT</td><td>0.88</td><td>0.87</td><td>0.82</td><td>0.88</td></tr><tr><td>VMAT</td><td>0.62</td><td>0.58</td><td>0.60</td><td>0.63</td></tr><tr><td>Soft tissue sarcoma</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>3DCRT</td><td>0.89</td><td>0.83</td><td>0.83</td><td>0.90</td></tr><tr><td>VMAT</td><td>0.75</td><td>0.65</td><td>0.69</td><td>0.78</td></tr><tr><td>All cancers</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>3DCRT</td><td>0.82</td><td>0.82</td><td>0.82</td><td>0.86</td></tr><tr><td>VMAT</td><td>1.59</td><td>1.36</td><td>1.43</td><td>1.63</td></tr></table> |
2f26f70ff60ca7c1741c74b047462fafdbbc3915a96a679766981298af295554.png | simple | <table><tr><td>Images</td><td>Positive</td><td>Negative</td></tr><tr><td>200</td><td>195</td><td>5</td></tr></table> |
53bf858d1709a541365c2bd3e61108ba7c36d00b6e3ff2f192f04a557eddbbe1.png | simple | <table><tr><td>Trait</td><td>Region</td><td>SNP</td><td>Closest gene</td><td>P value</td><td>Alleles ancestral>derived</td></tr><tr><td>Hair shape</td><td>1q21</td><td>rs11803731</td><td><i><underline>TCHH</underline></i></td><td>3 × 10<sup>−12</sup></td><td>A>T</td></tr><tr><td>Hair shape</td><td>2q12</td><td>rs3827760</td><td><i><underline>EDAR</underline></i></td><td>3 × 10<sup>−119</sup></td><td>A>G</td></tr><tr><td>Hair shape</td><td>10p14</td><td>rs17143387</td><td><i>GATA3</i></td><td>4 × 10<sup>−8</sup></td><td>T>G</td></tr><tr><td>Hair shape</td><td>16p11</td><td>rs11150606</td><td><i><underline>PRSS53</underline></i></td><td>7 × 10<sup>−9</sup></td><td>T>C</td></tr><tr><td>Beard thickness</td><td>2q12</td><td>rs365060</td><td><i>EDAR</i></td><td>1 × 10<sup>−15</sup></td><td>G>C</td></tr><tr><td>Beard thickness</td><td>4q12</td><td>rs4864809</td><td><i>LNX1</i></td><td>1 × 10<sup>−8</sup></td><td>A>G</td></tr><tr><td>Beard thickness</td><td>6q21</td><td>rs6901317</td><td><i>PREP</i></td><td>4 × 10<sup>−8</sup></td><td>G>T</td></tr><tr><td>Beard thickness</td><td>7q31</td><td>rs117717824</td><td><i>FOXP2</i></td><td>1 × 10<sup>−8</sup></td><td>G>T</td></tr><tr><td>Eyebrow thickness</td><td>3q22</td><td>rs112458845</td><td><i>FOXL2</i></td><td>4 × 10<sup>−10</sup></td><td>G>A</td></tr><tr><td>Monobrow</td><td>2q36</td><td>rs2218065</td><td><i>PAX3</i></td><td>5 × 10<sup>−8</sup></td><td>A>G</td></tr><tr><td>Hair greying</td><td>6p25</td><td>rs12203592</td><td><i>IRF4</i></td><td>3 × 10<sup>−13</sup></td><td>C>T</td></tr><tr><td>Hair colour</td><td>5p13</td><td>rs183671</td><td><i>SLC45A2</i></td><td>2 × 10<sup>−59</sup></td><td>T>G</td></tr><tr><td>Hair colour</td><td>6p25</td><td>rs12203592</td><td><i>IRF4</i></td><td>1 × 10<sup>−13</sup></td><td>C>T</td></tr><tr><td>Hair colour</td><td>11q14</td><td>rs598952</td><td><i>TYR</i></td><td>2 × 10<sup>−8</sup></td><td>T>A</td></tr><tr><td>Hair colour</td><td>15q13</td><td>rs12913832</td><td><i>HERC2/OCA2</i></td><td>5 × 10<sup>−104</sup></td><td>A>G</td></tr><tr><td>Hair colour</td><td>15q21</td><td>rs1426654</td><td><i>SLC24A5</i></td><td>1 × 10<sup>−18</sup></td><td>G>A</td></tr><tr><td>Balding</td><td>10q22</td><td>rs2814331</td><td><i>GRID1</i></td><td>4 × 10<sup>−9</sup></td><td>C>T</td></tr><tr><td>Balding</td><td>Xq12</td><td>rs4258142</td><td><i>AR/EDA2R</i></td><td>2 × 10<sup>−8</sup></td><td>C>T</td></tr></table> |
ce0ab89c258ca9879bf5d4eb42e3f90077465dcdbc90eb4a78c859569be3ac02.png | simple | <table><tr><td>Flexion angle and side</td><td>Involved</td><td>95% Confidence intervals</td><td>Uninvolved</td><td>95% Confidence intervals</td><td><i>P</i> value</td></tr><tr><td>Torque at 30 degrees</td><td>1.09</td><td>0.87–1.31</td><td>1.17</td><td>0.98–1.36</td><td><i>P</i> = 0.45</td></tr><tr><td>Torque at 60 degrees</td><td>1.75</td><td>1.4–2.1</td><td>2.09</td><td>1.77–2.41</td><td><i>P</i> = 0.08</td></tr></table> |
c37f3cf3fb3e72d0af6817132993ea81c08fa45ca2286e5c075b4c4fb9e2e845.png | simple | <table><tr><td>Intra-nuclear body</td><td>GO Term</td><td>Description</td><td>E-Value</td></tr><tr><td>Nucleolus</td><td>GO:0042254</td><td>Ribosome biogenesis and assembly</td><td>1.80E-19</td></tr><tr><td></td><td>GO:0022613</td><td>Ribonucleoprotein complex biogenesis and assembly</td><td>3.30E-15</td></tr><tr><td></td><td>GO:0016072</td><td>rRNA metabolic process</td><td>3.30E-14</td></tr><tr><td></td><td>GO:0006364</td><td>rRNA processing</td><td>3.30E-14</td></tr><tr><td></td><td>GO:0009059</td><td>Macromolecule biosynthetic process</td><td>2.90E-08</td></tr><tr><td></td><td>GO:0043228</td><td>Non-membrane-bound organelle</td><td>3.30E-08</td></tr><tr><td></td><td>GO:0043232</td><td>Intracellular non-membrane-bound organelle</td><td>3.30E-08</td></tr><tr><td></td><td>GO:0006412</td><td>Translation</td><td>5.70E-08</td></tr><tr><td></td><td>GO:0009058</td><td>Biosynthetic process</td><td>1.20E-06</td></tr><tr><td>PML nuclear body</td><td>GO:0006950</td><td>Response to stress</td><td>6.10E-09</td></tr><tr><td></td><td>GO:0006974</td><td>Response to DNA damage stimulus</td><td>1.70E-08</td></tr><tr><td></td><td>GO:0009719</td><td>Response to endogenous stimulus</td><td>2.30E-08</td></tr><tr><td></td><td>GO:0050896</td><td>Response to stimulus</td><td>4.00E-07</td></tr><tr><td></td><td>GO:0006281</td><td>DNA repair</td><td>4.40E-05</td></tr><tr><td></td><td>GO:0042770</td><td>DNA damage response, signal transduction</td><td>5.90E-05</td></tr><tr><td></td><td>GO:0007049</td><td>Cell cycle</td><td>1.40E-03</td></tr><tr><td></td><td>GO:0006464</td><td>Protein modification process</td><td>1.60E-03</td></tr><tr><td></td><td>GO:0022402</td><td>Cell cycle process</td><td>2.70E-03</td></tr><tr><td>Nuclear Speckle</td><td>GO:0016071</td><td>mRNA metabolic process</td><td>1.20E-61</td></tr><tr><td></td><td>GO:0006397</td><td>mRNA processing</td><td>4.80E-61</td></tr><tr><td></td><td>GO:0008380</td><td>RNA splicing</td><td>1.20E-58</td></tr><tr><td></td><td>GO:0005681</td><td>Spliceosome</td><td>1.90E-38</td></tr><tr><td></td><td>GO:0006396</td><td>RNA processing</td><td>5.80E-34</td></tr><tr><td></td><td>GO:0030529</td><td>Ribonucleoprotein complex</td><td>1.90E-26</td></tr><tr><td></td><td>GO:0003723</td><td>RNA binding</td><td>2.00E-25</td></tr><tr><td></td><td>GO:0016070</td><td>RNA metabolic process</td><td>1.70E-06</td></tr><tr><td></td><td>GO:0000377</td><td>RNA splicing, via transesterification reactions with bulged adenosine as nucleophile</td><td>4.10E-06</td></tr><tr><td></td><td>GO:0000398</td><td>Nuclear mRNA splicing, via spliceosome</td><td>4.10E-06</td></tr></table> |
54e83ee4a69ede988352e5b75a49fcb372cde88199335831a3268e32a6b60406.png | complex | <table><tr><td>Condition or therapy</td><td>No. (%)</td><td>BRS (ms/mmHg)</td><td><i>p</i> value for interaction</td></tr><tr><td colspan="4">Hypertension</td></tr><tr><td> Yes</td><td>68 (72)</td><td>8.5 ± 4.4</td><td rowspan="2">0.056</td></tr><tr><td> No</td><td>26 (28)</td><td>10.4 ± 4.6</td></tr><tr><td colspan="4">Hyperlipidemia</td></tr><tr><td> Yes</td><td>83 (88)</td><td>8.8 ± 4.4</td><td rowspan="2">0.424</td></tr><tr><td> No</td><td>11 (12)</td><td>10.0 ± 5.8</td></tr><tr><td colspan="4">Smoking</td></tr><tr><td> Yes</td><td>30 (32)</td><td>9.9 ± 4.5</td><td rowspan="2">0.177</td></tr><tr><td> No</td><td>64 (68)</td><td>8.5 ± 4.5</td></tr><tr><td colspan="4">Sulfonylurea use</td></tr><tr><td> Yes</td><td>25 (27)</td><td>7.1 ± 3.2</td><td rowspan="2">0.015</td></tr><tr><td> No</td><td>69 (73)</td><td>9.7 ± 4.8</td></tr><tr><td colspan="4">Insulin use</td></tr><tr><td> Yes</td><td>12 (13)</td><td>9.7 ± 5.6</td><td rowspan="2">0.556</td></tr><tr><td> No</td><td>82 (87)</td><td>8.9 ± 4.4</td></tr><tr><td colspan="4">RAAS inhibitor use</td></tr><tr><td> Yes</td><td>34 (36)</td><td>8.6 ± 4.8</td><td rowspan="2">0.284</td></tr><tr><td> No</td><td>60 (64)</td><td>9.2 ± 4.4</td></tr><tr><td colspan="4">Calcium-channel blocker use</td></tr><tr><td> Yes</td><td>32 (34)</td><td>8.5 ± 4.8</td><td rowspan="2">0.258</td></tr><tr><td> No</td><td>62 (66)</td><td>9.2 ± 4.4</td></tr><tr><td colspan="4">Beta-blocker use</td></tr><tr><td> Yes</td><td>5 (5)</td><td>8.4 ± 3.7</td><td rowspan="2">0.788</td></tr><tr><td> No</td><td>89 (95)</td><td>9.0 ± 4.6</td></tr><tr><td colspan="4">Statin use</td></tr><tr><td> Yes</td><td>28 (30)</td><td>9.0 ± 5.0</td><td rowspan="2">0.138</td></tr><tr><td> No</td><td>66 (70)</td><td>9.0 ± 4.4</td></tr></table> |
a0797c6d5a5003694e665466b9b5aa1277dc8b8de8300178e2d9348aedb910c2.png | simple | <table><tr><td>Model</td><td>Buc</td><td>Ind</td><td>Poo</td><td>Dis</td><td>Rec</td><td>Sub</td><td>All</td><td>STR (%)</td><td>Int</td><td>Cod</td><td>Tra</td><td>Sup</td><td>Com</td><td>Upd</td><td>USE (%)</td><td>Group</td></tr><tr><td>TCM</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1</td><td>16.7</td><td>B</td></tr><tr><td>CARBINE</td><td>1</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>28.6</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>B</td></tr><tr><td>Dewar</td><td>1</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>28.6</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>B</td></tr><tr><td>FORPRO1</td><td>0</td><td>1</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td><td>28.6</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>B</td></tr><tr><td>HARVCAR</td><td>0</td><td>1</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>28.6</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>B</td></tr><tr><td>CBMFPS1</td><td>0</td><td>1</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>28.6</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>B</td></tr><tr><td>Karjala</td><td>0</td><td>1</td><td>1</td><td>1</td><td>1</td><td>0</td><td>0</td><td>57.1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>C</td></tr><tr><td>FORCAR1</td><td>0</td><td>0</td><td>0</td><td>1</td><td>1</td><td>0</td><td>0</td><td>28.6</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>B</td></tr><tr><td>GORCAM</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>1</td><td>0</td><td>28.6</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>B</td></tr><tr><td>FORPRO2</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>0</td><td>1</td><td>85.7</td><td>1</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>33.3</td><td>C</td></tr><tr><td>Winjum</td><td>0</td><td>1</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>28.6</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>B</td></tr><tr><td>CBMFPS2</td><td>0</td><td>1</td><td>0</td><td>1</td><td>1</td><td>0</td><td>0</td><td>42.9</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>C</td></tr><tr><td>CO2FIX1</td><td>0</td><td>1</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td><td>28.6</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>16.7</td><td>B</td></tr><tr><td>CBMFPS3</td><td>0</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>85.7</td><td>0</td><td>0</td><td>1</td><td>1</td><td>0</td><td>1</td><td>50.0</td><td>A</td></tr><tr><td>Edinbu</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>B</td></tr><tr><td>CO2FIX2</td><td>0</td><td>1</td><td>0</td><td>1</td><td>1</td><td>0</td><td>0</td><td>42.9</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>16.7</td><td>C</td></tr><tr><td>EFISCEN</td><td>0</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>0</td><td>71.4</td><td>1</td><td>1</td><td>1</td><td>1</td><td>0</td><td>0</td><td>66.7</td><td>A</td></tr><tr><td>FORCAR2</td><td>0</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>0</td><td>71.4</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>16.7</td><td>C</td></tr><tr><td>XYLOIKO</td><td>0</td><td>1</td><td>0</td><td>0</td><td>1</td><td>1</td><td>1</td><td>57.1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>C</td></tr><tr><td>CO2FIX3</td><td>0</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>0</td><td>71.4</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>0</td><td>83.3</td><td>A</td></tr><tr><td>Perez‐G</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>1</td><td>0</td><td>28.6</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>B</td></tr><tr><td>White</td><td>0</td><td>1</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>28.6</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>B</td></tr><tr><td>Dias1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>B</td></tr><tr><td>HWPIPCC</td><td>0</td><td>0</td><td>1</td><td>1</td><td>0</td><td>1</td><td>0</td><td>42.9</td><td>1</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>33.3</td><td>C</td></tr><tr><td>Werne1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1</td><td>0</td><td>14.3</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>B</td></tr><tr><td>Green</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>0</td><td>0</td><td>71.4</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>C</td></tr><tr><td>CAMFor</td><td>0</td><td>1</td><td>1</td><td>1</td><td>1</td><td>0</td><td>0</td><td>57.1</td><td>1</td><td>1</td><td>1</td><td>0</td><td>0</td><td>0</td><td>50.0</td><td>A</td></tr><tr><td>Frankfu</td><td>0</td><td>0</td><td>1</td><td>1</td><td>0</td><td>0</td><td>0</td><td>28.6</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>16.7</td><td>B</td></tr><tr><td>Erikss</td><td>0</td><td>1</td><td>0</td><td>0</td><td>1</td><td>1</td><td>0</td><td>42.9</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>C</td></tr><tr><td>Dias2</td><td>1</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>28.6</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>B</td></tr><tr><td>Seidl</td><td>0</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>0</td><td>71.4</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>C</td></tr><tr><td>WOODCII</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>0</td><td>1</td><td>85.7</td><td>0</td><td>1</td><td>1</td><td>0</td><td>0</td><td>1</td><td>50.0</td><td>A</td></tr><tr><td>FORC‐ON</td><td>0</td><td>1</td><td>1</td><td>0</td><td>1</td><td>0</td><td>0</td><td>42.9</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>C</td></tr><tr><td>COT</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>100.0</td><td>1</td><td>0</td><td>1</td><td>1</td><td>0</td><td>1</td><td>66.7</td><td>A</td></tr><tr><td>Profft</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>0</td><td>85.7</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>C</td></tr><tr><td>Pingoud</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>1</td><td>0</td><td>28.6</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>B</td></tr><tr><td>Werne2</td><td>1</td><td>1</td><td>1</td><td>0</td><td>1</td><td>1</td><td>0</td><td>71.4</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>C</td></tr><tr><td>C‐HWP</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>14.3</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1</td><td>33.3</td><td>B</td></tr><tr><td>NFCMARS</td><td>0</td><td>1</td><td>1</td><td>1</td><td>0</td><td>1</td><td>1</td><td>71.4</td><td>0</td><td>1</td><td>1</td><td>1</td><td>0</td><td>1</td><td>66.7</td><td>A</td></tr><tr><td>Pukkala</td><td>0</td><td>1</td><td>1</td><td>0</td><td>1</td><td>1</td><td>0</td><td>57.1</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1</td><td>33.3</td><td>C</td></tr><tr><td>WoodCar</td><td>0</td><td>1</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>28.6</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>B</td></tr><tr><td>CAPSIS</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>0</td><td>85.7</td><td>1</td><td>1</td><td>1</td><td>0</td><td>1</td><td>1</td><td>83.3</td><td>A</td></tr><tr><td>BC‐HWP</td><td>0</td><td>1</td><td>1</td><td>1</td><td>1</td><td>0</td><td>1</td><td>71.4</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>C</td></tr><tr><td>LANDCAR</td><td>0</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>85.7</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>16.7</td><td>C</td></tr><tr><td>Earles</td><td>1</td><td>0</td><td>0</td><td>1</td><td>1</td><td>0</td><td>0</td><td>42.9</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>C</td></tr><tr><td>Klein</td><td>0</td><td>1</td><td>1</td><td>0</td><td>1</td><td>1</td><td>0</td><td>57.1</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>16.7</td><td>C</td></tr><tr><td>PRESTO</td><td>1</td><td>1</td><td>0</td><td>1</td><td>1</td><td>1</td><td>0</td><td>71.4</td><td>1</td><td>1</td><td>0</td><td>1</td><td>0</td><td>0</td><td>50.0</td><td>A</td></tr><tr><td>Pilli</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>B</td></tr><tr><td>Höglmei</td><td>0</td><td>1</td><td>1</td><td>0</td><td>1</td><td>1</td><td>0</td><td>57.1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.0</td><td>C</td></tr></table> |
f56c52d4ef4960ab2b8e84056034bc62f13c78129847f6b3f60a51d37b648a4b.png | complex | <table><tr><td>Genes</td><td>ID</td><td>adj.P-val</td><td>logFC</td></tr><tr><td colspan="4">Downregulated genes</td></tr><tr><td> GPI</td><td>208308_s_at</td><td>0.023</td><td>−1.44282</td></tr><tr><td> MLXIP</td><td>202519_at</td><td>0.023</td><td>−1.32908</td></tr><tr><td> TPP1</td><td>200742_s_at</td><td>0.023</td><td>−1.26717</td></tr><tr><td> NEU1</td><td>208926_at</td><td>0.023</td><td>−1.21158</td></tr><tr><td> ACTN1</td><td>208636_at</td><td>0.023</td><td>−1.20938</td></tr><tr><td> LAMP1</td><td>201551_s_at</td><td>0.040</td><td>−1.14585</td></tr><tr><td> MYOF</td><td>211864_s_at</td><td>0.027</td><td>−1.14455</td></tr><tr><td> GLB1</td><td>201576_s_at</td><td>0.037</td><td>−1.13821</td></tr><tr><td> NFKB1</td><td>209239_at</td><td>0.044</td><td>−1.13729</td></tr><tr><td> ACP2</td><td>202767_at</td><td>0.043</td><td>−1.08902</td></tr><tr><td> M6PR</td><td>200900_s_at</td><td>0.047</td><td>−1.06069</td></tr><tr><td> HGSNAT</td><td>218017_s_at</td><td>0.023</td><td>−1.05619</td></tr><tr><td colspan="4">Upregulated genes</td></tr><tr><td> UTP14A</td><td>221098_x_at</td><td>0.026</td><td>1.00982</td></tr><tr><td> KLHL23</td><td>213610_s_at</td><td>0.023</td><td>1.02244</td></tr><tr><td> EFCAB11</td><td>210525_x_at</td><td>0.023</td><td>1.02378</td></tr><tr><td> NUCKS1</td><td>217802_s_at</td><td>0.025</td><td>1.03147</td></tr><tr><td> FIP1L1</td><td>221007_s_at</td><td>0.023</td><td>1.03372</td></tr><tr><td> MBD4</td><td>214048_at</td><td>0.023</td><td>1.03480</td></tr><tr><td> PPFIBP1</td><td>203735_x_at</td><td>0.023</td><td>1.03706</td></tr><tr><td> INHBC</td><td>207688_s_at</td><td>0.026</td><td>1.04053</td></tr><tr><td> PPARA</td><td>210771_at</td><td>0.023</td><td>1.04131</td></tr><tr><td> EZR</td><td>217234_s_at</td><td>0.038</td><td>1.04663</td></tr><tr><td> CDC42BPA</td><td>214464_at</td><td>0.023</td><td>1.05413</td></tr><tr><td> INVS</td><td>211054_at</td><td>0.023</td><td>1.06234</td></tr><tr><td> BMP2K</td><td>37170_at</td><td>0.026</td><td>1.06702</td></tr><tr><td> RREB1</td><td>203704_s_at</td><td>0.045</td><td>1.07460</td></tr><tr><td> DMP1</td><td>217067_s_at</td><td>0.023</td><td>1.07594</td></tr></table> |
bc9ab81f9cd0ea3881ae1090000ed0a715e96a7511fcd9508e0ff405f038b6b7.png | complex | <table><tr><td>Level of Confidence</td><td>Low</td><td>Medium </td><td>High</td></tr><tr><td rowspan="7">Studies</td><td>Gessner et al. (1997-b)</td><td>Akaeda et al. (1998)</td><td>Gessner et al. (1997-a)</td></tr><tr><td>Prakash et al. (1971)</td><td>Bond and Medcoff (1958)</td><td>Knaack et al. (2016)</td></tr><tr><td>Rodrigue et al. (1990)</td><td>Garcia et al. (2004)</td><td>-</td></tr><tr><td>Sharifzadeh et al. (1991)</td><td>Garcia et al. (2005)</td><td>-</td></tr><tr><td>Tennant et al. (1955)</td><td>Gessner and Middaugh (1995)</td><td>-</td></tr><tr><td>Turnbull et al. (2013)</td><td>Langeland et al. (1984)</td><td>-</td></tr><tr><td>-</td><td>Popkiss et al. (1979)</td><td>-</td></tr></table> |
94d3002e0d5cbc138743031aca47aa25535262947555c4397aeda53a1bd8fb52.png | simple | <table><tr><td>Source</td><td>Allograft</td><td>Time from transplant</td><td>Risk factors</td><td>Presentation</td><td>Diagnostic test</td><td>Treatment</td><td>Outcome</td></tr><tr><td>Schaeffer et al. [9]</td><td>Heart</td><td>2 months</td><td>Travel to southeastern US</td><td>Perforated colon</td><td>BAL examination</td><td>Thiabendazole × 15 daysIvermectin × 15 days</td><td>Death</td></tr><tr><td>El Masry and O'Donnell [10]</td><td>Heart</td><td>41 days</td><td>From Kentucky</td><td>Respiratory distress</td><td>Alveolar tissue onautopsy</td><td>None</td><td>Death</td></tr><tr><td>Mizuno et al. [11]</td><td>Heart/kidney</td><td>28 days</td><td>From Florida</td><td>Respiratory distress</td><td>Autopsy findings</td><td>None</td><td>Death</td></tr><tr><td>Roxby et al. [8]</td><td>Heart</td><td>2 months</td><td>Immigrantfrom Ethiopia</td><td>DyspneaAbdominal painNausea</td><td>Sputumexamination</td><td>Oralivermectin</td><td>Death</td></tr><tr><td>Brügemann et al. [12]</td><td>Heart</td><td>6 weeks</td><td> </td><td>AbdominalpainAnorexiaNausea</td><td>Skin biopsy</td><td>Oral ivermectin × 15 daysAlbendazole oral × 10 days</td><td>Successfultreatment</td></tr><tr><td>Grover et al. [13]</td><td>Heart</td><td>4 weeks</td><td>From SoutheasternUS</td><td>Nauseavomiting</td><td>Duodenalbiopsy</td><td>Ivermectin</td><td>Death</td></tr></table> |
dae2594ab625f70e70cad0cfe8022b993d2244f44b991f3d3dcb9359c516f8ee.png | simple | <table><tr><td>Before</td><td>8 hours</td><td>24 hours</td><td>48 hours</td><td>5 days</td></tr><tr><td>23 ± 4</td><td>401 ± 27</td><td>383 ± 1</td><td>272 ± 9</td><td>130 ± 14</td></tr></table> |
a3a45aafd65afdf907e89e58542a171bbcc46b7728d93a33d9924c0ea78985dc.png | complex | <table><tr><td>sEPCRMedian [25/75]</td><td colspan="2">Malaria patients161.1 [124.4/213.4]N = 76</td><td colspan="2">Non-malaria patients130.6 [109.5/165.5]N = 67</td><td colspan="2">Villages238.0 [178.0/292.4]N = 71</td></tr><tr><td>H1 vs. Hx</td><td>150.3[135.0/200.6]N = 20P = 0.6</td><td>165.6[123.5/215.0]N = 56</td><td>115.6[108.9/131.8]N = 19P = 0.09</td><td>133.2[109.8/208.8 N = 48</td><td>208[173.0/247.0]N = 17P = 0.09</td><td>259.0[196.5/297.5]N = 54</td></tr><tr><td>H2 vs. Hx</td><td>160.3[123.9/216.3]N = 66P = 0.9</td><td>163.0[128.9/195.2]N = 10</td><td>126.7(108.9/154.6]N = 63P = 0.06</td><td>215.3[191.2/228.6]N = 4</td><td>247.0[178.0/294.0]N = 61P = 1.0</td><td>221.5[1855.0/276.5]N = 10</td></tr><tr><td>H3 vs. Hx</td><td>193.2[169.1/268.0]N = 16<i>P</i> <i>=</i> <i>0.009</i></td><td>153.3[122.6/208.2]N = 60</td><td>236.7[197.6/288.6]N = 13<i>P</i> <i><</i> <i>0.001</i></td><td>119.4[105.3/139.7]N = 54</td><td>493.0[361.0/628.4]N = 6<i>P</i> <i>=</i> <i>0.007</i></td><td>232.0[178.0/284.5]N = 65</td></tr><tr><td>H4 vs. Hx</td><td>156.6[120.6/203.0]N = 10P = 0.7</td><td>161.1[125.4/213.6]N = 66</td><td>131.2[120.6/169.4]N = 9P = 0.7</td><td>128.7[109.5/159.6]N = 58</td><td>231.3[194.0/283.0]N = 19P = 0.8</td><td>248.0[177.8/298.6]N = 52</td></tr></table> |
b695b98c7e994157e5bf5d8dd6cbb8dec8e6db2a11b4492acde6293c97f31390.png | complex | <table><tr><td>Item</td><td colspan="6">First sensation threshold</td><td colspan="6">Defecation urge threshold</td><td colspan="6">Pain detection threshold</td></tr><tr><td></td><td colspan="2">Before Treatment</td><td colspan="2">After Treatment</td><td colspan="2">Difference</td><td colspan="2">Before Treatment</td><td colspan="2">After Treatment</td><td colspan="2">Difference</td><td colspan="2">Before Treatment</td><td colspan="2">After Treatment</td><td colspan="2">Difference</td></tr><tr><td></td><td>Mean ± S.E</td><td>95% CI</td><td>Mean ± S.E</td><td>95% CI</td><td>Mean ± S.E</td><td>95% CI</td><td>Mean ± S.E</td><td>95% CI</td><td>Mean ± S.E</td><td>95% CI</td><td>Mean ± S.E</td><td>95% CI</td><td>Mean ± S.E</td><td>95% CI</td><td>Mean ± S.E</td><td>95% CI</td><td>Mean ± S.E</td><td>95% CI</td></tr><tr><td>Moxibustion group (n = 15)</td><td>22.27 ± 2.052</td><td>[21.13,23.40]</td><td>22.67 ± 0.63</td><td>[21.32,24.0]</td><td>0.40 ± 0.81</td><td>[−1.34,2.14]</td><td>40.07 ± 3.23</td><td>[33.13,47.00]</td><td>63.47 ± 2.01<sup>▲</sup></td><td>[59.15,67.78]</td><td>23.40 ± 2.88<sup>★</sup></td><td>[17.23,29.57]</td><td>89.07 ± 5.01</td><td>[78.33,99.81]</td><td>113.6 ± 7.51<sup>●</sup></td><td>[97.48,129.72]</td><td>24.53 ± 5.78<sup>○</sup></td><td>[12.14,36.92]</td></tr><tr><td>Control group (n = 13)</td><td>22.31 ± 3.351</td><td>[20.28,24.33]</td><td>21.69 ± 1.17</td><td>[19.14,24.2]</td><td>−0.62 ± 1.5</td><td>[−0.43,2.80]</td><td>41.31 ± 1.89</td><td>[37.19,45.42]</td><td>44.15 ± 1.55</td><td>[40.78,47.58]</td><td>2.85 ± 1.68</td><td>[−0.80,6.50]</td><td>89.62 ± 2.85</td><td>[83.41,95.82]</td><td>93.46 ± 2.67</td><td>[87.64,99.28]</td><td>3.85 ± 2.84</td><td>[−2.33,10.02]</td></tr></table> |
fa310476b25a969e9d96e73476df3b593413a2bade5872c97eafd6589eee067a.png | complex | <table><tr><td>Gene</td><td colspan="3">HCT116</td><td colspan="3">BxPC-3</td><td colspan="3">A427</td></tr><tr><td></td><td>Slope</td><td>Intercept</td><td>R<sup>2</sup></td><td>Slope</td><td>Intercept</td><td>R<sup>2</sup></td><td>Slope</td><td>Intercept</td><td>R<sup>2</sup></td></tr><tr><td><i>18S</i></td><td>0.09</td><td>0.16</td><td>0.98</td><td>0.14</td><td>-0.41</td><td>1.00</td><td>0.11</td><td>-0.16</td><td>0.94</td></tr><tr><td><i>ACTB</i></td><td>0.06</td><td>0.42</td><td>0.92</td><td>0.10</td><td>-0.03</td><td>0.94</td><td>0.06</td><td>0.41</td><td>0.99</td></tr><tr><td><i>ATUB</i></td><td>0.10</td><td>-0.01</td><td>0.96</td><td>0.14</td><td>-0.41</td><td>0.99</td><td>0.10</td><td>-0.01</td><td>0.95</td></tr><tr><td><i>B2M</i></td><td>0.10</td><td>-0.03</td><td>0.92</td><td>0.10</td><td>0.03</td><td>0.92</td><td>0.07</td><td>0.34</td><td>0.92</td></tr><tr><td><i>GAPDH</i></td><td>0.08</td><td>0.27</td><td>0.94</td><td>0.10</td><td>0.02</td><td>0.98</td><td>0.08</td><td>0.22</td><td>0.98</td></tr><tr><td><i>HPRT</i></td><td>0.09</td><td>0.08</td><td>0.94</td><td>0.10</td><td>0.05</td><td>0.86</td><td>0.08</td><td>0.16</td><td>0.96</td></tr><tr><td><i>POLR2L</i></td><td>0.06</td><td>0.4</td><td>0.98</td><td>0.06</td><td>0.43</td><td>0.92</td><td>0.04</td><td>0.60</td><td>0.97</td></tr><tr><td><i>PSMB6</i></td><td>0.07</td><td>0.35</td><td>0.97</td><td>0.09</td><td>0.14</td><td>0.99</td><td>0.05</td><td>0.53</td><td>0.99</td></tr><tr><td><i>RPLP0</i></td><td>0.09</td><td>0.09</td><td>0.94</td><td>0.11</td><td>-0.07</td><td>0.99</td><td>0.06</td><td>0.33</td><td>0.97</td></tr></table> |
e0e4bececc461bee5f75fd7a18371b8dbe982e32322678a01fa9bbef516312cd.png | simple | <table><tr><td>Age</td><td>Females (%)</td><td>Males (%)</td><td>Total (%)</td></tr><tr><td><30</td><td>16 (3.5)</td><td>23 (1.6)</td><td>39 (2.0)</td></tr><tr><td>30–49</td><td>314 (68.0)</td><td>704 (48.0)</td><td>1018 (52.8)</td></tr><tr><td>50–60</td><td>92 (19.9)</td><td>268 (18.3)</td><td>360 (18.7)</td></tr><tr><td>>60</td><td>40 (8.6)</td><td>470 (32.1)</td><td>510 (26.5)</td></tr><tr><td>Total</td><td>462 (100)</td><td>1465 (100)</td><td>1927 (100)</td></tr></table> |
c5012b49ce33ad87fc99c79177e33ada7309f55a35c7fe7dcb436451dca06fcd.png | complex | <table><tr><td colspan="2"></td><td colspan="4">Predicting from Overt Victimization</td><td colspan="4">Predicting from Relational Victimization</td></tr><tr><td colspan="2"></td><td colspan="2">CBCL Externalizing</td><td colspan="2">CBCL Internalizing</td><td colspan="2">CBCL Externalizing</td><td colspan="2">CBCL Internalizing</td></tr><tr><td colspan="2"></td><td>∆R<sup>2</sup></td><td>β</td><td>∆R<sup>2</sup></td><td>β</td><td>∆R<sup>2</sup></td><td>β</td><td>∆R<sup>2</sup></td><td>β</td></tr><tr><td colspan="2">Step 1</td><td>0.02</td><td></td><td>0.03</td><td></td><td>0.02</td><td></td><td>0.03</td><td></td></tr><tr><td> </td><td>Age</td><td></td><td>−0.12</td><td></td><td> 0.18</td><td></td><td>−0.12</td><td></td><td> 0.18</td></tr><tr><td colspan="2">Step 2</td><td>0.11</td><td></td><td>0.13</td><td></td><td>0.11</td><td></td><td>0.13</td><td></td></tr><tr><td> </td><td>Child Fearful Bias</td><td></td><td> 0.21</td><td></td><td> 0.07</td><td></td><td> 0.21</td><td></td><td> 0.07</td></tr><tr><td> </td><td>Parent Fearful Bias</td><td></td><td>−0.02</td><td></td><td>−0.10</td><td></td><td>−0.02</td><td></td><td>−0.10</td></tr><tr><td> </td><td>Parent TAS DIF</td><td></td><td> 0.32 *</td><td></td><td> 0.36 **</td><td></td><td> 0.32 *</td><td></td><td> 0.36 **</td></tr><tr><td colspan="2">Step 3</td><td>0.00</td><td></td><td>0.04</td><td></td><td>0.01</td><td></td><td>0.10 *</td><td></td></tr><tr><td> </td><td>Perceived Impairment</td><td></td><td> 0.02</td><td></td><td>−0.22</td><td></td><td>−0.14</td><td></td><td>−0.37 *</td></tr><tr><td colspan="2">Step 4</td><td>0.13 *</td><td></td><td>0.10 *</td><td></td><td>0.08</td><td></td><td>0.09</td><td></td></tr><tr><td> </td><td>Child-reported Victimization</td><td></td><td>−0.09</td><td></td><td>−0.10</td><td></td><td>−0.01</td><td></td><td>−0.12</td></tr><tr><td> </td><td>Parent-reported Victimization</td><td></td><td>0.40 **</td><td></td><td> 0.34 *</td><td></td><td> 0.31*</td><td></td><td> 0.35 *</td></tr></table> |
7e18f85365833999e16d2a831411c6b4ff9cfc18a17e80a88302f8f8965fe53e.png | simple | <table><tr><td>Symbol<sup>a</sup></td><td>Protein</td><td>Process</td><td>Alteration/disease</td></tr><tr><td><i>ADCYAP1R1</i></td><td>Adenylate cyclase-activating polypeptide receptor (PAC1)</td><td>Signaling pathway</td><td>Decreased second messenger</td></tr><tr><td><i>CASP3</i></td><td>Caspase 3</td><td>Protease</td><td>Apoptosis. Alzheimer’s disease</td></tr><tr><td><i>CCND1</i></td><td>G1/S-specific cyclin-D1</td><td>Interact with tumor suppressor protein Rb</td><td>Abnormal cell cycle G1/S transition</td></tr><tr><td><i>CNN1</i></td><td>Calporin (actin binding protein; fimbrin type)</td><td>Actin associated protein</td><td>Abnormal cohesion between parental centrioles</td></tr><tr><td><i>CREB1</i></td><td>cAMP-responsive element binding protein 1</td><td>Transcription factor</td><td>Altered development. ASD</td></tr><tr><td><i>CREM</i></td><td>cAMP-responsive element modulator</td><td>Transcription factor modulating CREB</td><td>Altered development. ASD</td></tr><tr><td><i>CTNNB1</i></td><td>β-catenin</td><td>Regulates the coordination of cell–cell adhesion and gene transcription</td><td>Altered asymmetric cell division, epithelial-to-mesenchymal transition. ASD</td></tr><tr><td><i>DYRK1A</i></td><td>Dual specificity tyrosine-phosphorylation- regulated kinase 1A</td><td>Nuclear signaling</td><td>Abnormal cell proliferation and may be involved in brain development. ASD</td></tr><tr><td><i>GNB1L</i></td><td>Guanine nucleotide-binding protein subunit β-like protein 1</td><td>Six WD40 repeat-containing protein</td><td>Abnormal cell cycle progression. Schizophrenia. ASD</td></tr><tr><td><i>FLT1</i></td><td>Vascular endothelial growth factor receptor 1</td><td>Protein kinase</td><td>Abnormal control of cell proliferation and differentiation. ASD</td></tr><tr><td><i>HIST1H1T</i></td><td>Histone H1t</td><td>Compaction of chromatin</td><td>Abnormal cell cycle and differentiation</td></tr><tr><td><i>HSD11B2</i></td><td>Corticosteroid 11-β-dehydrogenase isozyme 2</td><td>Hydrolysis of cortisol</td><td>Cortisol induction of growth-inhibition and/or pro-apoptosis embryonic development</td></tr><tr><td><i>MAPK1</i></td><td>Mitogen-activated protein kinase 1 (ERK2)</td><td>CREB1 phosphorylation signaling pathway</td><td>ASD</td></tr><tr><td><i>RGS3</i></td><td>Regulator of G-protein signaling 3</td><td>Ephrin-B signaling pathway</td><td>Early cell cycle exit and precocious differentiation</td></tr></table> |
6451d4e2f39e939ed39dba57ff2bff97e9d228d1ad9dd96f8bbeb4817d35f548.png | complex | <table><tr><td></td><td>Harmonic (<i>n</i> = 39)</td><td>Control (<i>n</i> = 40)</td><td><i>p</i>-value</td></tr><tr><td colspan="4">Total volume (ml)</td></tr><tr><td> Univariate</td><td>2908 ± 2453</td><td>3898 ± 5791</td><td>0.382</td></tr><tr><td> Multivariate-adjusted</td><td>2864 ± 715</td><td>3941 ± 706</td><td>0.293</td></tr><tr><td colspan="4">Duration of draining (days)</td></tr><tr><td> Univariate</td><td>23 ± 14</td><td>28 ± 15</td><td>0.195</td></tr><tr><td> Multivariate-adjusted</td><td>24 ± 2</td><td>27 ± 2</td><td>0.290</td></tr></table> |
6d324534584a8ecb12a2e00b5eddb80ab703bead0f47a08a6f04e7b5c10b5c92.png | simple | <table><tr><td>KEGG pathway</td><td><i>p</i> value</td><td>Number of DEGs found in the KEGG pathway</td><td>Ratio (%)</td></tr><tr><td>Pathways in cancer</td><td>2.1e-4</td><td>9</td><td>10.1</td></tr><tr><td>Cytokine-cytokine receptor interaction</td><td>2.1e-3</td><td>7</td><td>7.9</td></tr><tr><td>Basal cell carcinoma</td><td>2.9e-3</td><td>4</td><td>4.5</td></tr><tr><td>Retinol metabolism</td><td>3.3e-2</td><td>3</td><td>3.4</td></tr><tr><td>Hedgehog signaling pathway</td><td>3.5e-2</td><td>3</td><td>3.4</td></tr></table> |
09c1378ef56e593c48a1c40dc1f69224253994371cc4acb9c7ecc34d97d9df66.png | complex | <table><tr><td></td><td colspan="2">Underlying Diagnosis</td><td colspan="2">All Diagnoses</td></tr><tr><td></td><td>Median</td><td>95% UI</td><td>Median</td><td>95% UI</td></tr><tr><td>Adults</td><td>66.5</td><td>(65.9, 66.9)</td><td>75.9</td><td>(75.4, 76.3)</td></tr><tr><td>Children</td><td>38.5</td><td>(37.0, 40.0)</td><td>64.0</td><td>(61.4, 66.3)</td></tr><tr><td>Neonates</td><td>54.3</td><td>(52.2, 55.6)</td><td>58.9</td><td>(56.9, 60.5)</td></tr></table> |
669c06d2d6fbfc2c2b87c8886be9436569b79300b9c786ca1bd3b0aa14a72e40.png | simple | <table><tr><td>Indices and Its Statements <sup>a</sup></td><td>Total Sample <i>n</i> = 1107</td><td>Bottom Tertile <i>n</i> = 355/339</td><td>Middle Tertile <i>n</i> = 424/417</td><td>Upper Tertile <i>n</i> = 328/351</td><td><i>p</i>-Value</td></tr><tr><td>Perceived health concerns</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Health Concern Index <sup>b</sup></td><td>6.9 (3.7)</td><td>3.0 (0.7)</td><td>6.6 (0.9)</td><td>11.6 (2.3)</td><td><0.0001</td></tr><tr><td>I am concerned about gaining weight</td><td>3.1 (1.9)</td><td>1.0 (0.5)</td><td>3.6 (1.5)</td><td>4.6 (1.2)</td><td><0.0001</td></tr><tr><td>I am concerned about the risk of high blood pressure</td><td>2.0 (1.4)</td><td>1.0 (0.3)</td><td>1.5 (0.7)</td><td>3.7 (1.3)</td><td><0.0001</td></tr><tr><td>I am concerned about the risk of coronary heart disease</td><td>1.8 (1.3)</td><td>1.0 (0.3)</td><td>1.4 (0.8)</td><td>3.3 (1.4)</td><td><0.0001</td></tr><tr><td>Perceived nutrition concerns</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Nutrition Concern Index <sup>c</sup></td><td>17.1 (6.6)</td><td>10.0 (1.7)</td><td>16.1 (1.9)</td><td>25.1 (4.2)</td><td><0.0001</td></tr><tr><td>I am not concerned about getting a lot of salt in my food (re-coded)</td><td>3.7 (1.5)</td><td>3.4 (1.8)</td><td>3.8 (1.4)</td><td>3.7 (1.4)</td><td>0.1617</td></tr><tr><td>I am concerned about food additives in my food</td><td>2.6 (1.5)</td><td>1.4 (0.9)</td><td>2.7 (1.4)</td><td>3.5 (1.4)</td><td><0.0001</td></tr><tr><td>I am concerned about getting a lot of sugar in my food</td><td>2.4 (1.6)</td><td>1.1 (0.7)</td><td>2.1 (1.2)</td><td>4.2 (1.2)</td><td><0.0001</td></tr><tr><td>I am concerned about getting a lot of fat in my food</td><td>2.3 (1.6)</td><td>1.0 (0.4)</td><td>2.0 (1.3)</td><td>4.0 (1.3)</td><td><0.0001</td></tr><tr><td>I am concerned about getting sufficient energy in my food</td><td>2.2 (1.5)</td><td>1.1 (0.5)</td><td>2.2 (1.3)</td><td>3.2 (1.5)</td><td><0.0001</td></tr><tr><td>I am concerned about getting a lot of cholesterol in my food</td><td>2.1 (1.5)</td><td>1.0 (0.3)</td><td>1.7 (1.0)</td><td>3.6 (1.3)</td><td><0.0001</td></tr><tr><td>I am concerned about getting many calories</td><td>1.9 (1.3)</td><td>1.0 (0.5)</td><td>1.7 (1.0)</td><td>2.9 (1.5)</td><td><0.0001</td></tr></table> |
8da418d3a64253c9872a4e806f3c9752af63d7543b5bd7503e97139c46839a9c.png | complex | <table><tr><td rowspan="2">Pathways</td><td rowspan="2">Genes</td><td rowspan="2">Descriptions</td><td colspan="2">TPM</td><td colspan="2">NOISeq</td><td colspan="2">RT-qPCR</td></tr><tr><td><i>P. humilis</i></td><td><i>P. major</i></td><td>Log2FC</td><td><i>P</i>-adj</td><td>Log2FC</td><td><i>P</i></td></tr><tr><td rowspan="10">Wnt</td><td><i>WNT5A</i></td><td>Protein Wnt-5a</td><td>48.06</td><td>148.61</td><td>−1.63</td><td>0.00E+00</td><td>–</td><td>–</td></tr><tr><td><i>PRICKLE1</i></td><td>Prickle-like protein 1</td><td>14.86</td><td>55.20</td><td>−1.89</td><td>2.75E-06</td><td>−0.17</td><td>1.10E-01</td></tr><tr><td><i>WIF1</i>*†</td><td>Wnt inhibitory factor 1</td><td>7.28</td><td>57.05</td><td>−2.97</td><td>8.87E-06</td><td>−3.28</td><td>5.30E-06</td></tr><tr><td><i>NFATC3</i></td><td>Nuclear factor of activated T-cells, cytoplasmic 3</td><td>8.98</td><td>39.30</td><td>−2.13</td><td>9.47E-05</td><td>–</td><td>–</td></tr><tr><td><i>FZD4</i></td><td>Frizzled-4</td><td>16.67</td><td>89.95</td><td>−2.43</td><td>1.54E-04</td><td>–</td><td>–</td></tr><tr><td><i>LEF1</i></td><td>Lymphoid enhancer-binding factor 1</td><td>60.50</td><td>143.01</td><td>−1.24</td><td>1.77E-04</td><td>–</td><td>–</td></tr><tr><td><i>FRZB</i>*</td><td>Secreted frizzled-related protein 3</td><td>71.32</td><td>150.58</td><td>−1.08</td><td>3.47E-04</td><td>−3.23</td><td>4.12E-05</td></tr><tr><td><i>DAAM2</i></td><td>Disheveled-associated activator of morphogenesis 2</td><td>2.48</td><td>15.04</td><td>−2.60</td><td>3.47E-04</td><td>–</td><td>–</td></tr><tr><td><i>CCND1</i></td><td>G1/S-specific cyclin-D1</td><td>24.35</td><td>69.13</td><td>−1.51</td><td>4.18E-04</td><td>–</td><td>–</td></tr><tr><td><i>PRKACB</i></td><td>cAMP-dependent protein kinase catalytic subunit beta</td><td>34.22</td><td>73.42</td><td>−1.10</td><td>4.97E-04</td><td>–</td><td>–</td></tr><tr><td rowspan="3">MAPK/FGF</td><td><i>FGF17</i></td><td>Fibroblast growth factor 17</td><td>45.91</td><td>0.38</td><td>6.91</td><td>0.00E + 00</td><td>0.50</td><td>4.18E-01</td></tr><tr><td><i>FGF13</i>*†</td><td>Fibroblast growth factor 13</td><td>11.33</td><td>3.71</td><td>1.61</td><td>4.21E-04</td><td>7.37</td><td>1.23E-08</td></tr><tr><td><i>STK3</i></td><td>Serine/threonine-protein kinase 38</td><td>11.70</td><td>40.72</td><td>−1.80</td><td>4.64E-04</td><td>–</td><td>–</td></tr><tr><td rowspan="2">OCD</td><td><i>NFATC1</i>*</td><td>Nuclear factor of activated T-cells, cytoplasmic 1</td><td>5.82</td><td>39.32</td><td>−2.76</td><td>1.60E-08</td><td>−3.21</td><td>2.16E-05</td></tr><tr><td><i>ITGB3</i>*†</td><td>Integrin beta-3</td><td>0.76</td><td>6.43</td><td>−3.08</td><td>8.57E-05</td><td>−5.49</td><td>1.21E-06</td></tr><tr><td>Notch</td><td><i>HES5</i></td><td>Transcription factor HES-5</td><td>117.76</td><td>17.23</td><td>2.77</td><td>3.11E-04</td><td>0.22</td><td>6.83E-01</td></tr><tr><td>Calcium</td><td><i>CACNA1G</i></td><td>Voltage-dependent T-type calcium channel subunit alpha-1G</td><td>4.28</td><td>14.60</td><td>−1.77</td><td>5.79E-04</td><td>–</td><td>–</td></tr></table> |
aa290025f612aa856092d39e8bcc45a29d16b593ee50ed36b7dcc78b80c93118.png | simple | <table><tr><td><i>Variable</i></td><td><i>Mean (range) or no. (%)</i></td></tr><tr><td>Total operative time (mins)</td><td>204.94 (180–300)</td></tr><tr><td>Docking time (mins)</td><td>9.06 (5–30)</td></tr><tr><td>Undocking time (mins)</td><td>5 (2–10)</td></tr><tr><td>Time for esophageal mobilization (mins)</td><td>104.08 (80–170)</td></tr><tr><td>Estimated blood loss (ml)</td><td>86.75 (50–200)</td></tr><tr><td>Lymphnode yield (no.)</td><td>18.36 (13–24)</td></tr><tr><td>ICU stay (days)</td><td>1 (1–3)</td></tr><tr><td>Hospital stay (days)</td><td>10.37 (10–13)</td></tr><tr><td>Nil by mouth (days)</td><td>9.40 (8–12)</td></tr><tr><td>Conversion (no.)</td><td>Nil</td></tr><tr><td>Margin positivity (no.)</td><td>2 (2.41)</td></tr><tr><td>Adjuvant chemotherapy (no.)</td><td>15 (18.07)</td></tr><tr><td><i>Complications (no.)</i></td><td></td></tr><tr><td>Dysphagia for solids</td><td>6 (7.23)</td></tr><tr><td>Pleural effusion</td><td>3 (3.61)</td></tr><tr><td>Aspiration pneumonia</td><td>1 (1.20)</td></tr><tr><td>Recurrent palsy</td><td>2 (2.41)</td></tr><tr><td>Anastomotic leak</td><td>3 (3.61)</td></tr><tr><td>Chyle leak</td><td>1 (1.20)</td></tr><tr><td>Port site metastasis</td><td>1 (1.20)</td></tr><tr><td>Surgical site infection</td><td>1 (1.20)</td></tr><tr><td>Sepsis</td><td>1 (1.20)</td></tr></table> |
c51d7d354ea226dd88691d731d503ee2eca303527216e8eba72d5b043c154227.png | complex | <table><tr><td></td><td>Group A (<i>n</i> = 162)</td><td>Group B (<i>N</i> = 89)</td><td><i>p</i>-value</td></tr><tr><td>Median (IQR) age, years</td><td>67 (61–72)</td><td>68 (60–71)</td><td>0.846</td></tr><tr><td>Median (IQR) PSA. ng/ml</td><td>8.10 (6.05–14.00)</td><td>8.59 (5.65–12.32)</td><td>0.997</td></tr><tr><td>Median IQR) f/t PSA-ratio,%</td><td>12 (9–17)</td><td>13 (9–19)</td><td>0.309</td></tr><tr><td>Median (IQR) prostate volume, ml</td><td>48 (35–60)</td><td>50 (37–70)</td><td>0.087</td></tr><tr><td>Suspicous DRE, n (%)</td><td>23 (14%)</td><td>26 (29%)</td><td>0.007</td></tr><tr><td colspan="4">No. of prior biopsies, n (%)</td></tr><tr><td> Primary biopsy</td><td>53 (33%)</td><td>41 (46%)</td><td>0.041</td></tr><tr><td> 1</td><td>59 (36%)</td><td>28 (32%)</td><td>0.489</td></tr><tr><td> 2</td><td>33 (20%)</td><td>13 (15%)</td><td>0.308</td></tr><tr><td>≥3</td><td>17 (10%)</td><td>7 (8%)</td><td>0.655</td></tr><tr><td colspan="4">Localization of lesions with maximum PI-RADS on mpMRI, n (%)</td></tr><tr><td> Apex</td><td>72 (44%)</td><td>35 (39%)</td><td>0.505</td></tr><tr><td> Midgland</td><td>43 (27%)</td><td>32 (36%)</td><td>0.149</td></tr><tr><td> Base</td><td>47 (29%)</td><td>22 (25%)</td><td>0.555</td></tr><tr><td> Anterior</td><td>45 (28%)</td><td>28 (32%)</td><td>0.563</td></tr><tr><td>Median (IQR) no. of lesions per patient</td><td>1 (1–2)</td><td>1 (1–2)</td><td>0.451</td></tr><tr><td>Maximum diameter of lesions (mm)</td><td>14 (10–17)</td><td>13 (10–18)</td><td>0.885</td></tr><tr><td>Mean (SD) of cores taken per patient</td><td>13.7 (±1.6)</td><td>13.2 (±1.2)</td><td>0.009</td></tr><tr><td>Mean (SD) TBs per patient</td><td>3.8 (±1.5)</td><td>3.4 (±0.9)</td><td>0.031</td></tr><tr><td colspan="4">Maximum mpMRI Score, n (%)<sup>a</sup></td></tr><tr><td> PI-RADS 3</td><td>31 (19%)</td><td>8 (9%)</td><td>0.044</td></tr><tr><td> PI-RADS 4</td><td>83 (51%)</td><td>43 (48%)</td><td>0.693</td></tr><tr><td> PI-RADS 5</td><td>48 (30%)</td><td>38 (43%)</td><td>0.051</td></tr></table> |
98f793b7ee5f2624206b9e6d03f2271bdfa6f574be94e83d3952902519844594.png | complex | <table><tr><td>Background characteristics</td><td></td><td>Frequency</td><td>Percentage</td></tr><tr><td rowspan="2">Sex</td><td>Female</td><td>298</td><td>73.2</td></tr><tr><td>Male</td><td>109</td><td>26.8</td></tr><tr><td rowspan="5">Age</td><td>18-24</td><td>75</td><td>18.4</td></tr><tr><td>25-34</td><td>178</td><td>43.8</td></tr><tr><td>35-44</td><td>87</td><td>21.4</td></tr><tr><td>45-54</td><td>36</td><td>8.8</td></tr><tr><td>55+</td><td>31</td><td>7.6</td></tr><tr><td rowspan="4">Marital status</td><td>Married</td><td>335</td><td>82.3</td></tr><tr><td>Single</td><td>48</td><td>11.8</td></tr><tr><td>Divorced</td><td>16</td><td>3.9</td></tr><tr><td>Widowed</td><td>8</td><td>2.0</td></tr><tr><td rowspan="4">Educational level</td><td>Illiterate</td><td>45</td><td>11.0</td></tr><tr><td>Grade 1-8</td><td>111</td><td>27.3</td></tr><tr><td>Grade 9.12</td><td>120</td><td>29.5</td></tr><tr><td>College and above</td><td>131</td><td>32.2</td></tr><tr><td rowspan="4">Religion</td><td>Protestant</td><td>268</td><td>65.8</td></tr><tr><td>Orthodox</td><td>88</td><td>21.6</td></tr><tr><td>Muslim</td><td>27</td><td>6.6</td></tr><tr><td>Catholic</td><td>24</td><td>5.9</td></tr><tr><td rowspan="5">Occupation</td><td>Gov’t employee</td><td>139</td><td>34.2</td></tr><tr><td>House wife</td><td>137</td><td>33.7</td></tr><tr><td>Merchant</td><td>59</td><td>7.6</td></tr><tr><td>Daily laborer</td><td>31</td><td>14.5</td></tr><tr><td>Others*</td><td>41</td><td>10.1</td></tr></table> |
0ca3342e7119bd5ef4060aa0703bd0b400b9743a92fa73e51ddfc34574dab35e.png | complex | <table><tr><td></td><td>Pearson correlation</td><td colspan="3">Secondary structure and interactions</td></tr><tr><td></td><td></td><td>Target</td><td>Guide strand (intra-)</td><td>Guide strand (inter-)</td></tr><tr><td>Complete database</td><td><i>R</i></td><td>0.16</td><td>0.13</td><td>0.12</td></tr><tr><td></td><td>Significance</td><td><10<sup>−100</sup></td><td>1.1 × 10<sup>−72</sup></td><td>2.89 × 10<sup>−56</sup></td></tr><tr><td>Dataset with duplex stability −35 ≤ ΔG ≤ −25 kcal/mol</td><td><i>R</i></td><td>–</td><td>0.045</td><td>–</td></tr><tr><td></td><td>Significance</td><td>n.s.</td><td>0.0018</td><td>n.s.</td></tr></table> |
08e6a413d2ea990afa70da3b09cd45aeb93f3ba3ce010d1b05774c1eff38ecde.png | simple | <table><tr><td> Method </td><td> ASEF </td><td> nu-SVR </td><td> Deep CNN </td><td> Our method </td></tr><tr><td> fps </td><td> 66.7 </td><td> 0.82 </td><td> 8.3 </td><td> 10.5 </td></tr></table> |
c6ad05f85057ac44ef7783d0b7ee07023dc3b97cf805038050303b831378b1c3.png | simple | <table><tr><td></td><td>Odds ratio</td><td>95% CI</td></tr><tr><td>Age</td><td>1.04</td><td>1.01 to 1.07</td></tr><tr><td>Site of infection:</td><td></td><td></td></tr><tr><td> Lung</td><td>1</td><td></td></tr><tr><td> Abdomen</td><td>1.55</td><td>0.66 to 3.70</td></tr><tr><td> Catheter</td><td>0.72</td><td>0.15 to 3.43</td></tr><tr><td> Urinary tract</td><td>0.10</td><td>0.01 to 0.78</td></tr><tr><td> Others</td><td>0.70</td><td>0.25 to 1.94</td></tr><tr><td> Chronic alcohol abuse</td><td>3.20</td><td>0.90 to 11.42</td></tr><tr><td> Acquisition in hospital</td><td>2.03</td><td>0.98 to 4.36</td></tr><tr><td>SOFA score day 1 (failure):</td><td></td><td></td></tr><tr><td> Haematological</td><td>3.20</td><td>0.92 to 9.92</td></tr><tr><td> Cardiovascular</td><td>2.78</td><td>1.37 to 5.64</td></tr><tr><td> Neurological</td><td>2.39</td><td>0.76 to 7.48</td></tr><tr><td> Renal</td><td>1.97</td><td>0.73 to 5.27</td></tr><tr><td> Liver</td><td>1.67</td><td>0.46 to 6.08</td></tr><tr><td> Lung</td><td>1.65</td><td>0.81 to 3.36</td></tr><tr><td> ΔSOFA (3-1)</td><td>1.32</td><td>1.13 to 1.34</td></tr><tr><td> APACHE II Score</td><td>1.02</td><td>0.97 to 1.08</td></tr><tr><td> Pre ICU stay (days)</td><td>0.99</td><td>0.97 to 1.02</td></tr></table> |
611505bfc4286424d6c0c8267958c217d84cc855bbcb3584ad8cc55ac99abdc2.png | simple | <table><tr><td> </td><td>€</td><td>Reference/data source</td></tr><tr><td>Visit practice nurse (€/minute)</td><td>0.85</td><td>Vektis, information centre on costs and quality of health care in the Netherlands, established by health care insurers.</td></tr><tr><td>Mean salary costs men (€/hour)</td><td>32.49</td><td>Manual Hakkaart-van Roijen et al. [18]</td></tr><tr><td>Mean salary costs women (€/hour)</td><td>25.94</td><td>Manual Hakkaart-van Roijen et al. [18]</td></tr><tr><td>Transportation costs per visit</td><td>3.44</td><td>1.1 km * €0.20/km (back and forth: €0.44) + €3 parking costs, based on the manual of Hakkaart-van Roijen et al. [18]</td></tr><tr><td>Weighing scale</td><td>45</td><td>Mean price according to the “Consumentenbond” (Dutch consumers organisation)</td></tr><tr><td>Pedometer</td><td>40</td><td>Mean price according to “thuisvergelijken.nl” (website with reviews on web shops)</td></tr><tr><td>Blood pressure device</td><td>120</td><td>Mean price according to “bloeddrukmetershop.nl”</td></tr><tr><td>Food diary and step diary</td><td>5</td><td>Price according to “weightwatchers.nl”</td></tr><tr><td>Medication</td><td>variable</td><td>2012 prices according to “medicijnkosten.nl”, site of the College of Health Insurances</td></tr></table> |
bbddaddb84bd247a4135711b5ddefb3bb7b94db78487e4ffb52e022381303142.png | simple | <table><tr><td>Characteristics</td><td>Patientsn = 85</td></tr><tr><td>Age</td><td>66 (range 43-87)</td></tr><tr><td>Hypertension</td><td>34 (39%)</td></tr><tr><td>Hormone replacement therapy</td><td>21 (24%)</td></tr><tr><td>Obesity (BMI ≥ 30)</td><td>19 (22.3%)</td></tr><tr><td>Histology:</td><td></td></tr><tr><td> Endometrioid adenocarcinoma</td><td>73 (86%)</td></tr><tr><td> Adenosquamous adenocarcinoma</td><td>1 (1%)</td></tr><tr><td> Serous papillary adenocarcinoma</td><td>5 (6%)</td></tr><tr><td> Clear cell adenocarcinoma</td><td>5 (6%)</td></tr><tr><td> Carcinosarcoma</td><td>1 (1%)</td></tr><tr><td>Preoperative histological grade on biopsy</td><td></td></tr><tr><td> 1</td><td>41 (48.2%)</td></tr><tr><td> 2</td><td>22 (25.8%)</td></tr><tr><td> 3</td><td>11 (12.9%)</td></tr><tr><td> NP</td><td>11 (12.9%)</td></tr></table> |
48381c2ddf96b356ab2231f7d2c0f0634bc2314f2c29dc8485b6909e94c6748c.png | complex | <table><tr><td>Model – Variables</td><td colspan="2">Odds Ratios for eGFR < 75(95% Confidence Interval)n = 51 events</td><td>P interaction (<i>APOL1</i>x SES measure)</td><td colspan="2">Odds Ratios for Elevated ACR(95% Confidence Interval) n = 21 events</td><td>P interaction (<i>APOL1</i>x SES measure)</td></tr><tr><td></td><td>High-risk versus Low-risk<i>APOL1</i>variants</td><td>Low SES versus Higher SES Group</td><td></td><td>High-risk versus Low-risk<i>APOL1</i>variants</td><td>Low SES versus Higher SES Group</td><td></td></tr><tr><td><i>Additive Models</i></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>APOL1</i>, Education</td><td>1.60 (1.00, 2.57)</td><td>1.95 (1.50, 2.54)</td><td>0.4</td><td>3.89 (2.28, 6.63)</td><td>1.68 (0.34, 8.23)</td><td>0.823</td></tr><tr><td><i>APOL1</i>, Employment</td><td>2.06 (1.53, 2.78)</td><td>4.64 (3.40, 6.33)</td><td>0.017*</td><td>3.12 (1.73, 5.63)</td><td>1.32 (0.83, 2.08)</td><td>0.894</td></tr><tr><td><i>APOL1</i>, Health Insurance</td><td>1.92 (1.27, 2.90)</td><td>1.00 (0.53, 1.89)</td><td>0.662</td><td>3.04 (1.65, 5.60)</td><td>0.56 (0.14, 2.28)</td><td>**could not be determined</td></tr><tr><td><i>APOL1</i>, Regular Health Care Source</td><td>1.91 (1.15, 3.17)</td><td>0.54 (0.31, 0.94)</td><td>0.871</td><td>3.09 (1.56, 6.13)</td><td>0.64 (0.14, 2.86)</td><td>**could not be determined</td></tr></table> |
f0566ba6d843eeb7f1d50a563675c73e4395844944a54e89c96fca00e7ac8dd8.png | complex | <table><tr><td></td><td></td><td colspan="2">ConditionN(%)Median(IQR)</td><td></td></tr><tr><td></td><td>All</td><td>Experimental (<i>n</i> = 58)</td><td>SOC+ (<i>n</i> = 70)</td><td><i>p</i>-value</td></tr><tr><td colspan="5">Product use for IVP in the prior month</td></tr><tr><td> Water</td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>10 (7.8%)</td><td>5 (8.6%)</td><td>5 (7.1%)</td><td></td></tr><tr><td>Yes</td><td>118 (92.2%)</td><td>53 (91.4%)</td><td>65 (92.9%)</td><td>0.755<sup>a</sup></td></tr><tr><td colspan="5"> Soap</td></tr><tr><td>No</td><td>39 (30.5%)</td><td>22 (37.9%)</td><td>17 (24.3%)</td><td></td></tr><tr><td>Yes</td><td>89 (69.5%)</td><td>36 (62.1%)</td><td>53 (75.7%)</td><td>0.095</td></tr><tr><td colspan="5"> Cloth, sponge or a rag</td></tr><tr><td>No</td><td>33 (47.1%)</td><td>27 (46.6%)</td><td>33 (47.1%)</td><td></td></tr><tr><td>Yes</td><td>68 (53.1%)</td><td>31 (53.4%)</td><td>37 (52.9%)</td><td>> 0.999</td></tr><tr><td> Traditional medicines</td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>91 (71.1%)</td><td>43 (74.1%)</td><td>48 (68.6%)</td><td></td></tr><tr><td>Yes</td><td>37 (28.9%)</td><td>15 (25.9%)</td><td>22 (31.4%)</td><td>0.489</td></tr><tr><td colspan="5"> Herbs or flowers from outdoors</td></tr><tr><td>No</td><td>103 (80.5%)</td><td>46 (79.3%)</td><td>57 (81.4%)</td><td></td></tr><tr><td>Yes</td><td>25 (19.5%)</td><td>12 (20.7%)</td><td>13 (18.6%)</td><td>0.763</td></tr><tr><td colspan="5"> Lemon</td></tr><tr><td>No</td><td>115 (89.3%)</td><td>52 (89.7%)</td><td>63 (90.0%)</td><td></td></tr><tr><td>Yes</td><td>13 (10.2%)</td><td>6 (10.3%)</td><td>7 (10.0%)</td><td>> 0.999</td></tr><tr><td colspan="5"> Salt</td></tr><tr><td>No</td><td>117 (91.4%)</td><td>54 (93.1%)</td><td>63 (90.0%)</td><td></td></tr><tr><td>Yes</td><td>11 (8.6%)</td><td>4 (6.9%)</td><td>7 (10.0%)</td><td>0.753<sup>a</sup></td></tr><tr><td colspan="5"> Vinegar</td></tr><tr><td>No</td><td>124 (96.9%)</td><td>56 (96.6%)</td><td>68 (97.1%)</td><td></td></tr><tr><td>Yes</td><td>4 (3.1%)</td><td>2 (3.4%)</td><td>2 (2.9%)</td><td>0.848<sup>a</sup></td></tr><tr><td colspan="5">Laboratory parameters</td></tr><tr><td colspan="5"> Abnormal vaginal flora</td></tr><tr><td>No</td><td>30 (23.4%)</td><td>16 (27.6%)</td><td>14 (20.0%)</td><td></td></tr><tr><td>Yes</td><td>98 (76.6%)</td><td>42 (72.4%)</td><td>56 (80.0%)</td><td>0.213</td></tr><tr><td colspan="5"> Bacterial vaginosis</td></tr><tr><td>No</td><td>47 (36.7%)</td><td>24 (41.4%)</td><td>23 (32.9%)</td><td></td></tr><tr><td>Yes</td><td>81 (63.3%)</td><td>34 (58.6%)</td><td>47 (67.1%)</td><td>0.319</td></tr><tr><td colspan="5"> Plasma HIV RNA</td></tr><tr><td>Undetectable</td><td>100 (78.1%)</td><td>46 (79.3%)</td><td>54 (77.1%)</td><td></td></tr><tr><td>Detectable</td><td>28 (21.9%)</td><td>12 (20.7%)</td><td>16 (22.9%)</td><td>0.768</td></tr><tr><td colspan="5"> CVL HIV RNA</td></tr><tr><td>Undetectable</td><td>108 (84.4%)</td><td>50 (86.2%)</td><td>58 (82.9%)</td><td></td></tr><tr><td>Detectable</td><td>20 (15.6%)</td><td>8 (13.8%)</td><td>12 (17.1%)</td><td>0.603</td></tr><tr><td colspan="5"> Lower genital tract cytokines</td></tr><tr><td>IL-6 (<i>n</i> = 68; Exp = 35, SOC+ = 33)</td><td>289.9 (258.0)</td><td>306.3 (313.7)</td><td>282.6 (249.1)</td><td>0.944</td></tr><tr><td>IL-8 (<i>n</i> = 68; Exp = 35, SOC+ = 33)</td><td>332.5 (1781.9)</td><td>380.11 (1311.9)</td><td>227.5 (2285.5)</td><td>< 0.001</td></tr></table> |
5dcad109e5dfee8883f010ac50be1d6d5531524fa952b12236c4e2f5a30ba269.png | complex | <table><tr><td>Exposure (exposure contrast)</td><td>n</td><td colspan="2">ABI < 0.9</td><td></td><td colspan="2">ABI > 1.3</td></tr><tr><td>NO2 (25 μg/m3)</td></tr><tr><td>Model 1a</td><td>2,698</td><td>0.65</td><td>(0.28, 1.52)</td><td>1.91</td><td>(1.09, 3.33)</td></tr><tr><td>Model 2b (possible intermediates)</td><td>2,600</td><td>0.72</td><td>(0.29, 1.75)</td><td>1.98</td><td>(1.09, 3.6)</td></tr><tr><td>Traffic load in a 100 m bufferc (7,200,000 veh-m/day)</td></tr><tr><td>Model 1</td><td>2,698</td><td>0.92</td><td>(0.37, 2.3)</td><td>1.89</td><td>(1.1, 3.26)</td></tr><tr><td>Model 2 (possible intermediates)</td><td>2,600</td><td>1.02</td><td>(0.4, 2.61)</td><td>1.89</td><td>(1.07, 3.34)</td></tr><tr><td>Traffic intensity in nearest street (15,000 veh/day)</td></tr><tr><td>Model 1</td><td>2,698</td><td>0.47</td><td>(0.16, 1.41)</td><td>1.6</td><td>(1.08, 2.38)</td></tr><tr><td>Model 2 (possible intermediates)</td><td>2,600</td><td>0.48</td><td>(0.16, 1.46)</td><td>1.7</td><td>(1.13, 2.57)</td></tr><tr><td colspan="7">veh, vehicle. aEstimates adjusted by model 1: sex, age,sex–age interaction, smoking status, education, and marital status.bEstimates adjusted by model 2: sex, age, sex–age interaction, smokingstatus, education, marital status, BMI, HDL, waist circumference,systolic and diastolic blood pressure, weekly energy expenditure inphysical activity during leisure time (tertiles), adherence toMediterranean diet, plausibility of reported diet, medication treatment,and percentage of persons with low education at the census-tract level.cModels for traffic load were additionally adjusted for occupationalstatus.</td></tr></table> |
1fffdd2f412cf16bdbe3086636102374032b276ce015b90469a4f37d482cc724.png | complex | <table><tr><td>Section</td><td>Award 1 point if</td></tr><tr><td colspan="2">Selection bias (3 pts.)</td></tr><tr><td> Goal and inclusion</td><td>Goal of the study is stated and study explicitly states the inclusion criteria</td></tr><tr><td> Selection of patients</td><td>Selective recruitment of patients can be ruled out</td></tr><tr><td> Patient characteristics</td><td>Study reports the age range and mean age and states the distribution of men and women</td></tr><tr><td colspan="2">Outcome bias (3 pts.)</td></tr><tr><td> Definition of subsidence</td><td>Definition of subsidence, classification, and radiological tools to measure subsidence were stated</td></tr><tr><td> Clinical outcome</td><td>Clinical outcome was systematically evaluated in correlation to subsidence</td></tr><tr><td> Preoperative status</td><td>Preoperative status was stated for comparison with postoperative status</td></tr><tr><td colspan="2">Follow-up bias (2 pts.)</td></tr><tr><td rowspan="5"> Follow-up period</td><td>Follow-up range, period, and mean were given:</td></tr><tr><td> • If yes and prospective study: 2 points</td></tr><tr><td> • If yes and retrospective study: 1 point</td></tr><tr><td> • If no, but loss to follow-up < 20%: 1 point</td></tr><tr><td> • If too little information: 0 points</td></tr><tr><td colspan="2">Other bias (3 pts.)</td></tr><tr><td> Clinical evaluation</td><td>Evaluation was done independently from treating physician</td></tr><tr><td> Radiologic evaluation</td><td>Evaluation was done by an independent party, blinded to clinical results</td></tr><tr><td> Independence</td><td>Independence is explicitly stated, conflict of interest can be ruled out</td></tr><tr><td>Total (11 points)</td><td></td></tr></table> |
a158166369e37e425c8af7da43c98c74e1af9b1d17b6a9e97cb7ae2e0fde38f5.png | complex | <table><tr><td rowspan="2">Erosion Ratio (%)</td><td colspan="6"><i>σ</i><sub>3</sub> (MPa)</td></tr><tr><td>0.36</td><td>0.72</td><td>1.44</td><td>2.88</td><td>5.76</td><td>11.52</td></tr><tr><td>0.0</td><td>333</td><td>688</td><td>1290</td><td>1332</td><td>2663</td><td>3590</td></tr><tr><td>3.0</td><td>229</td><td>688</td><td>688</td><td>917</td><td>1086</td><td>1101</td></tr><tr><td>6.5</td><td>235</td><td>356</td><td>356</td><td>938</td><td>1147</td><td>1131</td></tr><tr><td>10.0</td><td>184</td><td>369</td><td>491</td><td>590</td><td>851</td><td>786</td></tr><tr><td>15.0</td><td>195</td><td>382</td><td>389</td><td>523</td><td>516</td><td>594</td></tr></table> |
5ed2eaef454799628e229fb078b436ee12b565ab156495908fab6f401bc7180a.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">Students, N = 65</td><td colspan="2">Mothers, N = 63</td></tr><tr><td>Pre</td><td>Post</td><td>Pre</td><td>Post</td></tr><tr><td>Cervical cancer is caused by HPV infection?</td><td>46%</td><td>100%</td><td>86%</td><td>97%</td></tr><tr><td>Cervical cancer is genetic?</td><td>51%</td><td>63%</td><td>71%</td><td>81%</td></tr><tr><td>All HPV infections lead to cervical cancer?</td><td>75%</td><td>49%</td><td>89%</td><td>76%</td></tr><tr><td>Cervical cancer is decreasing in recent years?</td><td>83%</td><td>92%</td><td>100%</td><td>98%</td></tr><tr><td>Cervical cancer is preventable?</td><td>72%</td><td>97%</td><td>70%</td><td>78%</td></tr><tr><td>Cervical cancer is asymptomatic usually in early stage?</td><td>65%</td><td>97%</td><td>98%</td><td>98%</td></tr><tr><td>Early detection of cervical cancer might save one’s life?</td><td>85%</td><td>92%</td><td>95%</td><td>97%</td></tr><tr><td>HPV is sexually transmitted?</td><td>NA</td><td>NA</td><td>91%</td><td>97%</td></tr><tr><td>If vaccinated, you don’t need to be screened?</td><td>NA</td><td>NA</td><td>98%</td><td>97%</td></tr><tr><td>Screening test should be done regularly?</td><td>NA</td><td>NA</td><td>92%</td><td>95%</td></tr><tr><td>HPV vaccination can prevent cervical cancer</td><td>NA</td><td>NA</td><td>95%</td><td>95%</td></tr><tr><td>Safe sex (steady partner, use of condoms) can prevent cervical cancer</td><td>NA</td><td>NA</td><td>75%</td><td>89%</td></tr><tr><td>Pap test can prevent cervical cancer</td><td>NA</td><td>NA</td><td>94%</td><td>95%</td></tr><tr><td>Healthy lifestyle (ie., regular exercise, disciplined lifestyle, healthy diet) can prevent cervical cancer</td><td>NA</td><td>NA</td><td>11%</td><td>11%</td></tr></table> |
f213f6dd59b85054a6584c0c87a42f3c554551af7efdefa3f6785afe2741bbe2.png | simple | <table><tr><td> </td><td>AS</td><td>Rett</td><td>MWS</td><td>FOXG1</td><td>KS</td><td>PMS</td><td>PHS</td><td>CS</td><td>CDKL5</td><td>MEF2C </td><td>ARTX</td></tr><tr><td>Microcephaly</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td> </td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Seizure</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td> </td><td>+</td><td>+</td><td>+</td><td>+</td><td> </td></tr><tr><td>Speech impairment</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td> </td><td>+</td><td>+</td></tr><tr><td>Ataxia</td><td>+</td><td>+</td><td> </td><td> </td><td> </td><td> </td><td>+</td><td>+</td><td> </td><td>+</td><td> </td></tr><tr><td>Stereotypical hand movements</td><td>+/−</td><td>+</td><td> </td><td>+</td><td> </td><td> </td><td>+</td><td> </td><td>+</td><td>+</td><td> </td></tr><tr><td>Tremulous/jerky limb movements </td><td>+</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Happy predisposition</td><td>+</td><td>+</td><td>+</td><td> </td><td> </td><td> </td><td>+</td><td> </td><td> </td><td> </td><td>+</td></tr><tr><td>Abnormal MRI</td><td> </td><td> </td><td>+</td><td>+</td><td> </td><td>+</td><td>+</td><td>+</td><td> </td><td> </td><td> </td></tr><tr><td>Hyperventilation/apnea episode</td><td> </td><td>+</td><td> </td><td> </td><td> </td><td> </td><td>+</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Sleep disturbances</td><td>+</td><td>+</td><td> </td><td>+</td><td>+</td><td>+</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Hirschsprung disease</td><td> </td><td> </td><td>+</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Lack of purposeful hand use</td><td> </td><td>+</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Prominent jaw/chin</td><td>+</td><td> </td><td>+</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Wide mouth </td><td>+</td><td> </td><td>+</td><td> </td><td> </td><td> </td><td>+</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Upturned ear lobes</td><td> </td><td> </td><td>+</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Genital anomalies</td><td> </td><td> </td><td> </td><td> </td><td>+</td><td> </td><td> </td><td> </td><td> </td><td> </td><td>+</td></tr><tr><td>Congenital heart disease </td><td> </td><td> </td><td>+</td><td> </td><td>+</td><td> </td><td> </td><td> </td><td> </td><td> </td><td>+</td></tr><tr><td>Developmental regression </td><td> </td><td>+</td><td> </td><td> </td><td> </td><td>+</td><td> </td><td>+</td><td> </td><td> </td><td> </td></tr><tr><td>Others </td><td> </td><td>In female only</td><td> </td><td> </td><td> </td><td>Mild overgrowth </td><td>Persistent finger pad Constipation</td><td>In male only </td><td> </td><td> </td><td>In male only HbH in blood smear</td></tr></table> |
45698c53a3ca3554d339ac5032d4d9bd2b731968ea251b741df6ee8fb417cffa.png | complex | <table><tr><td rowspan="2">Variable</td><td rowspan="2">Response options</td><td colspan="2">Total motorcycle riders</td><td colspan="2">Non-helmet user</td></tr><tr><td>Number</td><td>%</td><td>Number</td><td>%</td></tr><tr><td colspan="6">Helmet use experiences and attitudes</td></tr><tr><td rowspan="2">Been in accident before </td><td>No</td><td>12,649</td><td>66.6</td><td>5,479</td><td>43.5</td></tr><tr><td>Yes</td><td>6,349</td><td>33.4</td><td>2,890</td><td>45.7</td></tr><tr><td rowspan="3">Rider status when in accident </td><td>Rider</td><td>4,557</td><td>75.7</td><td>2,146</td><td>47.2</td></tr><tr><td>Passenger</td><td>1,370</td><td>22.8</td><td>601</td><td>44.1</td></tr><tr><td>Pedestrian</td><td>93</td><td>1.5</td><td>37</td><td>39.8</td></tr><tr><td rowspan="2">Have you ever used a helmet before</td><td>No</td><td>7,600</td><td>40.2</td><td>5,925</td><td>52.6</td></tr><tr><td>Yes</td><td>11,290</td><td>59.8</td><td>2,395</td><td>31.7</td></tr><tr><td rowspan="2">Perceived danger of not using a helmet</td><td>No</td><td>4,720</td><td>25.0</td><td>2,008</td><td>42.7</td></tr><tr><td>Yes</td><td>14,175</td><td>75.0</td><td>6,316</td><td>44.7</td></tr><tr><td rowspan="3">Aware of danger of not using a helmet </td><td>Low</td><td>840</td><td>4.4</td><td>425</td><td>50.7</td></tr><tr><td>Moderate</td><td>7,525</td><td>39.8</td><td>3,328</td><td>44.4</td></tr><tr><td>High</td><td>10,544</td><td>55.8</td><td>4,580</td><td>43.6</td></tr><tr><td rowspan="4">Perceived risk about being caught by the police because of not using a helmet</td><td>High risk</td><td>7,788</td><td>41.3</td><td>3,602</td><td>46.4</td></tr><tr><td>Moderate risk</td><td>7,411</td><td>39.3</td><td>3,271</td><td>44.3</td></tr><tr><td>Low risk</td><td>2,078</td><td>11.0</td><td>855</td><td>41.3</td></tr><tr><td>No risk</td><td>1,595</td><td>8.5</td><td>584</td><td>36.7</td></tr><tr><td rowspan="2">Ever been caught by police because of not using a helmet</td><td>No</td><td>8,918</td><td>52.8</td><td>3,839</td><td>38.6</td></tr><tr><td>Yes</td><td>9,983</td><td>47.2</td><td>4,483</td><td>50.4</td></tr><tr><td colspan="6">Exposure to road safety awareness (RSA) campaign</td></tr><tr><td rowspan="2">Heard advertising campaign on RSA </td><td>No</td><td>3,066</td><td>16.1</td><td>1,428</td><td>46.9</td></tr><tr><td>Yes</td><td>15,926</td><td>83.9</td><td>6,938</td><td>43.7</td></tr><tr><td rowspan="4">RTI campaign on radio or TV </td><td>Never</td><td>2,476</td><td>13.2</td><td>1,198</td><td>48.5</td></tr><tr><td>Not often</td><td>10,253</td><td>54.5</td><td>4,391</td><td>43.0</td></tr><tr><td>Frequently</td><td>5,493</td><td>29.2</td><td>2,409</td><td>44.0</td></tr><tr><td>Not sure</td><td>587</td><td>3.1</td><td>272</td><td>46.4</td></tr><tr><td rowspan="3">Talking to others about RSA in the media </td><td>Never</td><td>7,729</td><td>40.8</td><td>3,789</td><td>49.2</td></tr><tr><td>Ever</td><td>7,600</td><td>40.1</td><td>3,031</td><td>40.0</td></tr><tr><td>Not sure</td><td>3,620</td><td>19.1</td><td>1,533</td><td>42.6</td></tr><tr><td rowspan="5">How feel about RSA media </td><td>Not like</td><td>1,119</td><td>5.9</td><td>560</td><td>50.0</td></tr><tr><td>Like a little bit</td><td>11,676</td><td>61.7</td><td>5,148</td><td>44.3</td></tr><tr><td>Like very </td><td>5,173</td><td>27.3</td><td>2,205</td><td>42.7</td></tr><tr><td>much</td><td>955</td><td>5.0</td><td>433</td><td>45.4</td></tr><tr><td>Not sure</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="4">Follows the TV news report on RSA statistics </td><td>Never</td><td>2,614</td><td>13.8</td><td>1,256</td><td>48.2</td></tr><tr><td>Not often</td><td>9,841</td><td>52.0</td><td>4,415</td><td>45.0</td></tr><tr><td>Frequently</td><td>5,552</td><td>29.3</td><td>2,244</td><td>40.6</td></tr><tr><td>Not sure</td><td>912</td><td>4.8</td><td>436</td><td>48.2</td></tr></table> |
8520978a5bf5b506f7afcc29321fe2d9530e163f5012adb912c03a339a164f02.png | complex | <table><tr><td></td><td colspan="2">Conventional CPB</td><td colspan="2">Mini-CPB</td><td><i>P</i> value</td></tr><tr><td>Patients (no.)</td><td>22</td><td></td><td>22</td><td></td><td></td></tr><tr><td>Women/men (no.)</td><td>4/18</td><td></td><td>2/20</td><td></td><td>0.66</td></tr><tr><td>Age (years)</td><td>68</td><td>(63–71)</td><td>69</td><td>(66–74)</td><td>0.57</td></tr><tr><td>Body mass index</td><td>28.5</td><td>(25.3–32)</td><td>26.5</td><td>(25–31.3)</td><td>0.38</td></tr><tr><td>Acetylsalicylic acid (no.)</td><td>21</td><td></td><td>21</td><td></td><td></td></tr><tr><td>Beta blockers (no.)</td><td>21</td><td></td><td>20</td><td></td><td></td></tr><tr><td>ACE inhibitors (no.)</td><td>16</td><td></td><td>18</td><td></td><td>0.72</td></tr><tr><td>Statins (no.)</td><td>21</td><td></td><td>20</td><td></td><td></td></tr><tr><td>Diabetes mellitus (no.)</td><td>4</td><td></td><td>6</td><td></td><td>0.72</td></tr><tr><td>COPD (no.)</td><td>3</td><td></td><td>4</td><td></td><td></td></tr><tr><td>Prior myocardial infarction (no.)</td><td>12</td><td></td><td>9</td><td></td><td>0.37</td></tr><tr><td>Leukocytes (cells ×10<sup>9</sup>/L)</td><td>7.5</td><td>(6.8–8.5)</td><td>7.1</td><td>(6.3–8.8)</td><td>0.8</td></tr><tr><td>Ejection fraction (%)</td><td>64.5</td><td>(51.3–69.8)</td><td>60</td><td>(48.5–69.5)</td><td>0.35</td></tr></table> |
eb8f8033bfdd63cf00fdfcd47e0e3b4724092902b4227ed6e2079d0e04b876eb.png | simple | <table><tr><td>Cluster ID</td><td>#sequences</td><td>#non-redundant sequences</td><td>Description</td></tr><tr><td>CAM_CL_2057</td><td>20,508</td><td>24</td><td>Reverse transcriptase (HIV)</td></tr><tr><td>CAM_CL_1132</td><td>18,882</td><td>1,406</td><td>Cytochrome c oxidase subunit I</td></tr><tr><td>CAM_CL_2568</td><td>15,405</td><td>6,091</td><td>ABC transporter</td></tr><tr><td>CAM_CL_4367</td><td>15,228</td><td>771</td><td>Cytochrome b</td></tr><tr><td>CAM_CL_49</td><td>14,751</td><td>7,389</td><td>Short-chain dehydrogenase</td></tr><tr><td>CAM_CL_3510</td><td>13,255</td><td>5,173</td><td>Immunoglobulin</td></tr><tr><td>CAM_CL_2630</td><td>13,140</td><td>3,297</td><td>Envelope glycoprotein</td></tr><tr><td>CAM_CL_160</td><td>13,054</td><td>3,897</td><td>Kinases</td></tr><tr><td>CAM_CL_4556</td><td>12,403</td><td>6,345</td><td>Response regulator</td></tr><tr><td>CAM_CL_481</td><td>12,078</td><td>5,477</td><td>Transcription regulator</td></tr></table> |
a3c25689a8c02397be1171e9b2012d567596330d75e0fb26f76fdafb54fb25f8.png | complex | <table><tr><td rowspan="2">Cell line</td><td colspan="3">dCK activity</td><td colspan="3">dGK activity</td></tr><tr><td>48 h</td><td>72 h</td><td>Quiescence</td><td>48 h</td><td>72 h</td><td>Quiescence</td></tr><tr><td></td><td colspan="3"><i>pmol/min/mg</i></td><td colspan="3"><i>pmol/min/mg</i></td></tr><tr><td>C1</td><td>19.3 ± 0.8</td><td>13.6 ± 0.6</td><td>7.3 ± 0.1</td><td>0.31 ± 0.02</td><td>0.31 ± 0.06</td><td>0.61 ± 0.18</td></tr><tr><td>C2</td><td>17.1 ± 0.2</td><td>12.9 ± 0.2</td><td>5.8 ± 0.2</td><td>0.20 ± 0.02</td><td>0.41 ± 0.03</td><td>0.43 ± 0.02</td></tr><tr><td>P1</td><td>14.8 ± 0.9</td><td>10.7 ± 0.4</td><td>9.5 ± 0.3</td><td>≤0.01</td><td>0.03 ± 0.01</td><td>0.02 ± 0.00</td></tr><tr><td>P2</td><td>14.5 ± 0.2</td><td>13.5 ± 0.1</td><td>8.1 ± 1.4</td><td>0.04 ± 0.01</td><td>0.05 ± 0.00</td><td>≤0.01</td></tr><tr><td>P3</td><td>16.5 ± 0.3</td><td>11.4 ± 0.2</td><td>8.0 ± 1.2</td><td>0.04 ± 0.01</td><td>0.16 ± 0.01</td><td>≤0.01</td></tr></table> |
a0167810805f6be70fdf9c98fac8a5cc8dbceb0009b69ebcb10151ec0cd1ec62.png | complex | <table><tr><td rowspan="2">Dependant Variable</td><td colspan="2">Worse-than-Dead</td><td colspan="2">Euthanasia</td></tr><tr><td>Coefficient</td><td>Standard Error</td><td>Coefficient</td><td>Standard Error</td></tr><tr><td>Third Level Education</td><td>−0.155</td><td>(0.167)</td><td>−0.077</td><td>(0.255)</td></tr><tr><td colspan="5">Age Group (Base: 18–35)</td></tr><tr><td> 36–45</td><td>0.304</td><td>(0.207)</td><td>0.328</td><td>(0.32)</td></tr><tr><td> 46–60</td><td>0.471*</td><td>(0.228)</td><td>0.318</td><td>(0.42)</td></tr><tr><td> 61+</td><td>1.168***</td><td>(0.274)</td><td>0.585</td><td>(0.489)</td></tr><tr><td>Male</td><td>−0.298</td><td>(0.17)</td><td>−0.113</td><td>(0.251)</td></tr><tr><td>Married/Living as Married</td><td>−0.158</td><td>(0.204)</td><td>−0.07</td><td>(0.303)</td></tr><tr><td>Dependants Under 18 (Y/N)</td><td>−0.098</td><td>(0.208)</td><td>0.412</td><td>(0.359)</td></tr><tr><td>Visual Analogue Scale</td><td>0.004</td><td>(0.006)</td><td>−0.012</td><td>(0.008)</td></tr><tr><td>Experienced a serious illness</td><td>−0.287</td><td>(0.264)</td><td>−0.765*</td><td>(0.3)</td></tr><tr><td>In favour of Legalisation of Euthanasia (see scenario in Fig. 1)</td><td>1.003*</td><td>(0.394)</td><td>–</td><td>–</td></tr><tr><td colspan="5">Religiosity (Base: A few times a year or less)</td></tr><tr><td> Monthly</td><td>–</td><td>–</td><td>−0.454</td><td>(0.318)</td></tr><tr><td> Weekly</td><td>–</td><td>–</td><td>−1.369***</td><td>(0.328)</td></tr><tr><td colspan="5">Mobility (Base: No Problems)</td></tr><tr><td> Slight problems</td><td>0.194</td><td>(0.114)</td><td>–</td><td>–</td></tr><tr><td> Moderate problems</td><td>0.326**</td><td>(0.109)</td><td>–</td><td>–</td></tr><tr><td> Severe problems</td><td>0.476***</td><td>(0.12)</td><td>–</td><td>–</td></tr><tr><td> Unable</td><td>0.419***</td><td>(0.112)</td><td>–</td><td>–</td></tr><tr><td colspan="5">Self-care (Base: No Problems)</td></tr><tr><td> Slight problems</td><td>0.263*</td><td>(0.128)</td><td>–</td><td>–</td></tr><tr><td> Moderate problems</td><td>0.34*</td><td>(0.131)</td><td>–</td><td>–</td></tr><tr><td> Severe problems</td><td>0.528***</td><td>(0.143)</td><td>–</td><td>–</td></tr><tr><td> Unable</td><td>0.444***</td><td>(0.102)</td><td>–</td><td>–</td></tr><tr><td colspan="5">Usual Activities (Base: No Problems)</td></tr><tr><td> Slight problems</td><td>0.304*</td><td>(0.134)</td><td>–</td><td>–</td></tr><tr><td> Moderate problems</td><td>0.477**</td><td>(0.156)</td><td>–</td><td>–</td></tr><tr><td> Severe problems</td><td>0.443***</td><td>(0.118)</td><td>–</td><td>–</td></tr><tr><td> Unable</td><td>0.335***</td><td>(0.091)</td><td>–</td><td>–</td></tr><tr><td colspan="5">Paid/Discomfort (Base: No Problems)</td></tr><tr><td> Slight problems</td><td>0.253*</td><td>(0.116)</td><td>–</td><td>–</td></tr><tr><td> Moderate problems</td><td>0.182</td><td>(0.116)</td><td>–</td><td>–</td></tr><tr><td> Severe problems</td><td>0.614***</td><td>(0.111)</td><td>–</td><td>–</td></tr><tr><td> Extreme problems</td><td>0.852***</td><td>(0.138)</td><td>–</td><td>–</td></tr><tr><td colspan="5">Anxiety/Depression (Base: No Problems)</td></tr><tr><td> Slight problems</td><td>0.221</td><td>(0.128)</td><td>–</td><td>–</td></tr><tr><td> Moderate problems</td><td>0.313*</td><td>(0.14)</td><td>–</td><td>–</td></tr><tr><td> Severe problems</td><td>0.867***</td><td>(0.159)</td><td>–</td><td>–</td></tr><tr><td> Extreme problems</td><td>0.858***</td><td>(0.133)</td><td>–</td><td>–</td></tr><tr><td>Constant</td><td>−3.331***</td><td>(0.626)</td><td>2.05**</td><td>(0.748)</td></tr><tr><td>Rho<sup>a</sup></td><td></td><td></td><td>−0.801*</td><td>(0.402)</td></tr><tr><td>Number of observations<sup>a</sup></td><td></td><td></td><td></td><td>1600</td></tr><tr><td>Number of clusters<sup>a</sup></td><td></td><td></td><td></td><td>160</td></tr></table> |
f3b27493ba90f7d54bd3aab218f6ef39925f7249bff347d8a3e67fa807ccf10a.png | simple | <table><tr><td>Clinical trial</td><td>Number of patients</td><td>Experimental arm</td><td>Control arm</td><td>Overall/annual fracture incidence</td><td>References</td></tr><tr><td>ATAC</td><td>9366</td><td>Anastrozole</td><td>Tamoxifen</td><td>Overall: 11 vs. 7.7%Annual: 2.93 vs. 1.90%</td><td>[57, 58]</td></tr><tr><td>IBIS II bone sub-study</td><td>1410</td><td>Anastrozole</td><td>Placebo</td><td>Annual: 1.37 vs. 1.26%</td><td>[100]</td></tr><tr><td>BIG 1.98</td><td>4895</td><td>Letrozole</td><td>Tamoxifen</td><td>Overall: 9.3 vs. 6.5%Annual: 2.71 vs. 1.872%</td><td>[59]</td></tr><tr><td>MA-17</td><td>5187</td><td>Letrozole</td><td>Placebo</td><td>Overall: 3.6 vs. 2.9%</td><td>[60]</td></tr><tr><td>IES</td><td>4274</td><td>Exemestane</td><td>Tamoxifen</td><td>Overall: 7 vs. 5%Annual: 2.01 vs. 1.60%</td><td>[61]</td></tr><tr><td>ABCSG-18</td><td>3420</td><td>AI + denosumab</td><td>AI + placebo</td><td>Overall: 5 vs. 9.6%</td><td>[107]</td></tr></table> |
595dc48fb8d19770385b0f0aff740ac55ffaa157f56c5ff85acd50376427cffb.png | simple | <table><tr><td>Instrument</td><td>Baseline</td><td>Follow-up</td></tr><tr><td>SCAN [38]</td><td>x</td><td></td></tr><tr><td>PANSS [41]</td><td>x</td><td>x</td></tr><tr><td>Insight Scale [39]</td><td>x</td><td>x</td></tr><tr><td>Early Signs Scale [40]</td><td>x</td><td>x</td></tr><tr><td>DUP [42]</td><td></td><td>x</td></tr><tr><td>PAS [44]</td><td></td><td>x</td></tr><tr><td>Encounter Form [45]</td><td></td><td>x</td></tr></table> |
46d1d68d8938f02a7b827cce6fe32e939a524e154c2e77581fcb25d13c56eb16.png | simple | <table><tr><td><i>How detected</i></td><td>% of total</td></tr><tr><td>Test recommended by general practitioners</td><td>27.1</td></tr><tr><td>Sexual partner tracing</td><td>21.7</td></tr><tr><td>Voluntary testing</td><td>12.1</td></tr><tr><td>Blood donors</td><td>9.7</td></tr><tr><td>HIV test done in hospitals</td><td>8.9</td></tr><tr><td>Persons with other sexually transmitted infections</td><td>8.3</td></tr><tr><td>Pregnant women</td><td>1.6</td></tr><tr><td>Other</td><td>10.6</td></tr><tr><td><i>Total</i></td><td>100% (n = 4276)</td></tr></table> |
c3f901d1efc53ce42b67908cc57c12c330f69467e1d7c8d5260bc953dd889f46.png | simple | <table><tr><td>Gender</td><td>NO. examined</td><td>NO. positive</td><td>Prevalence (%)</td></tr><tr><td>Male</td><td>52</td><td>9</td><td>17.31</td></tr><tr><td>Female</td><td>140</td><td>11</td><td>7.86</td></tr><tr><td>Total</td><td>192</td><td>20</td><td>10.42</td></tr></table> |
48bfebcd2c8d3198092dab020e613da789846aac0261209e6efa2d73c21bc5bb.png | complex | <table><tr><td>Objective</td><td>Activity</td></tr><tr><td>Training To understand the nutrient content and ingredients in processed and fast food and make a homemade burger</td><td>‘Ready, steady, cook’. Demonstration used a fast food burger recipe to illustrate poor quality of ‘fast food’. Peer supporters then made their own burger for lunch (meat or vegetarian) to demonstrate the difference in ingredients</td></tr><tr><td> To taste different fruit and vegetables</td><td>‘Taste trial’. Fresh fruit and vegetables were plated. Peer supporter volunteers were blindfolded and asked to guess the name of the fruit or vegetable they had tried, and describe the taste and texture</td></tr><tr><td> To emphasize the range of physical activity options</td><td>‘A-Z’. Peer supporters were asked to think of a physical activity beginning with each letter of the alphabet</td></tr><tr><td> To understand what sedentary behaviour is and its health implications</td><td>‘Before and after’ role plays. Sedentary behaviour (before) changed to active behaviour (after), e.g. taking the lift changed to walking the stairs</td></tr><tr><td> To consider barriers to physical activity and think of solutions</td><td>‘Barrier wall’. A wall of cardboard box ‘bricks’ was constructed. Peer supporters were asked to think of barriers to physical activity, which were written onto the bricks. Peer supporters who thought of solutions to barriers were allowed to remove the relevant brick until the wall was demolished</td></tr><tr><td> To develop communication skills for their role</td><td>‘Role play’. Peer supporters improvised conversations with their peers based on key messages about physical activity or healthy eating</td></tr><tr><td> To use goal setting to change health behaviour</td><td>‘Goal setting’. Peer supporters set themselves a small challenge in relation to physical activity or healthy eating. This was revisited at the follow-up sessions</td></tr><tr><td colspan="2">Support ‘follow-up sessions’</td></tr><tr><td> To understand the salt, sugar, fat and fibre content of various foods</td><td>A game of top trump cards. Cards display different food products. The winning card has the ‘healthiest’ level of a selected ingredient, e.g. salt, sugar, fat or fibre</td></tr><tr><td> To remind peer supporters of the importance of breakfast</td><td>A morning session with a discussion about how to make healthy choices at breakfast during which volunteers serve breakfast to their peers</td></tr><tr><td> To evaluate health promotion posters</td><td>Peer supporters complete jigsaws of current health promotion posters relating to physical activity and healthy eating, and discuss which they consider would have the greatest impact on their peers</td></tr><tr><td> To experience physical activity</td><td>Physical activity sessions including skipping, circus skills and Frisbee</td></tr></table> |
2655e12d6ed652a3533a02fa3336c77ba9589c0f4f4aed9288143129fad56bc9.png | complex | <table><tr><td></td><td>RA</td><td>AS</td><td>HC</td><td>P</td></tr><tr><td colspan="5">HAT (ng/h/mg)</td></tr><tr><td>(mean ± SEM)</td><td>126.8 ± 16.4</td><td>68.2 ± 8.1</td><td>111.3 ± 15.5</td><td>RA <i>vs</i> HC:NS*</td></tr><tr><td></td><td></td><td></td><td></td><td>AS <i>vs</i> HC: p=0.05*</td></tr><tr><td colspan="5">HDAC (pmol/min/mg)</td></tr><tr><td>(mean ± SEM)</td><td>3915.9 ±790.3</td><td>1984.6 ± 249.0</td><td>4778.9 ± 752.3</td><td>RA vs HC:NS*</td></tr><tr><td></td><td></td><td></td><td></td><td>AS vs HC: p=0.01*</td></tr><tr><td colspan="5">Ratio HDAC/HAT</td></tr><tr><td>(mean ± SEM)</td><td>49.1 ± 16.7</td><td>35.6 ± 6.9</td><td>65.4 ± 16.7</td><td>NS*</td></tr><tr><td colspan="5">HAT + TSA (ng/h/mg)</td></tr><tr><td>(mean ± SEM)</td><td>153.2 ± 30.3</td><td>81.2 ± 9.9</td><td>112.6 ± 21</td><td>HAT <i>vs</i> HAT + TSA**:HC:NS</td></tr><tr><td></td><td></td><td></td><td></td><td>RA: NS AS: NS</td></tr><tr><td colspan="5">HAT + Sirt (ng/h/mg)</td></tr><tr><td>(mean ± SEM)</td><td>113.1 ± 14.0</td><td>71.9 ± 6.2</td><td>107.9 ± 15.9</td><td>HAT <i>vs</i> HAT+ Sirt** HC:NS</td></tr><tr><td></td><td></td><td></td><td></td><td>RA: p = 0.01</td></tr><tr><td></td><td></td><td></td><td></td><td>AS: NS</td></tr><tr><td colspan="5">HDAC + TSA (pmol/min/mg)</td></tr><tr><td>(mean ± SEM)</td><td>2457.1± 316.4</td><td>2134.2 ± 426.3</td><td>3450.6 ± 709.1</td><td>HDAC <i>vs</i> HDAC + TSA** HC:NS</td></tr><tr><td></td><td></td><td></td><td></td><td>RA: NS AS: NS</td></tr><tr><td colspan="5">HDAC + Sirt (pmol/min/mg)</td></tr><tr><td>(mean ± SEM)</td><td>2440.6 ± 446.4</td><td>1975.4 ± 313.2</td><td>2341.6 ± 242.7</td><td>HDAC <i>vs</i> HDAC + Sirt**</td></tr><tr><td></td><td></td><td></td><td></td><td>HC: p = 0.07</td></tr><tr><td></td><td></td><td></td><td></td><td>RA: NS AS: NS</td></tr></table> |
523253ca629cf682dc28e137903f3a934900c837816e734a2a5e9cfcc248c2f1.png | simple | <table><tr><td>Path</td><td>Mediator</td><td>Coeff.</td><td><i>SE</i></td><td><i>t</i></td><td><i>p</i></td></tr><tr><td>Interaction variable to mediators</td><td>Identity Compatibility</td><td>0.12</td><td>0.04</td><td>2.93</td><td>0.00</td></tr><tr><td></td><td>Identity Expression</td><td>0.08</td><td>0.04</td><td>2.29</td><td>0.02</td></tr><tr><td>Mediators to outcome variable</td><td>Identity Compatibility</td><td>0.24</td><td>0.12</td><td>1.96</td><td>0.05</td></tr><tr><td></td><td>Identity Expression</td><td>0.26</td><td>0.10</td><td>2.49</td><td>0.01</td></tr></table> |
109f15295f6b080b3155efd96dd35837df49b47c08834c84d79e3e062e1396b9.png | complex | <table><tr><td rowspan="2">Variable</td><td rowspan="2">B</td><td rowspan="2">SE</td><td rowspan="2">Wald</td><td rowspan="2"><i>P</i> value</td><td rowspan="2">Odds ratio</td><td colspan="2">95 % confidence interval for EXP(B)</td></tr><tr><td>Lower limit</td><td>Upper limit</td></tr><tr><td>Percentage of monocytes expressing PD-L1</td><td>1.943</td><td>0.745</td><td>6.811</td><td>0.009</td><td>6.981</td><td>1.622</td><td>30.041</td></tr><tr><td>Lymphocytes</td><td>0.088</td><td>0.794</td><td>0.012</td><td>0.912</td><td>1.092</td><td>0.230</td><td>5.173</td></tr><tr><td>SOFA score</td><td>1.550</td><td>0.687</td><td>5.091</td><td>0.024</td><td>4.713</td><td>1.226</td><td>18.117</td></tr><tr><td>SAPS II</td><td>1.558</td><td>0.723</td><td>4.646</td><td>0.031</td><td>4.749</td><td>1.152</td><td>19.584</td></tr><tr><td>Number of comorbidities</td><td>1.887</td><td>0.726</td><td>6.761</td><td>0.009</td><td>6.598</td><td>1.591</td><td>27.352</td></tr><tr><td>Constant</td><td>−4.133</td><td>0.918</td><td>20.256</td><td>0.000</td><td>0.016</td><td></td><td></td></tr></table> |
d1a9801fa1281cf82e9d96437a8683f780970512639bfa30efb56defed097c18.png | simple | <table><tr><td>Psychological and other health measures (Denominator<sup>a</sup>)</td><td><i>n</i> = 609</td></tr><tr><td>HADs anxiety subscale (607)</td><td></td></tr><tr><td> Normal</td><td>316 (52.1)</td></tr><tr><td> Mild/possible case</td><td>120 (19.8)</td></tr><tr><td> Probable/moderate/severe case</td><td>171 (28.2)</td></tr><tr><td>HADs depression subscale (609)</td><td></td></tr><tr><td> Normal</td><td>392 (64.4)</td></tr><tr><td> Mild/possible case</td><td>119 (19.5)</td></tr><tr><td> Probable/moderate/severe case</td><td>98 (16.1)</td></tr><tr><td>Pain self-efficacy score (593), mean (SD)</td><td>34.1 (14.6)</td></tr><tr><td>Illness perceptions questionnaire-short form (IPQ-R)</td><td></td></tr><tr><td> Timeline-‘back/leg pain will last for a long time (agree or strongly agree) (609)</td><td>345 (56.7)</td></tr><tr><td> Personal control-‘what I do can determine whether back/leg pain gets better (agree or strongly agree) (605)</td><td>367 (60.7)</td></tr><tr><td> Identity score (0–7) (584), mean (SD)</td><td>5.9 (1.3)</td></tr><tr><td>General Health (608)</td><td></td></tr><tr><td> Excellent/very good</td><td>146 (24.0)</td></tr><tr><td> Good</td><td>241 (39.5)</td></tr><tr><td> Fair</td><td>172 (28.3)</td></tr><tr><td> Poor</td><td>50 (8.2)</td></tr><tr><td><i>Co-morbidities</i><sup>b</sup><i>(609)</i></td><td></td></tr><tr><td> None</td><td>371 (60.9)</td></tr><tr><td> One other health problem</td><td>158 (25.9)</td></tr><tr><td> Two or more other health problems</td><td>80 (13.1)</td></tr><tr><td>EQ—5D—3L summary index (590)</td><td>0.44 (0.32)</td></tr></table> |
7d2633c6345a34747376b859c4457ede23985e9d00488354c587bbc00f6adda0.png | complex | <table><tr><td>Patient’s parameters</td><td>Low (<i>n</i> = 82)</td><td>High (<i>n</i> = 79)</td><td><i>P</i> value</td></tr><tr><td>Sex, male/female</td><td>44/38</td><td>54/25</td><td>0.075</td></tr><tr><td>Median age, years (range)</td><td>51.5 (10–87)</td><td>61 (17–93)</td><td>0.009</td></tr><tr><td>Median WBC, × 10<sup>9</sup>/L (range)</td><td>7.7 (1.0–185.4)</td><td>31.1 (0.3–528.0)</td><td>0.004</td></tr><tr><td>Median hemoglobin, g/L (range)</td><td>75 (40–133)</td><td>78.5 (32–144)</td><td>0.144</td></tr><tr><td>Median platelets, × 10<sup>9</sup>/L (range)</td><td>42 (5–447)</td><td>33 (3–399)</td><td>0.262</td></tr><tr><td>Median BM blasts, % (range)</td><td>44 (3.0–94.5)</td><td>43 (1–99)</td><td>0.339</td></tr><tr><td colspan="3">Karyotype classification</td><td>0.010</td></tr><tr><td> Favorable</td><td>29 (35%)</td><td>14 (18%)</td><td></td></tr><tr><td> Intermediate</td><td>37 (45%)</td><td>55 (70%)</td><td></td></tr><tr><td> Poor</td><td>12 (15%)</td><td>9 (11%)</td><td></td></tr><tr><td> No data</td><td>4 (5%)</td><td>1 (1%)</td><td></td></tr><tr><td colspan="3">Karyotype</td><td>0.048</td></tr><tr><td> Normal</td><td>28 (34%)</td><td>42 (54%)</td><td></td></tr><tr><td> t(8;21)</td><td>7 (9%)</td><td>5 (6%)</td><td></td></tr><tr><td> t(16;16)</td><td>0 (0%)</td><td>1 (1%)</td><td></td></tr><tr><td> t(15;17)</td><td>22 (27%)</td><td>8 (10%)</td><td></td></tr><tr><td> t(9;22)</td><td>0 (0%)</td><td>1 (1%)</td><td></td></tr><tr><td> + 8</td><td>3 (4%)</td><td>4 (5%)</td><td></td></tr><tr><td> − 5/5q−</td><td>1 (1%)</td><td>2 (3%)</td><td></td></tr><tr><td> − 7/7q−</td><td>1 (1%)</td><td>0 (0%)</td><td></td></tr><tr><td> Complex</td><td>10 (12%)</td><td>6 (8%)</td><td></td></tr><tr><td> Others</td><td>6 (7%)</td><td>9 (11%)</td><td></td></tr><tr><td> No data</td><td>4 (5%)</td><td>1 (1%)</td><td></td></tr><tr><td colspan="4">Gene mutation</td></tr><tr><td> <i>CEBPA</i> (+/−)</td><td>10/66</td><td>7/61</td><td>0.617</td></tr><tr><td> <i>NPM1</i> (+/−)</td><td>6/70</td><td>11/57</td><td>0.195</td></tr><tr><td> <i>FLT3</i>-ITD (+/−)</td><td>6/70</td><td>13/55</td><td>0.053</td></tr><tr><td> <i>c-KIT</i> (+/−)</td><td>4/72</td><td>1/67</td><td>0.370</td></tr><tr><td> <i>N/K-RAS</i> (+/−)</td><td>4/72</td><td>8/60</td><td>0.228</td></tr><tr><td> <i>IDH1/2</i> (+/−)</td><td>2/74</td><td>6/62</td><td>0.149</td></tr><tr><td> <i>DNMT3A</i> (+/−)</td><td>2/74</td><td>9/59</td><td>0.025</td></tr><tr><td> <i>U2AF1</i> (+/−)</td><td>3/73</td><td>3/65</td><td>1.000</td></tr><tr><td> <i>SRSF2</i> (+/−)</td><td>3/75</td><td>4/66</td><td>0.708</td></tr><tr><td> <i>SETBP1</i> (+/−)</td><td>1/77</td><td>1/69</td><td>1.000</td></tr><tr><td>CR (+/−)</td><td>40/35</td><td>22/52</td><td>0.005</td></tr></table> |
ef5edf48829192bb390fd9319452f96947789b84d3d37f4705d454517759f331.png | simple | <table><tr><td></td><td>The Akershus Birth Cohort Study</td><td>All woman who gave birth in Norway in 2010</td></tr><tr><td>Mean maternal age</td><td>31.3 years</td><td>30.2 years</td></tr><tr><td>First time mothers</td><td>48.9 %</td><td>42.6 %</td></tr><tr><td>Smoking during pregnancy</td><td>6.6 %</td><td>7.2 %</td></tr><tr><td>Single women</td><td>1.1 %</td><td>9.1 %</td></tr><tr><td>Elective caesarean section</td><td>5.0 %</td><td>6.5 %</td></tr></table> |
a7ab1155c4c83b78dfbcfe71351ce82cb4eec6d411e75791893b520af63766d0.png | simple | <table><tr><td>Cut-off</td><td><i>Mean score</i><i>(95%CI)</i></td><td><i>All</i><i>(n = 497)</i></td><td>Male(n = 217)</td><td>Female(n = 280)</td><td>65+(n = 242)</td><td>75+(n = 201)</td><td>90+(n = 54)</td></tr><tr><td>≥5</td><td>6.91 (6.67-7.15)</td><td>202 (40.6%)</td><td>69 (31.8%)</td><td>133 (47.5%)</td><td>99 (40.9%)</td><td>82 (40.8%)</td><td>21 (38.9%)</td></tr><tr><td>≥6</td><td>7.57 (7.33-7.81)</td><td>150 (30.2%)</td><td>51 (23.5%)</td><td>99 (35.4%)</td><td>71 (29.3%)</td><td>62 (30.8%)</td><td>17 (31.5%)</td></tr><tr><td>≥7</td><td>8.19 (7.94-8.44)</td><td>108 (21.7%)</td><td>33 (15.2%)</td><td>75 (26.8%)</td><td>52 (21.5%)</td><td>43 (21.4%)</td><td>13 (24.1%)</td></tr><tr><td>≥8</td><td>8.97 (8.68-9.26)</td><td>65 (13.0%)</td><td>21 (9.6%)</td><td>44 (15.7%)</td><td>32 (13.2%)</td><td>23 (11.4%)</td><td>10 (18.5%)</td></tr></table> |
cfeee4d87748ab13a94d74f2951a51b2c7bc0472e5e3851e12a220b31c886256.png | complex | <table><tr><td> </td><td colspan="2">Vitamin D</td><td colspan="2">Vitamin D</td><td colspan="2">Dyslipidemia</td><td colspan="2">Overweight</td></tr><tr><td> </td><td colspan="2">deficiency</td><td colspan="2">Insufficiency</td><td colspan="2"> </td><td colspan="2"> </td></tr><tr><td> </td><td>Adjusted</td><td><i>P</i></td><td>Adjusted</td><td><i>P</i></td><td>Adjusted</td><td><i>P</i></td><td>Adjusted</td><td><i>P</i></td></tr><tr><td> </td><td>OR (95% CI)</td><td> </td><td>OR (95% CI)</td><td> </td><td>OR (95% CI)</td><td> </td><td>OR (95% CI)</td><td> </td></tr><tr><td><i>GC</i>rs2282679 T > G</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>TT</td><td>1</td><td> </td><td>1</td><td> </td><td>1</td><td> </td><td>1</td><td> </td></tr><tr><td>TG- GG</td><td>3.53 (1.38 - 9.80)</td><td>0.008</td><td>2.34 (1.15 - 4.90)</td><td>0.02</td><td>0.41 (0.21 - 0.84)</td><td>0.01</td><td>1.60 (0.70 – 3.36)</td><td>0.20</td></tr><tr><td><i>GC</i>rs2298849 T > C</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>CC - TC</td><td>1</td><td> </td><td>1</td><td> </td><td>1</td><td> </td><td>1</td><td> </td></tr><tr><td>TT</td><td>3.40 (1.46 - 7.89)</td><td>0.004</td><td>0.82 (0.51 - 1.31)</td><td>0.41</td><td>0.67 (0.40 - 1.11)</td><td>0.12</td><td>1.76 (1.04 - 2.98)</td><td>0.04</td></tr><tr><td><i>NADSYN1</i>rs12785878 G > T</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>TT - GT</td><td>1</td><td> </td><td>1</td><td> </td><td>1</td><td> </td><td>1</td><td> </td></tr><tr><td>GG</td><td>1.72 (0.69 - 4.24)</td><td>0.54</td><td>1.80 (1.12 - 2.87)</td><td>0.01</td><td>1.72 (1.04 - 2.86)</td><td>0.03</td><td>1.02 (0.62 - 1.69)</td><td>0.93</td></tr></table> |
10dd52959bcb682663332a3db9040f80fcd2bfbf697fdef40caa09a735e3c264.png | simple | <table><tr><td>Patellar dislocation <i>N</i> = 51</td><td>Group ANonoperatively treated patients<i>n</i> = 33</td><td>Group BPatients treated operatively during acute phase<i>n</i> = 7</td><td>Group CPatients treated operatively due to recurrence <i>n</i> = 11</td></tr><tr><td>Girls : boys</td><td>16 : 17</td><td>4 : 3</td><td>9 : 2 </td></tr><tr><td>Age at injury (years)<sup>a</sup></td><td>13.5 ± 1.3</td><td>12.6 ± 2.3</td><td>13.3 ± 1.5 </td></tr><tr><td>Follow-up time (years)<sup>a</sup></td><td>7.7 ± 1.5</td><td>7.0 ± 1.4</td><td>7.3 ± 1.5</td></tr><tr><td>Trochlear dysplasia</td><td>67% (22 of 33)</td><td>83% (5 of 6)</td><td>64% (7 of 11)</td></tr><tr><td>Patella alta</td><td>33% (11 of 33)</td><td>33% (2 of 6)</td><td>38% (3 of 8)</td></tr><tr><td>Subjective knee function<sup>a</sup></td><td> </td><td> </td><td> </td></tr><tr><td> KOOS subscales at follow-up<sup>b</sup></td><td> </td><td> </td><td> </td></tr><tr><td>(i) Pain (M = 92, F = 92)</td><td>90 ± 14</td><td>92 ± 8</td><td>86 ± 9</td></tr><tr><td>(ii) Symptoms (M = 87, F = 89)</td><td>82 ± 14</td><td>82 ± 11</td><td>78 ± 12</td></tr><tr><td>(iii) Function in daily living (M = 94, F = 95)</td><td>94 ± 12</td><td>97 ± 4</td><td>93 ± 6</td></tr><tr><td>(iv) Sports and recreation (M = 85, F = 86)</td><td>77 ± 24</td><td>79 ± 15</td><td>66 ± 17</td></tr><tr><td>(v) Quality of life (M = 85, F = 84)</td><td>69 ± 20</td><td>76 ± 19</td><td>60 ± 14</td></tr><tr><td> Kujala score at follow-up<sup>c</sup></td><td>84 ± 10</td><td>84 ± 7</td><td>75 ± 15</td></tr><tr><td>Objective knee function<sup>a</sup></td><td> </td><td> </td><td> </td></tr><tr><td> Peak torque/body weight</td><td> </td><td> </td><td> </td></tr><tr><td>(i) Extension (90 degr/s)</td><td>187.2 ± 59.5</td><td>195.6 ± 57.4</td><td>157.9 ± 63.2</td></tr><tr><td> </td><td>M: 220 ± 43</td><td>M: 242 ± 50</td><td>M: 231 ± 30</td></tr><tr><td> </td><td>F: 152 ± 56</td><td>F: 161 ± 34</td><td>F: 142 ± 57</td></tr><tr><td>(ii) Flexion (90 degr/s)</td><td>106.3 ± 34.4</td><td>103.6 ± 31.7</td><td>113.8 ± 57.6</td></tr><tr><td> </td><td>M: 128 ± 26</td><td>M: 124 ± 36</td><td>M: 208 ± 77</td></tr><tr><td> </td><td>F: 83 ± 27</td><td>F: 88 ± 20</td><td>F: 93 ± 26</td></tr><tr><td>(iii) H/Q ratio<sup>e</sup></td><td>0.58 ± 0.16</td><td>0.54 ± 0.12</td><td>1.03 ± 1.30</td></tr><tr><td> LSI, peak torque in extension<sup>f</sup></td><td>86 ± 17%</td><td>89 ± 15%</td><td>81 ± 32%</td></tr><tr><td> 30 s mini squat test injured side<sup>g</sup></td><td>35 ± 15</td><td>36 ± 18</td><td>34 ± 13</td></tr><tr><td> LSI, 30 s mini-squat test<sup>f</sup></td><td>93 ± 21%</td><td>97 ± 8%</td><td>99 ± 32%</td></tr><tr><td>Redislocation after latest treatment<sup>h</sup></td><td>67% (22 of 33) </td><td>43% (3 of 7)</td><td>18% (2 of 11)</td></tr></table> |
35a83c076c1f1a898ec5d7150af412fabba0b4d958a3c6a35e92adff71b803c8.png | simple | <table><tr><td></td><td>Aspira-aA</td><td>Tecnis ZCB00</td><td><i>p</i> value</td></tr><tr><td>UDVA (logMAR)</td><td>0.14 ± 0.13</td><td>0.12 ± 0.15</td><td>0.25</td></tr><tr><td>CDVA (logMAR)</td><td>0.07 ± 0.09</td><td>0.04 ± 0.09</td><td>0.22</td></tr><tr><td>Sphere ∆ (D)</td><td>−0.22 ± 0.67</td><td>−0.50 ± 0.52</td><td>0.29</td></tr><tr><td>Depth of focus (D)</td><td>0.61 ± 0.33</td><td>0.65 ± 0.29</td><td>0.74</td></tr><tr><td>Corneal asphericity with a pupil size of 4 mm</td><td>0.19 ± 0.24</td><td>0.26 ± 0.16</td><td>0.19</td></tr></table> |
7b1d5240c3e2bd2d521097b888233681c52ff1f51c38370b2bddcb9edbc3cd37.png | complex | <table><tr><td></td><td></td><td colspan="8">DVH analysis: H (MCTPS, RBE = 1.1) - H (TPS, RBE = 1.1)</td></tr><tr><td>Patient</td><td>ROI</td><td>D5</td><td>D10</td><td>D20</td><td>D33</td><td>D50</td><td>D66</td><td>D75</td><td>D95</td></tr><tr><td rowspan="5">A</td><td>PTV</td><td>2,0</td><td>1,7</td><td>1,2</td><td>0,9</td><td>0,6</td><td>0,0</td><td>0,0</td><td>-3,2</td></tr><tr><td><i>Temporal lobe left</i></td><td>-4,1</td><td>−2,3</td><td>0,0</td><td>0,6</td><td>0,9</td><td>0,6</td><td>0,6</td><td>0,0</td></tr><tr><td><i>Temporal lobe right</i></td><td>−6,7</td><td>−3,8</td><td>−4,4</td><td>−1,7</td><td>−1,5</td><td>−1,7</td><td>−2,0</td><td>−0,3</td></tr><tr><td><i>Brain stem</i></td><td>−0,9</td><td>−2,0</td><td>−1,7</td><td>−1,5</td><td>−0,6</td><td>0,0</td><td>−0,3</td><td>0,0</td></tr><tr><td><i>Optical system</i></td><td>−3,5</td><td>−4,9</td><td>−7,5</td><td>−9,9</td><td>−8,1</td><td>−5,2</td><td>−1,2</td><td>0,0</td></tr><tr><td rowspan="5">B</td><td>PTV</td><td>1,5</td><td>0,9</td><td>0,3</td><td>0,6</td><td>0,3</td><td>0,3</td><td>0,3</td><td>−1,8</td></tr><tr><td><i>Optic nerve left</i></td><td>−0,9</td><td>−1,5</td><td>−0,3</td><td>0,3</td><td>−0,3</td><td>0,0</td><td>0,0</td><td>−0,3</td></tr><tr><td><i>Chiasma</i></td><td>1,5</td><td>1,2</td><td>0,3</td><td>−1,8</td><td>−2,1</td><td>0,6</td><td>2,1</td><td>2,1</td></tr><tr><td><i>Optic nerve right</i></td><td>2,1</td><td>1,8</td><td>0,9</td><td>−0,9</td><td>−0,6</td><td>0,9</td><td>0,6</td><td>0,0</td></tr><tr><td><i>Brain stem</i></td><td>−3,0</td><td>−5,1</td><td>−9,0</td><td>−5,4</td><td>1,5</td><td>3,6</td><td>2,7</td><td>0,9</td></tr><tr><td rowspan="4">C</td><td>PTV</td><td>0,6</td><td>0,6</td><td>0,0</td><td>0,3</td><td>0,3</td><td>0,6</td><td>0,6</td><td>−0,9</td></tr><tr><td><i>Optic nerve (right)</i></td><td>1,2</td><td>1,5</td><td>1,2</td><td>0,6</td><td>0,9</td><td>0,9</td><td>0,9</td><td>1,8</td></tr><tr><td><i>Chiasma</i></td><td>0,3</td><td>0,0</td><td>−2,7</td><td>−9,0</td><td>−3,9</td><td>−5,4</td><td>−0,3</td><td>−0,3</td></tr><tr><td><i>Brain stem</i></td><td>−9,6</td><td>−7,2</td><td>−1,5</td><td>0,9</td><td>0,3</td><td>0,0</td><td>0,0</td><td>−0,3</td></tr><tr><td rowspan="3">D</td><td>PTV</td><td>2,0</td><td>1,7</td><td>1,4</td><td>0,6</td><td>0,3</td><td>0,3</td><td>0,3</td><td>1,1</td></tr><tr><td><i>Eye (left)</i></td><td>1,4</td><td>2,2</td><td>3,4</td><td>3,6</td><td>3,6</td><td>3,1</td><td>2,8</td><td>1,4</td></tr><tr><td><i>Optic nerve (left)</i></td><td>−3,1</td><td>−2,5</td><td>−2,5</td><td>−0,8</td><td>2,8</td><td>3,4</td><td>2,8</td><td>0,8</td></tr></table> |
06ee44de51dfc3229c950144ee0af03d673dce90dff6eb4bcae800f4ed852731.png | complex | <table><tr><td></td><td>Number of persons</td><td>Mean age (range) in years</td><td>Males/females</td><td>Smokers (non-/NA/current /ex)<sup>a</sup></td><td>Steroid treatment (no/NA/yes)<sup>a</sup></td><td>Non-steroidal anti-inflammatory drug (no/NA/yes)<sup>a</sup></td><td>Mean duration of symptoms (range) in months<sup>b</sup></td></tr><tr><td>Group I</td><td>6</td><td>71 (65–78)</td><td>3/3</td><td>4/1/0/1</td><td>5/1/0</td><td>6/0/0</td><td>11 (1–24)</td></tr><tr><td>Group II</td><td>12</td><td>68 (42–85)</td><td>5/7</td><td>5/1/1/5</td><td>5/1/6</td><td>2/2/8</td><td>62 (12–150)</td></tr><tr><td>Group III</td><td>11</td><td>56 (40–73)</td><td>5/6</td><td>4/0/1/6</td><td>7/3/1</td><td>4/5/2</td><td>9 (2–18)</td></tr><tr><td>Controls</td><td>10</td><td>42 (20–59)</td><td>5/5</td><td>6/0/4/0</td><td></td><td></td><td></td></tr><tr><td>Radiation accident victims</td><td>3</td><td>38 (27–48)</td><td>2/1</td><td colspan="4">Estimated protracted dose [10]: 2.7; 0.5; 1.0 Gy</td></tr></table> |
933cc87cf6ade0362862694e45bf3dd13292a3b39cd47a72ebdc85521c20c0a7.png | simple | <table><tr><td>Interface</td><td>Process (μm)</td><td>Supply (V)</td><td>ENOB (bits)</td><td>Area (mm<sup>2</sup>)</td><td>Power (μW)</td><td>BW (kHz)</td><td>FOM (pJ/conv)</td></tr><tr><td>[28]</td><td>0.16</td><td>1.2</td><td>12.5</td><td>0.15</td><td>10.3</td><td>1.25</td><td>8300</td></tr><tr><td>[29]</td><td>0.09</td><td>1.0</td><td>10.4</td><td>N/A</td><td>3.0</td><td>1.56</td><td>1.4</td></tr><tr><td>[30]</td><td>0.35</td><td>3.0</td><td>9.3</td><td>0.09</td><td>54.0</td><td>12.60</td><td>3.4</td></tr><tr><td>[32]</td><td>0.32</td><td>3.0</td><td>9.8</td><td>0.52</td><td>84.0</td><td>2.60</td><td>4.5</td></tr><tr><td>[34]</td><td>0.18</td><td>0.5</td><td>7.2</td><td>0.01</td><td>1.1</td><td>2.34</td><td>1.6</td></tr><tr><td>This work</td><td>0.18</td><td>0.8</td><td>7.4</td><td>0.01</td><td>0.8</td><td>2.17</td><td>1.5</td></tr></table> |
195d0571291dcedc8edad8a1d337607618e500c6b920f059f7e6d3fd0bc8a2cb.png | simple | <table><tr><td></td><td>Cut-off</td><td>Sensitivity</td><td>Specificity</td><td>Positive predictive value</td><td>Negative predictive value</td></tr><tr><td>CRP (mg/L)</td><td>≥28</td><td>100.00</td><td>97.37</td><td>97.40</td><td>100.00</td></tr><tr><td>Fibrinogen (mg/dL)</td><td>≥480</td><td>89.47</td><td>92.11</td><td>91.90</td><td>89.70</td></tr><tr><td>IL-6 (pg/mL)</td><td>≥105.8</td><td>76.32</td><td>94.74</td><td>93.50</td><td>80.00</td></tr><tr><td>ESR (mm/h)</td><td>≥42</td><td>73.68</td><td>84.21</td><td>82.40</td><td>76.20</td></tr><tr><td>WBC (10<sup>3</sup> <i>μ</i>/L)</td><td>≥11.6</td><td>71.05</td><td>90.70</td><td>87.10</td><td>78.00</td></tr></table> |
6925d3fa84ee937805380450d8d5aa7eebcf6d8d3a557b4d2271bf125e9da2d0.png | complex | <table><tr><td>DNA amount [μg]</td><td>Plus reagent [μl]</td><td>Ratio lipid to DNA</td><td>Quality</td><td>Cells in suspension</td><td>Fluor. intensity</td><td>Transfection efficiency [%]</td></tr><tr><td rowspan="5">0.25</td><td rowspan="5">0.25</td><td>1.0:1</td><td>1</td><td>0</td><td>+</td><td>0.6</td></tr><tr><td>2.0:1</td><td>2</td><td>0</td><td>+</td><td>0.5</td></tr><tr><td>2.5:1</td><td>2</td><td>0</td><td>+</td><td>3.1</td></tr><tr><td>3.0:1</td><td>2</td><td>0</td><td>+</td><td>3.8</td></tr><tr><td>4.0:1</td><td>4</td><td>0</td><td>++</td><td>26</td></tr><tr><td rowspan="4">0.5</td><td rowspan="4">0.5</td><td>1.0:1</td><td>2</td><td>0</td><td>+</td><td>2.6</td></tr><tr><td>2.0:1</td><td>4</td><td>1</td><td>+</td><td>26</td></tr><tr><td>2.5:1</td><td>3</td><td>1</td><td>++</td><td>50</td></tr><tr><td>3.0:1</td><td>5</td><td>2</td><td>++</td><td>52</td></tr><tr><td rowspan="2">0.5</td><td rowspan="2">1.0</td><td>2.5:1</td><td>4</td><td>1</td><td>++</td><td>24</td></tr><tr><td>3.0:1</td><td>4</td><td>2</td><td>++</td><td>45</td></tr><tr><td rowspan="4">0.75</td><td rowspan="4">0.75</td><td>1.0:1</td><td>4</td><td>0</td><td>++</td><td>28</td></tr><tr><td>2.0:1</td><td>5</td><td>1</td><td>++</td><td>37</td></tr><tr><td>2.5:1</td><td>5</td><td>1</td><td>++</td><td>28</td></tr><tr><td>3.0:1</td><td>5</td><td>1</td><td>++</td><td>21</td></tr></table> |
a4e33b587441db9d86c491ac82176bad863d7e92d9acd80869242731bf2903fc.png | complex | <table><tr><td>Primary outcome measures</td><td>Generic quality of life</td><td>SF-36</td></tr><tr><td></td><td>Functional health status</td><td>FIM</td></tr><tr><td>Secondary outcome measures</td><td>Anxiety and depression</td><td>HADS</td></tr><tr><td></td><td>Cognitive functioning</td><td>MMSE</td></tr><tr><td></td><td>Extent to which individual ADL treatment goals are met</td><td>COPM</td></tr><tr><td colspan="3">Note: Costs will be assessed using the PRODISQ, a cost questionnaire and hospital database data</td></tr></table> |
351e9a02afdb4d1b01487b1d0c86757cfbd3f502368993af2b397d901e905e5f.png | complex | <table><tr><td rowspan="2">Age (years)</td><td colspan="3">Influenza A</td><td colspan="3">Influenza B</td></tr><tr><td>Positive</td><td>Equivocal</td><td>Negative</td><td>Positive</td><td>Equivocal</td><td>Negative</td></tr><tr><td><3</td><td>13.0 (9)</td><td>5.8 (4)</td><td>81.1 (56)</td><td>14.5 (10)</td><td>5.8 (4)</td><td>79.7 (55)</td></tr><tr><td>3–4</td><td>9.7 (6)</td><td>6.4 (4)</td><td>83.9 (52)</td><td>25.8 (16)</td><td>4.8 (3)</td><td>69.3 (43)</td></tr><tr><td>4–5</td><td>14.9 (7)</td><td>8.5 (4)</td><td>76.6 (36)</td><td>27.7 (13)</td><td>10.6 (5)</td><td>61.7 (29)</td></tr><tr><td>5–6</td><td>18.7 (9)</td><td>6.2 (3)</td><td>75.0 (36)</td><td>33.3 (16)</td><td>14.6 (7)</td><td>52.1 (25)</td></tr><tr><td>6–12.5</td><td>24.1 (14)</td><td>10.3 (6)</td><td>65.5 (38)</td><td>58.6 (34)</td><td>13.8 (8)</td><td>27.6 (16)</td></tr><tr><td>All</td><td>15.8 (45)</td><td>7.4 (21)</td><td>76.7 (218)</td><td>31.3 (89)</td><td>9.5 (27)</td><td>59.1 (168)</td></tr></table> |
189d77d79c8bd184cc64af1bd02325edc0605b5a180ee0ff4c61b184f2f32f3e.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">2011</td><td colspan="2">2012</td><td colspan="2">2013</td><td colspan="2">2014</td><td colspan="2">2015</td></tr><tr><td colspan="2">Odds Ratio (95% CI)</td><td colspan="2">Odds Ratio (95% CI)</td><td colspan="2">Odds Ratio (95% CI)</td><td colspan="2">Odds Ratio (95% CI)</td><td colspan="2">Odds Ratio (95% CI)</td></tr><tr><td>Model 4</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>women (ref)</td><td>-</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td></tr><tr><td>men</td><td>-</td><td></td><td>0.99 (0.68–1.46)</td><td>ns</td><td>1.08 (0.71–1.64)</td><td>ns</td><td>1.57 (1.03–2.39)</td><td>*</td><td>1.21 (0.81–1.81)</td><td>ns</td></tr><tr><td>20–29</td><td>-</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td></tr><tr><td>30–39</td><td>-</td><td></td><td>1.73 (0.81–3.67)</td><td>ns</td><td>1.19 (0.54–2.63)</td><td>ns</td><td>2.12 (0.97–4.65)</td><td>ns</td><td>2.24 (0.98–5.15)</td><td>ns</td></tr><tr><td>40–49</td><td>-</td><td></td><td>1.82 (0.84–3.94)</td><td>ns</td><td>2.30 (1.02–5.19)</td><td>*</td><td>2.56 (1.16–5.66)</td><td>*</td><td>2.62 (1.17–5.89)</td><td>*</td></tr><tr><td>50–59</td><td>-</td><td></td><td>2.53 (1.19–5.34)</td><td>*</td><td>2.80 (1.26–6.23)</td><td>*</td><td>3.41 (1.55–7.51)</td><td>**</td><td>2.55 (1.16–5.61)</td><td>*</td></tr><tr><td>60 or over</td><td>-</td><td></td><td>3.39 (1.70–6.77)</td><td>***</td><td>2.76 (1.36–5.61)</td><td>**</td><td>3.80 (1.91–7.55)</td><td>***</td><td>4.02 (1.96–8.25)</td><td>***</td></tr><tr><td>mountainous area (ref)</td><td>-</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td></tr><tr><td>central area</td><td>-</td><td></td><td>0.69 (0.38–1.23)</td><td>ns</td><td>0.57 (0.28–1.16)</td><td>ns</td><td>0.85 (0.45–1.59)</td><td>ns</td><td>0.60 (0.32–1.13)</td><td>ns</td></tr><tr><td>coastal area other than EOAs</td><td>-</td><td></td><td>0.90 (0.45–1.78)</td><td>ns</td><td>0.57 (0.25–1.28)</td><td>ns</td><td>0.90 (0.44–1.84)</td><td>ns</td><td>0.57 (0.28–1.16)</td><td>ns</td></tr><tr><td>EOAs</td><td>-</td><td></td><td>0.90 (0.34–2.36)</td><td>ns</td><td>0.89 (0.29–2.80)</td><td>ns</td><td>0.98 (0.38–2.52)</td><td>ns</td><td>0.75 (0.26–2.17)</td><td>ns</td></tr><tr><td>Q1 (relief regarding regional disasters)</td><td>-</td><td></td><td>1.02 (0.66–1.58)</td><td>ns</td><td>0.95 (0.61–1.48)</td><td>ns</td><td>1.02 (0.67–1.55)</td><td>ns</td><td>1.10 (0.73–1.65)</td><td>ns</td></tr><tr><td>Q2 (relief regarding of radiation)</td><td>-</td><td></td><td>0.70 (0.44–1.10)</td><td>ns</td><td>1.53 (0.92–2.56)</td><td>ns</td><td>1.35 (0.85–2.15)</td><td>ns</td><td>1.06 (0.69–1.61)</td><td>ns</td></tr><tr><td>Q3 (familiarity with the medical service)</td><td>-</td><td></td><td>1.10 (0.67–1.80)</td><td>ns</td><td>1.76 (1.06–2.91)</td><td>*</td><td>1.16 (0.70–1.92)</td><td>ns</td><td>1.52 (0.88–2.63)</td><td>ns</td></tr><tr><td>Q4 (familiarity with the welfare service)</td><td>-</td><td></td><td>1.49 (0.97–2.28)</td><td>ns</td><td>1.40 (0.87–2.26)</td><td>ns</td><td>1.92 (1.21–3.06)</td><td>**</td><td>1.18 (0.72–1.94)</td><td>ns</td></tr><tr><td>Q5 (evaluation of prefectural reconstruction)</td><td>-</td><td></td><td>1.36 (0.78–2.36)</td><td>ns</td><td>1.00 (0.55–1.82)</td><td>ns</td><td>0.68 (0.41–1.11)</td><td>ns</td><td>0.80 (0.52–1.23)</td><td>ns</td></tr><tr><td>Q6 (bonds with other local people)</td><td>-</td><td></td><td>0.93 (0.62–1.39)</td><td>ns</td><td>1.94 (1.26–3.00)</td><td>**</td><td>1.09 (0.71–1.66)</td><td>ns</td><td>1.46 (0.97–2.21)</td><td>ns</td></tr></table> |
f896df80bb5cd20310f1d4064f6d395dac0b0514fbd34a4d86c27a6ae84a11a4.png | simple | <table><tr><td>Variable</td><td>Coefficient</td><td>Standard error</td><td><i>P</i>-value</td><td>Relative risk (95% CI)</td></tr><tr><td>Disease-free survival</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> AST (>50 IU/L)</td><td>0.381</td><td>0.136</td><td>0.016</td><td>1.379 (1.062 to 1.789)</td></tr><tr><td> Liver cirrhosis</td><td>0.296</td><td>0.119</td><td>0.043</td><td>1.292 (1.009 to 1.654)</td></tr><tr><td> Perioperative transfusion</td><td>0.301</td><td>0.118</td><td>0.008</td><td>1.386 (1.090 to 1.763)</td></tr><tr><td> Multiple tumors</td><td>0.553</td><td>0.134</td><td>0.013</td><td>1.564 (1.097 to 2.230)</td></tr><tr><td> Microvascular invasion</td><td>0.382</td><td>0.128</td><td>< 0.001</td><td>1.604 (1.255 to 2.050)</td></tr><tr><td> Edmondson-Steiner grade III to IV</td><td>0.321</td><td>0.131</td><td>0.014</td><td>1.379 (1.066 to 1.784)</td></tr><tr><td>Overall survival</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Serum albumin (≤3.5 g/dL)</td><td>0.587</td><td>0.166</td><td>< 0.001</td><td>1.798 (1.298 to 2.490)</td></tr><tr><td> Platelet count (≤100,000/mm<sup>3</sup>)</td><td>0.442</td><td>0.167</td><td>0.008</td><td>1.557 (1.122 to 2.161)</td></tr><tr><td> Perioperative transfusion</td><td>0.477</td><td>0.140</td><td>0.001</td><td>1.610 (1.224 to 2.118)</td></tr><tr><td> Perioperative morbidity</td><td>0.353</td><td>0.143</td><td>0.013</td><td>1.423 (1.076 to 1.883)</td></tr><tr><td> Tumor size (>3 cm)</td><td>0.313</td><td>0.154</td><td>0.043</td><td>1.367 (1.010 to 1.850)</td></tr><tr><td> Multiple tumors</td><td>0.679</td><td>0.147</td><td>< 0.001</td><td>1.973 (1.478 to 2.633)</td></tr><tr><td> Macrovascular invasion</td><td>0.581</td><td>0.227</td><td>0.011</td><td>1.789 (1.145 to 2.793)</td></tr><tr><td> Edmondson-Steiner grade III to IV</td><td>0.419</td><td>0.147</td><td>0.004</td><td>1.521 (1.141 to 2.028)</td></tr></table> |
85fec4e9b3f4b55719d6a7ce4e8e37cecd4079d1eb5ed7098756eb948b646b60.png | complex | <table><tr><td rowspan="2">12-month falls recall</td><td colspan="3">Daily calendar</td></tr><tr><td>Falls, <i>N</i> (%)</td><td>No falls, <i>N</i> (%)</td><td> </td></tr><tr><td>Falls</td><td>692 (77%)</td><td>70 (6%)</td><td>762</td></tr><tr><td>No falls</td><td>206 (23%)</td><td>1128 (94%)</td><td>1334</td></tr><tr><td> </td><td>898</td><td>1198</td><td>2096</td></tr></table> |
88d17f7198652220e6e327c4205fa4dae84a3e461e26302f9d26368d453809d1.png | simple | <table><tr><td>Inclusion criteria</td><td>Exclusion criteria</td></tr><tr><td>Age ≥ 18 years</td><td>History of previous major hepatic surgery (i.e. more than three liver segments) or biliary major surgery (except gall-bladder surgery by laparoscopy if more than 6 months previously)</td></tr><tr><td>Patients with liver metastases requiring a hepatectomy of ≥ 2 segments</td><td>Patients with cirrhosis or sinusoidal obstruction syndrome with portal hypertension</td></tr><tr><td>Eastern Cooperative Oncology Group performance status ≤ 1</td><td>Pregnant women</td></tr><tr><td>Adequate bone marrow and liver function at baseline (defined by platelet count ≥ 100 × 10<sup>9</sup>/L, and haemoglobin of ≥ 9 g/dL, and total bilirubin ≤ 1.5 × upper limit of normal, and transaminases ≤ 5× upper limit of normal)</td><td></td></tr><tr><td>Recovered from prior anti-neoplasic treatment-related toxicity (grade <2 persistent treatment-related toxicity as per Common Terminology Criteria for Adverse Events v4 are accepted</td><td></td></tr><tr><td>Willingness for follow-up visits</td><td></td></tr><tr><td>Covered by a medical insurance</td><td></td></tr><tr><td>Signed and dated informed consent indicating that the patient has been informed of all aspects of the trial prior to enrolment</td><td></td></tr></table> |
7c8f6badb125def57345a030629e6f6d034b7a3d8984399c1dfed4917bd33039.png | simple | <table><tr><td></td><td>First comprehension test(<i>n</i> = 30)</td><td>Second comprehension test(<i>n</i> = 35)</td></tr><tr><td>Items</td><td>Patients reporting difficulties in understanding items (%)</td><td>Patients reporting difficulties in understanding items (%)</td></tr><tr><td>4</td><td>6.7</td><td>0</td></tr><tr><td>9</td><td>6.7</td><td>0</td></tr><tr><td>15</td><td>0</td><td>5.7</td></tr><tr><td></td><td>Patients reporting difficulties in understanding questions (%)</td><td>Patients reporting difficulties in understanding questions (%)</td></tr><tr><td>Demographic 1</td><td>30.0</td><td>0</td></tr><tr><td>Demographic 3</td><td>13.3</td><td>0</td></tr><tr><td>Demographic 4</td><td>6.7</td><td>0</td></tr></table> |
64da799a7e1384ee9d95584cc0c16bcfd079b63a3463e75cfe3dfa743c7a3656.png | simple | <table><tr><td><i>Variable</i></td><td><i>β</i></td><td><i>Std error</i></td><td>p<i>-value</i></td><td><i>Exp β</i></td><td><i>95% CI for exp β</i></td></tr><tr><td>Age</td><td>0.003</td><td>0.016</td><td>0.856</td><td>0.997</td><td>0.996–1.029</td></tr><tr><td>Literate</td><td>–0.248</td><td>0.482</td><td>0.607</td><td>0.781</td><td>0.304–2.008</td></tr><tr><td>NYHA</td><td>0.236</td><td>0.510</td><td>0.664</td><td>1.266</td><td>0.446–3.440</td></tr><tr><td>SBP</td><td>0.002</td><td>0.008</td><td>0.809</td><td>1.002</td><td>0.986–1.018</td></tr><tr><td>Creatinine</td><td>0.272</td><td>0.793</td><td>0.732</td><td>1.312</td><td>0.227–6.209</td></tr><tr><td>Congestion score</td><td>0.005</td><td>0.019</td><td>0.012</td><td>1.007</td><td>0.976–1.021</td></tr></table> |
b7ac2c3f00d07d1c8df4ebc784f55f77cd9c6c47f7016fd862748ec588ecba3a.png | simple | <table><tr><td>1</td><td>F 5′-TATAGGTACCAATTTATGGCAGTCATTA-3′</td><td>Amplification</td></tr><tr><td>2</td><td>R 5′-ATATGAGCTCGCTGGCCCGTGGCTGGAT-3′</td><td> </td></tr><tr><td>3</td><td>S 5′-GTCCTTTTCTAGTGTATTGTGTTTGTTAATATTTG-3′</td><td>A→G</td></tr><tr><td>4</td><td>Compl 5′-CAAATATTAACAAACACAATACACTAGAAAAGGAC-3′</td><td> </td></tr><tr><td>5</td><td>S 5′-GCTCCCACTAATGTGGTATTTAACTTTTGAAAGATCTTTAG-3′</td><td>NFκB (−1537)</td></tr><tr><td>6</td><td>Compl 5′-CTAAAGATCTTTCAAAAGTTAAATACCACATTAGTGGGAGC-3′</td><td> </td></tr><tr><td>7</td><td>S 5′-GCTTTAAATAATTCTACAATATTTTGTGTATTTTGC-3′</td><td>HNF-3</td></tr><tr><td>8</td><td>Compl 5′-GCAAAATACACAAAATATTGTAGAATTATTTAAAGC-3′</td><td> </td></tr><tr><td>9</td><td>S 5′-CAGAAAATATCGGTAATAAAAAAAGTTAAAGATCTTC-3′</td><td>Pou-IV</td></tr><tr><td>10</td><td>Compl 5′-GAAGATCTTTAACTTTTTTTATTACCGATATTTTCTG-3′</td><td> </td></tr><tr><td>11</td><td>S 5′-GGAGGCTCCCTCCCCCCCCTCCAGCGC-3′</td><td>Sp1 (−236)</td></tr><tr><td>12</td><td>Compl 5′-GCGCTGGAGGGGAGGGAGGGAGCCTCC-3′</td><td> </td></tr><tr><td>13</td><td>S 5′-GACCCGGCGCAGCACACCAACCGCGAGCAGAAC-3′</td><td>Ets</td></tr><tr><td>14</td><td>Compl - 5′-GTTCTGCTCGCGGTTGGTGTGCTGCGCCGGGTC-3′</td><td> </td></tr><tr><td>15</td><td>S 5′-CGCTGCGGGCGCTTGCTGCCAGAACCTTG-3′</td><td>Sp1 (−124)</td></tr><tr><td>16</td><td>Compl 5′-CAAGGTTCTGGCAGCAAGCGCCCGCAGCG-3′</td><td> </td></tr><tr><td>17</td><td>S 5′-CTTAAAGCACAGCCCATCACAGTTTTCATCCAGC-3′</td><td>NFκB (−40)</td></tr><tr><td>18</td><td>Compl 5′-GCTGGATGAAAACTGTGATGGGCTGTGCTTTAA-3′</td><td> </td></tr></table> |
3b8b1178f3542b3ccb926da06f2328eefe34bde9175b8dec8cd059bce149aa82.png | simple | <table><tr><td> </td><td>Kappa</td><td>% Agreement</td><td>Interpretation (Landis and Koch [21])</td></tr><tr><td><i>DSM-IV </i></td><td> </td><td> </td><td> </td></tr><tr><td> BN</td><td>0.66</td><td>99%</td><td>Substantial</td></tr><tr><td> BED</td><td>0.46</td><td>92%</td><td>Moderate</td></tr><tr><td> EDNOS</td><td>0.55</td><td>86%</td><td>Moderate</td></tr><tr><td><i>DSM-5 </i></td><td> </td><td> </td><td> </td></tr><tr><td> BN</td><td>0.66</td><td>99%</td><td>Substantial</td></tr><tr><td> BED</td><td>0.42</td><td>91%</td><td>Moderate</td></tr><tr><td>OSFED</td><td> </td><td> </td><td> </td></tr><tr><td> Sub-BED</td><td>0.48</td><td>96%</td><td>Moderate</td></tr><tr><td> PD</td><td>−0.01</td><td>97%</td><td>Poor</td></tr><tr><td> NES </td><td>0.14</td><td>91%</td><td>Poor</td></tr><tr><td> Other</td><td>0.59</td><td>94%</td><td>Moderate</td></tr></table> |
cd0e16f1c6babcdab23a5ccf00f5900cb525f32e1e9020b9e1bf1c155bf6c7e2.png | simple | <table><tr><td>Home</td><td>Number of Occupant</td><td>Baby Age</td><td>Shared Room</td><td>Average Temp. of the Environment</td></tr><tr><td>Home 1</td><td>3</td><td>8 months</td><td>No</td><td>21°</td></tr><tr><td>Home 2</td><td>5</td><td>10 months</td><td>Yes</td><td>22.5°</td></tr><tr><td>Home 3</td><td>4</td><td>14 months</td><td>No</td><td>19°</td></tr><tr><td>Home 4</td><td>3</td><td>3 months</td><td>No</td><td>20.5°</td></tr><tr><td>Home 5</td><td>6</td><td>9 months</td><td>Yes</td><td>24.5°</td></tr></table> |
4450b452bf32dfd14de868bdabbfb5d4963358fdee6c15dca90f8a7ab44492d4.png | simple | <table><tr><td>Analyte</td><td>LOD <sup>a</sup> (μg/mL)</td><td>LOQ <sup>b</sup> (μg /mL)</td><td>Rec. <sup>c</sup> (%)</td><td>ME <sup>d</sup> (%)</td><td>Conc. Range <sup>e</sup> (μg /mL)</td><td>(<i>r</i><sup>2</sup>) <sup>f</sup></td></tr><tr><td>retinol</td><td>0.002</td><td>0.005</td><td>102.6 ± 8.9</td><td>108.5 ± 9.1</td><td>0.005–10</td><td>0.990</td></tr><tr><td>25-hydroxycholecalciferol</td><td>0.003</td><td>0.011</td><td>92.0 ± 3.2</td><td>87.3 ± 1.4</td><td>0.011–5</td><td>0.995</td></tr><tr><td>retinol acetate</td><td>0.002</td><td>0.008</td><td>103.4 ± 1.5</td><td>95.1 ± 1.7</td><td>0.008–10</td><td>0.995</td></tr><tr><td>α-tocotrienol</td><td>0.113</td><td>0.376</td><td>99.0 ± 5.3</td><td>89.9 ± 3.4</td><td>0.376–5</td><td>0.992</td></tr><tr><td>cholecalciferol</td><td>0.005</td><td>0.018</td><td>102.9 ± 2.9</td><td>89.6 ± 1.3</td><td>0.018–10</td><td>0.998</td></tr><tr><td>astaxanthin</td><td>0.001</td><td>0.003</td><td>102.3 ± 2.6</td><td>100.1 ± 3.3</td><td>0.003–1</td><td>0.995</td></tr><tr><td>lutein</td><td>0.008</td><td>0.028</td><td>86.1 ± 1.4</td><td>91.0 ± 2.0</td><td>0.028–10</td><td>0.992</td></tr><tr><td>zeaxanthin</td><td>0.422</td><td>1.406</td><td>86.2 ± 2.2</td><td>86.9 ± 3.2</td><td>1.406–10</td><td>0.992</td></tr><tr><td>cantaxanthin</td><td>0.002</td><td>0.006</td><td>100.1 ± 2.5</td><td>103.5 ± 8.0</td><td>0.006–1</td><td>0.992</td></tr><tr><td><i>E</i>-β-apo-8′-carotenal</td><td>0.003</td><td>0.010</td><td>103.6 ± 2.1</td><td>100.4 ± 1.4</td><td>0.010–10</td><td>0.994</td></tr><tr><td>cryptoxanthin</td><td>0.244</td><td>0.812</td><td>104.8 ± 3.2</td><td>94.0 ± 2.3</td><td>0.812–10</td><td>0.993</td></tr><tr><td>13-<i>Z-</i>β-carotene</td><td>0.056</td><td>0.187</td><td>100.6 ± 2.0</td><td>87.8 ± 1.0</td><td>0.187–10</td><td>0.992</td></tr><tr><td>α-carotene</td><td>0.022</td><td>0.073</td><td>104.2 ± 5.4</td><td>102.8 ± 3.9</td><td>0.073–5</td><td>0.994</td></tr><tr><td>β-carotene</td><td>0.041</td><td>0.138</td><td>101.1 ± 2.2</td><td>95.7 ± 5.3</td><td>0.138–5</td><td>0.999</td></tr><tr><td>9-<i>Z</i>-β-carotene</td><td>0.293</td><td>0.975</td><td>97.4 ± 6.7</td><td>91.5 ± 2.4</td><td>0.975–10</td><td>0.996</td></tr><tr><td>5-<i>Z</i>-lycopene</td><td>0.189</td><td>0.631</td><td>104.6 ± 8.2</td><td>96.5 ± 3.3</td><td>0.631–10</td><td>0.998</td></tr></table> |
82492890f67b1108f5e656a7416d9ba74cdc47d03074bfd9fd49c26e5651f0ec.png | simple | <table><tr><td>Variables</td><td>Unadjusted odds ratio (95% CI)</td><td>P-value</td><td>Adjusted odds ratio (95% CI)</td><td>P-value</td></tr><tr><td>Age*</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>6-19 (reference)</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>20-39</td><td>2.87 (1.98,4.16)</td><td>0.001</td><td>1.85 (1.00,3.43)</td><td>0.050</td></tr><tr><td>40-59</td><td>2.75 (1.67,4.52)</td><td>0.001</td><td>1.83 (1.03,3.25)</td><td>0.042</td></tr><tr><td>Sex</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Males (reference)</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Females</td><td>1.36 (1.09,1.69)</td><td>0.011</td><td>1.47 (1.10,1.97)</td><td>0.015</td></tr><tr><td>Immigrant status</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Non-Immigrant (reference)</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Immigrant</td><td>1.15 (0.76,1.75)</td><td>0.479</td><td>1.43 (1.05,1.95)</td><td>0.028</td></tr><tr><td>Education</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>> High school (reference)</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>< High school</td><td>0.63 (0.39,1.04)</td><td>0.068</td><td>0.65 (0.05,0.82)</td><td>0.002</td></tr><tr><td>Employment status</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Full-time employed (reference)</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Part-time employed</td><td>1.01 (0.52,1.97)</td><td>0.964</td><td>1.37 (0.85,2.22)</td><td>0.176</td></tr><tr><td>Unemployed</td><td>0.83 (0.66,1.05)</td><td>0.104</td><td>1.23 (0.96,1.57)</td><td>0.094</td></tr><tr><td>Income</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Higher (reference)</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Upper middle</td><td>2.05 (1.58,2.66)</td><td>0.001</td><td>1.61 (1.25,2.08)</td><td>0.002</td></tr><tr><td>Lower middle</td><td>3.74 (2.49,5.60)</td><td>0.001</td><td>2.95 (1.69,5.15)</td><td>0.001</td></tr><tr><td>Lower</td><td>4.21 (2.73,6.50)</td><td>0.001</td><td>2.64 (1.59,4.38)</td><td>0.001</td></tr><tr><td>Insurance</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Private (reference)</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Public</td><td>1.81 (0.99,3.30)</td><td>0.054</td><td>1.21 (0.49,2.97)</td><td>0.655</td></tr><tr><td>None</td><td>3.08 (2.39,3.99)</td><td>0.001</td><td>2.35 (1.62,3.40)</td><td>0.001</td></tr><tr><td>Self-reported oral health</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Good to excellent (reference)</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Fair to poor</td><td>4.11 (3.18,5.3)</td><td>0.001</td><td>3.04 (2.34,3.94)</td><td>0.001</td></tr><tr><td>Oral health</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>D (decayed teeth)</td><td>1.09 (1.02,1.17)</td><td>0.018</td><td>1.20 (1.13,1.28)</td><td>0.001</td></tr><tr><td>M (missing teeth)</td><td>1.04 (0.99,1.10)</td><td>0.140</td><td>1.07 (1.05,1.1)</td><td>0.001</td></tr></table> |
1a8c29e5f74d4946e97576278064c612f05b0b794ec422f0d93db97f2ad2b2a3.png | complex | <table><tr><td>Sl no. P.I.</td><td>year</td><td>State/UT</td><td>Setting</td><td>Age group</td><td>N</td><td>Prev. (%)</td></tr><tr><td>1. Jiloha [72]</td><td>1981</td><td>Haryana</td><td>rural</td><td>5-12</td><td>715</td><td>20.7</td></tr><tr><td colspan="7">Used questionnaire (t) and reporting questionnaire for children (p), clinical interview. Diagnosis was made as per ICD-9.</td></tr><tr><td>2. Devsigamani [22]</td><td>1990</td><td>TN</td><td>urban</td><td>8-12</td><td>755</td><td>33.7</td></tr><tr><td colspan="7">Rutter B scale was used as a screening instrument and diagnosis was made as per ICD- 9 after clinical interview.</td></tr><tr><td>3. Mehta [74]</td><td>1997</td><td>WB</td><td>rural</td><td>8-10</td><td>8-10</td><td>460</td></tr><tr><td colspan="7">Rutter B scale (Hindi adaptation), Malin’s test of verbal intelligence, VSMS, Gessell’s drawing test were used. Diagnosis was made as per DSM-III-R.</td></tr><tr><td>4. Banerjee [75]</td><td>1997</td><td>WB</td><td>rural</td><td>8-10</td><td>460</td><td>33.33</td></tr><tr><td colspan="7">Rutter’s B scale was used as screening instrument and ICD-9 was used to make the diagnosis</td></tr><tr><td>5. Gupta [73]</td><td>2001</td><td>Punjab</td><td>urban</td><td>9-11</td><td>957</td><td>45.6</td></tr><tr><td colspan="7">Rutter’s B scale was used as screening instrument and ICD-10 was used to make the diagnosis</td></tr><tr><td>6. Malhotra [76]</td><td>2002</td><td>Chandigarh</td><td>urban</td><td>4-11</td><td>963</td><td>6.33</td></tr><tr><td colspan="7">Rutter B scale, pre-school behaviour checklist, Childhood Psychopathology Measurement Schedule was used. Diagnosis was made as per ICD-10.</td></tr><tr><td>7. Bansal [77]</td><td>2011</td><td>Punjab</td><td>urban</td><td>10-15</td><td>982</td><td>20.2</td></tr><tr><td colspan="7">Childhood Psychopathology Measurement Schedule was used and Diagnosis was made as per ICD-10.</td></tr></table> |
1e4a895090643b302b22585eaca2b34266e007dae37f6fa9df94023ffdf308ac.png | simple | <table><tr><td></td><td>BUN(mg/dL)</td><td>Creatinine(mg/dL)</td><td>Na<sup>+</sup>(mEq/L)</td><td>K<sup>+</sup>(mEq/L)</td><td>Cl<sup>−</sup>(mEq/L)</td><td>HCO<sub>3</sub><sup>−</sup>(mEq/L)</td></tr><tr><td>Saline/Control</td><td>24.7 ± 1</td><td>0.25 ± 0</td><td>147.3 ± 1</td><td>3.8 ± 0</td><td>94.1 ± 1</td><td>22.7 ± 0</td></tr><tr><td>BC-NE</td><td>40.1 ± 1*</td><td>0.45 ± 0</td><td>135.8 ± 5</td><td>7.9 ± 1*</td><td>90.7 ± 4</td><td>23.7 ± 0</td></tr><tr><td>BC-S</td><td>44.3 ± 3*</td><td>0.53 ± 0*</td><td>132.5 ± 4*</td><td>10.3 ± 2*</td><td>89.5 ± 3</td><td>18.5 ± 2</td></tr></table> |
9036b4899b7b36fbce03437eb5c5d63d36827ddd48f9112055fb81f6f46cb814.png | simple | <table><tr><td>No. of lines</td><td>Common genes</td><td>Mean expression</td><td>Median expression</td></tr><tr><td>1</td><td>47</td><td>131.28</td><td>8.05</td></tr><tr><td>2</td><td>70</td><td>16.34</td><td>3.93</td></tr><tr><td>3</td><td>64</td><td>190.57</td><td>2.51</td></tr><tr><td>4</td><td>104</td><td>11.32</td><td>2.17</td></tr><tr><td>5</td><td>107</td><td>5.58</td><td>1.48</td></tr><tr><td>6</td><td>155</td><td>24.31</td><td>1.26</td></tr><tr><td>7</td><td>348</td><td>4.52</td><td>1.10</td></tr><tr><td>8</td><td>975</td><td>28.30</td><td>0.85</td></tr><tr><td>9</td><td>31909</td><td>19.93</td><td>3.65</td></tr></table> |
22bec2e30a48f52c4b7ca1c4eaaed4556682f9b283f385280271881a022be021.png | complex | <table><tr><td rowspan="2">Year</td><td rowspan="2">Total sniffers</td><td colspan="3">Sniffer prevalence rate per 1000 population</td></tr><tr><td>Median</td><td>Inter-quartile range</td><td>Range (Min-Max)</td></tr><tr><td>2006</td><td>604</td><td>141.6</td><td>70.1–180.0</td><td>31.4–307.3</td></tr><tr><td>2008</td><td>265</td><td>10.4</td><td>0–71.4</td><td>0–196.9</td></tr><tr><td>2012</td><td>93</td><td>3.7</td><td>0–11.1</td><td>0–186.6</td></tr><tr><td>2014</td><td>66</td><td>5.5</td><td>0–20.8</td><td>0–48.5</td></tr></table> |
f60e27fdeb0673842fac06e017ea0baa0e1473c5dbcf578a1169e79f88b50e47.png | complex | <table><tr><td rowspan="3">PDB</td><td rowspan="3">Ag size</td><td colspan="6">Epitope prediction</td><td rowspan="2" colspan="2">Random</td></tr><tr><td colspan="3">EpiPred</td><td colspan="3">DiscoTope 2.0</td></tr><tr><td>Precision (%)</td><td>Recall (%)</td><td>MCC</td><td>Precision (%)</td><td>Recall (%)</td><td>MCC</td><td>Precision (%)</td><td>Recall (%)</td></tr><tr><td>4hj0</td><td>92</td><td>32</td><td>90</td><td>0.27</td><td>0</td><td>0</td><td>0.0</td><td>29</td><td>50</td></tr><tr><td>1tzh</td><td>94</td><td>1</td><td>6</td><td>0.04</td><td>73</td><td>87</td><td>0.72</td><td>12</td><td>25</td></tr><tr><td>4am0</td><td>96</td><td>13</td><td>70</td><td>0.09</td><td>33</td><td>20</td><td>0.19</td><td>14</td><td>60</td></tr><tr><td>2ih3</td><td>97</td><td>16</td><td>64</td><td>0.08</td><td>0</td><td>0</td><td>0.0</td><td>15</td><td>27</td></tr><tr><td>4i77</td><td>97</td><td>23</td><td>55</td><td>0.0</td><td>0</td><td>0</td><td>0.0</td><td>21</td><td>31</td></tr><tr><td>3q1s</td><td>113</td><td>19</td><td>81</td><td>0.15</td><td>0</td><td>0</td><td>0.0</td><td>20</td><td>37</td></tr><tr><td>1p2c</td><td>129</td><td>0</td><td>0</td><td>0.0</td><td>100</td><td>5</td><td>0.0</td><td>39</td><td>32</td></tr><tr><td>4ht1</td><td>131</td><td>5</td><td>14</td><td>0.05</td><td>0</td><td>0</td><td>0.0</td><td>28</td><td>44</td></tr><tr><td>3ab0</td><td>136</td><td>33</td><td>73</td><td>0.34</td><td>0</td><td>0</td><td>0.0</td><td>33</td><td>52</td></tr><tr><td>1v7m</td><td>145</td><td>26</td><td>77</td><td>0.29</td><td>0</td><td>0</td><td>0.0</td><td>9</td><td>16</td></tr><tr><td>4g3y</td><td>148</td><td>3</td><td>8</td><td>0.04</td><td>100</td><td>17</td><td>0.33</td><td>11</td><td>25</td></tr><tr><td>2vxt</td><td>156</td><td>4</td><td>9</td><td>0.04</td><td>47</td><td>36</td><td>0.3</td><td>14</td><td>23</td></tr><tr><td>3u9p</td><td>169</td><td>31</td><td>100</td><td>0.47</td><td>6</td><td>5</td><td>0.0</td><td>8</td><td>15</td></tr><tr><td>3o2d</td><td>178</td><td>32</td><td>64</td><td>0.28</td><td>0</td><td>0</td><td>0.0</td><td>9</td><td>16</td></tr><tr><td>1fns</td><td>196</td><td>0</td><td>0</td><td>0.0</td><td>100</td><td>7</td><td>0.0</td><td>33</td><td>11</td></tr><tr><td>3ma9</td><td>197</td><td>0</td><td>0</td><td>0.0</td><td>0</td><td>0</td><td>0.0</td><td>21</td><td>33</td></tr><tr><td>3rvv</td><td>223</td><td>25</td><td>93</td><td>0.39</td><td>15</td><td>17</td><td>0.07</td><td>6</td><td>15</td></tr><tr><td>3raj</td><td>230</td><td>0</td><td>0</td><td>0.0</td><td>0</td><td>0</td><td>0.0</td><td>24</td><td>21</td></tr><tr><td>1nfd</td><td>239</td><td>7</td><td>23</td><td>0.04</td><td>92</td><td>70</td><td>0.75</td><td>10</td><td>15</td></tr><tr><td>3i50</td><td>273</td><td>0</td><td>0</td><td>0.0</td><td>0</td><td>0</td><td>0.0</td><td>1</td><td>6</td></tr><tr><td>3gjf</td><td>276</td><td>15</td><td>66</td><td>0.2</td><td>5</td><td>11</td><td>0.05</td><td>6</td><td>15</td></tr><tr><td>3liz</td><td>329</td><td>26</td><td>68</td><td>0.34</td><td>0</td><td>0</td><td>0.0</td><td>10</td><td>15</td></tr><tr><td>3pgf</td><td>358</td><td>2</td><td>4</td><td>0.0</td><td>0</td><td>0</td><td>0.0</td><td>13</td><td>18</td></tr><tr><td>3zkm</td><td>375</td><td>32</td><td>88</td><td>0.46</td><td>0</td><td>0</td><td>0.0</td><td>11</td><td>15</td></tr><tr><td>3r1g</td><td>381</td><td>37</td><td>100</td><td>0.57</td><td>0</td><td>0</td><td>0.0</td><td>7</td><td>9</td></tr><tr><td>4jr9</td><td>409</td><td>19</td><td>85</td><td>0.34</td><td>46</td><td>50</td><td>0.46</td><td>4</td><td>11</td></tr><tr><td>4ene</td><td>442</td><td>0</td><td>0</td><td>0.0</td><td>0</td><td>0</td><td>0.0</td><td>1</td><td>5</td></tr><tr><td>3o0r</td><td>449</td><td>8</td><td>70</td><td>0.19</td><td>0</td><td>0</td><td>0.0</td><td>2</td><td>14</td></tr><tr><td>3t3p</td><td>453</td><td>0</td><td>0</td><td>0.0</td><td>25</td><td>4</td><td>0.0</td><td>4</td><td>6</td></tr><tr><td>1n8z</td><td>581</td><td>0</td><td>0</td><td>0.0</td><td>0</td><td>0</td><td>0.0</td><td>6</td><td>5</td></tr></table> |
3d2339a6911e4d995c5cc18e61a36b597517957fc5381f9ca00c2c47f8327659.png | simple | <table><tr><td>Floors</td><td>0</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td></tr><tr><td>Real floor altitude (m)</td><td>0</td><td>5.3</td><td>10.68</td><td>15.05</td><td>19.47</td><td>24.41</td></tr><tr><td>Estimated floor altitude (m)</td><td>0</td><td>4.81</td><td>10.03</td><td>14.48</td><td>18.86</td><td>23.74</td></tr><tr><td>Error</td><td>0</td><td>0.48</td><td>0.65</td><td>0.57</td><td>0.61</td><td>0.66</td></tr></table> |
7e1d59cb10f132e8c8db9ab47a7d62ba5b85dc2cf288302b4a95087620f287a4.png | simple | <table><tr><td>Family</td><td>Sire</td><td>Dam</td><td>M</td><td>F</td><td>M:F</td><td>LG5-14 Y <i>p</i></td><td>LG13 Y <i>p</i></td><td>LG13 W <i>p</i></td><td>System</td></tr><tr><td>RAD 1</td><td>1</td><td>1</td><td>12</td><td>12</td><td>0.50</td><td>0.6843</td><td>NI</td><td>0.0001</td><td>LG13 ZW</td></tr><tr><td>RAD 2</td><td>2</td><td>2</td><td>9</td><td>8</td><td>0.53</td><td>0.0023</td><td>0.6199</td><td>1</td><td>LG5-14 XY</td></tr><tr><td>1</td><td>1</td><td>1</td><td>10</td><td>36</td><td>0.22</td><td>0.1639</td><td>NI</td><td>0.0012</td><td>LG13 ZW</td></tr><tr><td>2</td><td>3</td><td>3</td><td>8</td><td>8</td><td>0.50</td><td>0.0087</td><td>NI</td><td>0.0001</td><td>LG13 ZW</td></tr><tr><td>3</td><td>3</td><td>3</td><td>9</td><td>8</td><td>0.53</td><td>0.3469</td><td>NI</td><td>0.0152</td><td>LG13 ZW</td></tr><tr><td>4</td><td>4</td><td>4</td><td>6</td><td>26</td><td>0.19</td><td>NI</td><td>NI</td><td>0.0192</td><td>LG13 ZW</td></tr><tr><td>5</td><td>5</td><td>5</td><td>4</td><td>6</td><td>0.40</td><td>1</td><td>0.5714</td><td>0.0048</td><td>LG13 ZW</td></tr><tr><td>6</td><td>6</td><td>6</td><td>4</td><td>10</td><td>0.29</td><td>0.2208</td><td>1</td><td>0.015</td><td>LG13 ZW</td></tr><tr><td>7</td><td>6</td><td>7</td><td>10</td><td>9</td><td>0.53</td><td>0.1534</td><td>NI</td><td>0.009</td><td>LG13 ZW</td></tr><tr><td>8</td><td>7</td><td>8</td><td>2</td><td>13</td><td>0.13</td><td>1</td><td>0.0128</td><td>NI</td><td>LG13 XY</td></tr><tr><td>9</td><td>7</td><td>9</td><td>16</td><td>22</td><td>0.42</td><td>0.72</td><td>0.0001</td><td>0.752</td><td>LG13 XY</td></tr><tr><td>10</td><td>8</td><td>10</td><td>12</td><td>14</td><td>0.46</td><td>0.0001</td><td>0.2177</td><td>1</td><td>LG5-14 XY</td></tr><tr><td>11</td><td>8</td><td>11</td><td>12</td><td>10</td><td>0.55</td><td>0.003</td><td>0.0092</td><td>0.6914</td><td>LG5-14 XY</td></tr><tr><td>12</td><td>8</td><td>12</td><td>15</td><td>11</td><td>0.58</td><td>0.0001</td><td>0.4283</td><td>0.4279</td><td>LG5-14 XY</td></tr><tr><td>13</td><td>8</td><td>13</td><td>12</td><td>7</td><td>0.63</td><td>0.0002</td><td>0.3261</td><td>0.3498</td><td>LG5-14 XY</td></tr><tr><td>14</td><td>8</td><td>14</td><td>4</td><td>2</td><td>0.67</td><td>0.0667</td><td>0.4</td><td>1</td><td>LG5-14 XY</td></tr><tr><td>15</td><td>9</td><td>15</td><td>12</td><td>10</td><td>0.55</td><td>0.0015</td><td>0.3246</td><td>0.1312</td><td>LG5-14 XY</td></tr><tr><td>16</td><td>9</td><td>16</td><td>13</td><td>8</td><td>0.62</td><td>0.0237</td><td>NI</td><td>0.2031</td><td>LG5-14 XY</td></tr><tr><td>17</td><td>9</td><td>17</td><td>15</td><td>8</td><td>0.65</td><td>0.0083</td><td>0.2213</td><td>NI</td><td>LG5-14 XY</td></tr><tr><td>18</td><td>10</td><td>18</td><td>11</td><td>5</td><td>0.69</td><td>0.0256</td><td>0.5962</td><td>1</td><td>LG5-14 XY</td></tr><tr><td>19</td><td>11</td><td>19</td><td>5</td><td>4</td><td>0.56</td><td>0.444</td><td>0.0079</td><td>NI</td><td>LG13 XY + LG5-14 XY</td></tr><tr><td>20</td><td>12</td><td>20</td><td>9</td><td>11</td><td>0.45</td><td>1</td><td>1</td><td>0.1789</td><td>Unknown</td></tr><tr><td>21</td><td>6</td><td>21</td><td>12</td><td>26</td><td>0.32</td><td>0.6792</td><td>0.2305</td><td>NI</td><td>Unknown</td></tr><tr><td>22</td><td>13</td><td>22</td><td>7</td><td>9</td><td>0.44</td><td>0.3024</td><td>0.1262</td><td>0.3147</td><td>Unknown</td></tr><tr><td>23</td><td>13</td><td>23</td><td>14</td><td>17</td><td>0.45</td><td>1</td><td>1</td><td>0.4809</td><td>Unknown</td></tr><tr><td>24</td><td>13</td><td>24</td><td>20</td><td>23</td><td>0.47</td><td>0.3652</td><td>0.7619</td><td>0.0755</td><td>Unknown</td></tr><tr><td>25</td><td>13</td><td>25</td><td>22</td><td>20</td><td>0.52</td><td>0.3783</td><td>0.0414</td><td>1</td><td>Unknown</td></tr></table> |
e22e186ed0dd8d1a6fa0c7f92d6d2cd04b584f2fd140fed7bcb7b98d163c6412.png | simple | <table><tr><td>Cognitive domain</td><td>Age group</td><td>Standardised mean difference (95% CI)</td><td>Number of participants/studies</td><td>Heterogeneity - I<sup>2 </sup>test</td></tr><tr><td>Attention & concentration</td><td>Children aged 6-18</td><td>0.62 (0.26 to 0.98)*</td><td>132/2 (4 arms)**</td><td>0%</td></tr><tr><td></td><td>Pre-menopausal women</td><td>0.53 (-0.06 to 1.12)</td><td>47/1</td><td>Not relevant</td></tr><tr><td>Intelligence</td><td>Children aged 6-18</td><td>0.02 (-0.22 to 0.27)</td><td>2289/4 (9 arms)**</td><td>82%</td></tr><tr><td></td><td>Pre-menopausal women</td><td>0.62 (0.15 to 1.10)*</td><td>76/2</td><td>0%</td></tr><tr><td>Memory</td><td>Children aged 6-18</td><td>0.33 (-0.19 to 0.85)</td><td>132/2 (4 arms)**</td><td>35%</td></tr><tr><td></td><td>Pre-menopausal women</td><td>0.09 (-0.31 to 0.50)</td><td>123/3</td><td>18%</td></tr><tr><td>Psychomotor</td><td>Children aged 6-18</td><td>0.19 (-0.17 to 0.54)</td><td>132/2 (4 arms)**</td><td>0%</td></tr><tr><td></td><td>Pre-menopausal women</td><td>0.09 (-0.32 to 0.50)</td><td>123/3</td><td>21%</td></tr><tr><td>Scholastic aptitude</td><td>Children aged 6-18</td><td>0.03 (-0.63 to 0.69)</td><td>1799/3 (6 arms)**</td><td>96%</td></tr><tr><td></td><td>Pre-menopausal women</td><td>0.77 (-0.08 to 1.62)</td><td>25/1</td><td>Not relevant</td></tr></table> |
04c526437855b892b389bd0f4d3e39ae3b48dd2226e282e2884d2e73dae5a291.png | simple | <table><tr><td>Marshall score</td><td> n (%)</td></tr><tr><td>1 No visible intracranial pathology</td><td>14 (13)</td></tr><tr><td>2 Cisterns present with midline shift 0-5 mm; no high or mixed density lesion > 25 ml.</td><td>36 (32)</td></tr><tr><td>3 Cisterns compressed or absent with midline shift 0-5 mm.</td><td>43 (39)</td></tr><tr><td>4 Midline shift > 5 mm;or surgically evacuated lesion;and non-evacuated high or mixed density lesion >25 ml</td><td>18 (16)</td></tr></table> |
3f5d08d809f45e7ab53107c691ac1478133172c4e8f03bb80f6366364463c3c3.png | complex | <table><tr><td>Index</td><td>Source</td><td>df</td><td><i>F</i></td><td><i>P</i></td></tr><tr><td rowspan="3">Sward height</td><td>W</td><td>1,12</td><td>3.26</td><td>0.096</td></tr><tr><td>G</td><td>1,12</td><td>49.33</td><td><0.001*</td></tr><tr><td>W × G</td><td>1,12</td><td>0.64</td><td>0.438</td></tr><tr><td rowspan="3">Sward coverage</td><td>W</td><td>1,12</td><td>0.95</td><td>0.348</td></tr><tr><td>G</td><td>1,12</td><td>15.86</td><td>0.002*</td></tr><tr><td>W × G</td><td>1,12</td><td>0.11</td><td>0.751</td></tr><tr><td rowspan="3">Plant litter mass</td><td>W</td><td>1,12</td><td>1.06</td><td>0.323</td></tr><tr><td>G</td><td>1,12</td><td>35.61</td><td><0.001*</td></tr><tr><td>W × G</td><td>1,12</td><td>12.17</td><td>0.004*</td></tr><tr><td rowspan="3">N in graminoids</td><td>W</td><td>1,12</td><td>4.01</td><td>0.068</td></tr><tr><td>G</td><td>1,12</td><td>60.13</td><td><0.001*</td></tr><tr><td>W × G</td><td>1,12</td><td>0.53</td><td>0.483</td></tr><tr><td rowspan="3">Larval growth rate</td><td>W</td><td>1,12</td><td>2.76</td><td>0.122</td></tr><tr><td>G</td><td>1,12</td><td>25.38</td><td><0.001*</td></tr><tr><td>W × G</td><td>1,12</td><td>2.71</td><td>0.126</td></tr><tr><td rowspan="4">Pupal weight</td><td>Sex</td><td>1,155</td><td>343.92</td><td><0.001*</td></tr><tr><td>W</td><td>1,155</td><td>2.10</td><td>0.149</td></tr><tr><td>G</td><td>1,155</td><td>33.29</td><td><0.001*</td></tr><tr><td>W × G</td><td>1,155</td><td>0.001</td><td>0.983</td></tr><tr><td rowspan="3">Potential fecundity</td><td>W</td><td>1,77</td><td>2.33</td><td>0.131</td></tr><tr><td>G</td><td>1,77</td><td>21.06</td><td><0.001*</td></tr><tr><td>W × G</td><td>1,77</td><td>0.01</td><td>0.931</td></tr><tr><td rowspan="3">Overwintering survival rate</td><td>W</td><td>1,12</td><td>0.001</td><td>0.977</td></tr><tr><td>G</td><td>1,12</td><td>2.27</td><td>0.158</td></tr><tr><td>W × G</td><td>1,12</td><td>0.20</td><td>0.666</td></tr><tr><td rowspan="3">Pupal density</td><td>W</td><td>1,12</td><td>0.97</td><td>0.345</td></tr><tr><td>G</td><td>1,12</td><td>33.51</td><td><0.001*</td></tr><tr><td>W × G</td><td>1,12</td><td>1.44</td><td>0.254</td></tr><tr><td rowspan="3">Reduction in AGB</td><td>W</td><td>1,12</td><td>2.48</td><td>0.142</td></tr><tr><td>G</td><td>1,12</td><td>163.30</td><td><0.001*</td></tr><tr><td>W × G</td><td>1,12</td><td>7.33</td><td>0.019*</td></tr><tr><td rowspan="3">Reduction in graminoid cover</td><td>W</td><td>1,12</td><td>0.42</td><td>0.530</td></tr><tr><td>G</td><td>1,12</td><td>91.35</td><td><0.001*</td></tr><tr><td>W × G</td><td>1,12</td><td>2.83</td><td>0.119</td></tr></table> |
38dbc2af30906d03c3380045511871725f8d51f7245434886db59fa306d0537f.png | complex | <table><tr><td></td><td>Condition</td><td>Rest</td><td>Exercise</td><td>Recovery</td></tr><tr><td rowspan="3">IL-2</td><td>Normoxia</td><td>2.80 ± 0.93</td><td>4.62 ± 1.62</td><td>4.40 ± 3.13</td></tr><tr><td>Hypoxia</td><td>1.74 ± 1.18</td><td>3.14 ± 1.30</td><td>0.73 ± 0.54</td></tr><tr><td>Hypoxia + Carbo</td><td>0.14 ± 0.20</td><td>0.39 ± 0.54</td><td>3.60 ± 4.65 <sup>a,b</sup></td></tr><tr><td rowspan="3">IL-4</td><td>Normoxia</td><td>1.39 ± 1.08</td><td>0.63 ± 0.48</td><td>0.42 ± 0.24</td></tr><tr><td>Hypoxia</td><td>0.84 ± 0.94</td><td>0.41 ± 0.24</td><td>1.39 ± 2.42</td></tr><tr><td>Hypoxia + Carbo</td><td>0.63 ± 0.30</td><td>0.38 ± 0.20</td><td>0.52 ± 0.48</td></tr><tr><td rowspan="3">IL-2/IL-4</td><td>Normoxia</td><td>3.50 ± 0.3</td><td>11.25 ± 7.82</td><td>13.11 ± 11.54</td></tr><tr><td>Hypoxia</td><td>3.49 ± 0.24</td><td>9.20 ± 5.37</td><td>2.06 ± 2.05</td></tr><tr><td>Hypoxia + Carbo</td><td>0.21 ± 0.22 <sup>c,d</sup></td><td>1.25 ± 1.75</td><td>11.84 ± 15.38 <sup>a,b</sup></td></tr></table> |
0899bc3fff2d9e68d4328a7d6a31d16355d6359c8a8368319a5a0d5d0dfa03cd.png | complex | <table><tr><td>Variable</td><td>B coefficient</td><td>HR</td><td>CI 95%</td><td><i>P</i> value</td></tr><tr><td colspan="5">Risk factors</td></tr><tr><td>TLS</td><td>0.509</td><td>1.663</td><td>1.124–2.462</td><td>0.011</td></tr><tr><td>LFT ≥2.5 UNL</td><td>0.490</td><td>1.663</td><td>1.147–2.325</td><td>0.007</td></tr><tr><td colspan="5">Protective factors</td></tr><tr><td>Early CR</td><td>−1.227</td><td>0.293</td><td>0.204–0.421</td><td>0.0001</td></tr><tr><td>Allogenic HSCT</td><td>−0.709</td><td>0.492</td><td>0.292–0.828</td><td>0.008</td></tr><tr><td>Platelets</td><td>−0.004</td><td>0.996</td><td>0.995–0.998</td><td>0.0001</td></tr></table> |
f79a2e3938d9d7e9cac1293bfccc5a0e7300a56dd5743a292518fbc67ac58812.png | simple | <table><tr><td>Study site</td><td>Latitude</td><td>Longitude</td></tr><tr><td>Aimi (Ai)</td><td>35°20.9′ N</td><td>133°24.2′ E</td></tr><tr><td>Nawa (Nw)</td><td>35°30.0′ N</td><td>133°30.5′ E</td></tr><tr><td>Nakayama (Nk)</td><td>35°30.7′ N</td><td>133°33.9′ E</td></tr><tr><td>Akasaki (Ak)</td><td>35°27.8′ N</td><td>133°38.3′ E</td></tr><tr><td>Tohaku (Th)</td><td>35°29.3′ N</td><td>133°39.2′ E</td></tr><tr><td>Kurayoshi (Ku)</td><td>35°23.4′ N</td><td>133°44.7′ E</td></tr><tr><td>Togo (Tg)</td><td>35°28.0′ N</td><td>133°55.1′ E</td></tr><tr><td>Yura (YuA, YuB)*</td><td>35°28.5′ N</td><td>133°44.5′ E</td></tr><tr><td>Otsuka (Ot)</td><td>35°29.0′ N</td><td>134°09.1′ E</td></tr><tr><td>Kawahara (Ka)</td><td>35°23.5′ N</td><td>134°11.2′ E</td></tr><tr><td>Koge (Ko)</td><td>35°24.5′ N</td><td>134°19.9′ E</td></tr><tr><td>Fukube (Fu)</td><td>35°32.4′ N</td><td>134°15.4′ E</td></tr></table> |
f10fdccdda0fcda8c6dba93f2bdaefcd2463bb3c7c405cee65fb4e38d83f8b29.png | complex | <table><tr><td></td><td></td><td>n(%)</td></tr><tr><td rowspan="2">Frontal</td><td>Left</td><td>4 (15%)</td></tr><tr><td>Right</td><td>4 (15%)</td></tr><tr><td rowspan="2">Temporal</td><td>Left</td><td>3 (11%)</td></tr><tr><td>Right</td><td>0 (0%)</td></tr><tr><td rowspan="2">Parieto‐occipital</td><td>Left</td><td>1 (3.8%)</td></tr><tr><td>Right</td><td>2 (7.7%)</td></tr><tr><td rowspan="2">Cerebellar</td><td>Left</td><td>3 (12%)</td></tr><tr><td>Right</td><td>5 (19%)</td></tr><tr><td>Vermis</td><td></td><td>3 (12%)</td></tr><tr><td>Brain stem</td><td></td><td>1 (3.8%)</td></tr></table> |
ac3ae421e05e6309b2a73324ff94069b59c803be4c26ec03d9f8b5b33733edb5.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">n Pla a 2</td><td colspan="2">nPhl p 4</td><td colspan="2">nJugr2</td></tr><tr><td>nPla a 2</td><td>nPla a 2 + rPla a 1</td><td>nPhl p 4</td><td>nPhl p 4 +Phl p1/Phl p 5/Phl p 6/Phl p 11</td><td>nJugr2</td><td>nJug r2 + rJugr1</td></tr><tr><td>Mean sIgE levels (ISU)</td><td>1.94</td><td>4.6</td><td>0.75</td><td>1.49</td><td>0.19</td><td>1.10</td></tr><tr><td>U Mann–Whitney sig.</td><td>0.00</td><td></td><td>0.00</td><td></td><td>0.00</td><td></td></tr></table> |
fc9335dd491ef5f7985b6de9b5eefbc8fb758c0c25344e17ab00df390d37a615.png | complex | <table><tr><td rowspan="2">Characteristic</td><td colspan="3">Pneumonia</td></tr><tr><td>Probable Non-bacterial (n = 49)</td><td>Probable Bacterial (n = 54)</td><td><i>P</i> Value<sup>a</sup></td></tr><tr><td>Age, mean (SD), mo</td><td>19 (10.5)</td><td>17.4 (11.6)</td><td>.14</td></tr><tr><td>Male sex, %</td><td>50%</td><td>51%</td><td>.90</td></tr><tr><td>Weight-for-age <i>z</i> score, mean (SD)</td><td>−1.03 (1.10)</td><td>−1.37 (1.21)</td><td>.24</td></tr><tr><td>Respiratory rate, mean (SD), respirations/min</td><td>57.0 (12.0)</td><td>62.6 (9.8)</td><td>.007</td></tr><tr><td>Oxygen saturation, mean (SD), %</td><td>96.3 (2.64)</td><td>92.84 (7.09)</td><td><.01</td></tr><tr><td>WBC count, mean (SD), ×10<sup>9</sup>/L</td><td>10.1 (6.42)</td><td>23.7 (10.6)</td><td><.01</td></tr><tr><td>Hemoglobin, mean (SD), g/dL</td><td>10.3 (1.53)</td><td>8.65 (1.74)</td><td><.01</td></tr><tr><td>Molecular marker concentration, median (IQR) [No.]</td><td></td><td></td><td></td></tr><tr><td> Lpc-2, ng/mL</td><td>[42] 81.7 (45.7–109)</td><td>[45] 282 (155–365)</td><td><.001</td></tr><tr><td> CRP, μg/mL</td><td>[41] 175 (182–278)</td><td>[47] 283 (142–350)</td><td><.001</td></tr><tr><td> vWF, mU/mL</td><td>[34] 810 (647–1201)</td><td>[45] 1514 (1205–2036)</td><td><.001</td></tr></table> |
6ae8e953844c0f4b34a0b9000c01a27418e25254324b603eeb72ba6562cc45af.png | simple | <table><tr><td>TR<sup><i>a</i></sup></td><td>Pathway name</td><td>Known pathway genes</td><td>Genes clustered with the TR<sup><i>b</i></sup></td><td>TRE</td><td>Ref</td></tr><tr><td><i>betI</i> (<i>B1590</i>)</td><td>glycine betaine synthesis</td><td><i>betABTI</i></td><td><i>betABTI</i></td><td>choline</td><td>[21]</td></tr><tr><td><i>catR</i> (<i>A2107</i>)</td><td>benzoate degradation</td><td><i>catABCR</i></td><td><i>catABCR</i></td><td>cis, cis-muconate</td><td>[22]</td></tr><tr><td><i>cymR</i> (<i>A3550</i>)</td><td>p-cumate catabolism</td><td><i>cymAaAbAcAdBCDEFHG</i></td><td><i>cymAaAbAcAd─CDE─ ─ ─</i></td><td>p-cumate</td><td>[23]</td></tr><tr><td><i>cysB</i> (<i>A2466</i>)</td><td>sulfur metabolism</td><td><i>cysABPTWA</i></td><td><i>cysABPTW</i></td><td>N-acetyl-serine</td><td>[24]</td></tr><tr><td><i>glpR</i> (<i>A0643</i>)</td><td>glycerol metabolism</td><td><i>glpABCDKFR</i></td><td><i>glp─ ─ ─DKFR</i></td><td>glycerol-3-phosphate</td><td>[25]</td></tr><tr><td><i>hpaR</i> (<i>B2027</i>)</td><td>hydroxyphenylacetate catabolism</td><td><i>hpaGEDFHIR</i></td><td><i>hpaGEDFHIR</i></td><td>4-hydroxy-phenylacetate</td><td>[26]</td></tr><tr><td><i>kynR</i> (<i>A0736</i>)</td><td>oxidative tryptophan degradation</td><td><i>kynABU</i></td><td><i>kynABU</i></td><td>L-kynurenine</td><td>[27]</td></tr><tr><td><i>hutC</i> (<i>A2946</i>)</td><td>histidine degradation</td><td><i>hutHUIFGC</i></td><td><i>hutHUIFGC</i></td><td>urocanate</td><td>[28, 29]</td></tr><tr><td><i>rcoM</i> (<i>A2142</i>)</td><td>carbon monoxide oxidation</td><td><i>coxBCMSLDEFGHIK</i></td><td><i>cox ─ ─SMLDE ─G ─ ─ ─</i></td><td>carbon monoxide</td><td>[30]</td></tr><tr><td><i>modEB2851</i>)</td><td>molybdate transport</td><td><i>modABCDE</i></td><td><i>modABC─E</i></td><td>molybdenum</td><td>[31]</td></tr></table> |
417a8212af8a8dba61feaa53aa006638007fd770b43bb3d5a377aa72b1178661.png | complex | <table><tr><td>Compounds</td><td colspan="3">Content (μg/g of dry plant material weight)</td><td>Approximate RT (min)</td></tr><tr><td> </td><td>MT<sup>a</sup></td><td>MG<sup>a</sup></td><td>MOK<sup>a</sup></td><td> </td></tr><tr><td>phenolic acids</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Hydroxyphenyl acetic acid</td><td>914.26 ± 3.42</td><td>2053.42 ± 532.2</td><td>nd<sup>b</sup></td><td>2.425</td></tr><tr><td>gallic acid</td><td>723.19 ± 4.1</td><td>744.72 ± 12.1</td><td>2780.57 ± 492.1</td><td>6.0</td></tr><tr><td>syringic acid</td><td>119.31 ± 4.2</td><td>148.45 ± 33.3</td><td>-</td><td>14.35</td></tr><tr><td>Ferulic acid</td><td>250.18 ± 3.2</td><td>41.64 ± 6.2</td><td>4657.94 ± 840.1</td><td>24.66</td></tr><tr><td>Methyl galate</td><td>Nd</td><td>229.84 ± 99.2</td><td>nd</td><td>3.61</td></tr><tr><td>Vanillic acid</td><td>1189.39 ± 973.3</td><td>614.72 ± 41.2</td><td>nd</td><td>15.96</td></tr><tr><td>Hydroxybis</td><td>132.2 ± 0.3</td><td>5581.77 ± 531.7</td><td>nd</td><td>3.69</td></tr><tr><td>flavonoids</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Tyrosin</td><td>5013.06 ± 934.1</td><td>59.48 ± 3.9</td><td>nd</td><td>5.85</td></tr><tr><td>flavone</td><td>128.6 ± 0.4</td><td>65.65 ± 9.6</td><td>5512.01 ± 372.2</td><td>9.16</td></tr><tr><td>Vanillin</td><td>1079.26 ± 57.1</td><td>126.08 ± 15.8</td><td>nd</td><td>17.56</td></tr><tr><td>(+)- Catechin hydrate</td><td>18.01 ± 0.22</td><td>4.9 ± 0.7</td><td>nd</td><td>19.68</td></tr><tr><td>Rutin</td><td>609.62 ± 0.6</td><td>88.54 ± 2.8</td><td>nd</td><td>23.65</td></tr></table> |
e74af2534c17df30b9d853c708e66eafe98b768f9b6c1bf3a751590d04935625.png | complex | <table><tr><td rowspan="2">Variables</td><td colspan="3">Tertiles of plasma manganese concentrations (μg/L)</td></tr><tr><td>1 (Lowest) ≤ 4.21 μg/L</td><td>2 4.21–6.84</td><td>3 (Highest) ≥ 6.84 μg/L</td></tr><tr><td><i>n</i>(NGT/T2D)</td><td>538/780</td><td>541/377</td><td>535/457</td></tr><tr><td>Crude</td><td>2.08 (1.75, 2.47)</td><td>1</td><td>1.23 (1.02, 1.47)</td></tr><tr><td>Model 1</td><td>2.08 (1.73, 2.49)</td><td>1</td><td>1.28 (1.05, 1.55)</td></tr><tr><td>Model 2</td><td>2.15 (1.75, 2.63)</td><td>1</td><td>1.54 (1.23, 1.92)</td></tr><tr><td>Model 3</td><td>1.89 (1.53, 2.33)</td><td>1</td><td>1.56 (1.23, 1.97)</td></tr><tr><td colspan="4">Model 1, adjusted for age, sex, and body mass index. Model 2, adjusted for Model 1, current smoking status, current alcohol drinking status, physical activity, family history of diabetes, and hypertension. Model 3, adjusted for Model 2, plasma iron, plasma copper, and plasma selenium.</td></tr></table> |
5675e0e968fd9ce7906c492fb3f9da3dab08fa1c880dacdc4277320a1859d2a5.png | simple | <table><tr><td></td><td>TBI + PCD (<i>N</i> = 19)</td><td>Control (<i>N</i> = 17)</td><td>Significance</td></tr><tr><td>Mean age in years (SD)</td><td>32.00 (9.04)</td><td>30.94 (7.48)</td><td><i>F</i><sub>1,35</sub> = 0.14, <i>p</i> = 0.72</td></tr><tr><td>Mean BMI (SD)</td><td>29.30 (3.76)</td><td>31.65 (4.82)</td><td><i>F</i><sub>1,35</sub> = 2.03, <i>p</i> = 0.16</td></tr><tr><td>Gender, % (No)</td><td></td><td></td><td>N/A</td></tr><tr><td> Male</td><td>100.0% (19)</td><td>100.0% (17)</td><td></td></tr><tr><td>Race, % (No)</td><td></td><td></td><td>χ<sup>2</sup> = 4.22, <i>p</i> = 0.52</td></tr><tr><td> Caucasian</td><td>73.8% (14)</td><td>58.8% (10)</td></tr><tr><td> Mixed</td><td>15.8% (3)</td><td>11.8% (2)</td><td></td></tr><tr><td> All other</td><td>10.4% (2)</td><td>19.4% (5)</td><td></td></tr><tr><td>Rank, % (No)</td><td></td><td></td><td>χ<sup>2</sup> = 0.97, <i>p</i> = 0.62</td></tr><tr><td> Lower enlisted</td><td>57.9% (11)</td><td>58.8% (10)</td><td></td></tr><tr><td> Senior NCO</td><td>36.8% (7)</td><td>35.3% (6)</td><td></td></tr><tr><td> Officer</td><td>5.2% (1)</td><td>5.9% (1)</td><td></td></tr><tr><td>Sleep diagnoses, % (No)</td><td></td><td></td><td>χ<sup>2</sup> = 2.79, <i>p</i> = 0.43</td></tr><tr><td> OSA</td><td>10.5% (2)</td><td>5.9% (1)</td><td></td></tr><tr><td> Insomnia</td><td>31.6% (8)</td><td>23.5% (4)</td><td></td></tr><tr><td> OSA + insomnia</td><td>31.5% (6)</td><td>58.8% (10)</td><td></td></tr><tr><td> None</td><td>15.8% (3)</td><td>11.8% (2)</td><td></td></tr><tr><td>Depression severity (QIDS)</td><td>9.6 (5.1)</td><td>8.7 (4.8)</td><td><i>F</i><sub>1,35</sub> = 2.42, <i>p</i> = 0.10</td></tr><tr><td>PTSD severity (PCL-M)</td><td>32.05 (18.8)</td><td>29.90 (15.1)</td><td><i>F</i><sub>1,35</sub> = 2.31, <i>p</i> = 0.14</td></tr><tr><td>Prescribed medications, % yes (no)</td><td>36.8% (6)</td><td>41.2% (7)</td><td>χ<sup>2</sup> = 1.51, <i>p</i> = 0.51</td></tr><tr><td> SSRI</td><td>15.8% (3)</td><td>11.8% (2)</td><td></td></tr><tr><td> Prazosin</td><td>21.1% (4)</td><td>17.6% (3)</td><td></td></tr><tr><td> Anti-hypertensive</td><td>15.8% (3)</td><td>23.5% (4)</td><td></td></tr></table> |
8bd15c082e600ebd46a468a03abb849cb165dc9a9362425871bc8320245e0fc3.png | complex | <table><tr><td rowspan="2">Factors</td><td colspan="3">Syphilis infection(n=77)</td><td colspan="3">HCV infection (n=30)</td><td colspan="3">Unprotected sex</td></tr><tr><td>%</td><td>OR(95% CI)</td><td>AOR(95% CI)</td><td>%</td><td>OR(95% CI)</td><td>AOR(95% CI)</td><td>%</td><td>OR(95% CI)</td><td>AOR(95% CI)</td></tr><tr><td>Gender</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Male</td><td>7.9</td><td>1.0</td><td>1.0</td><td>3.9</td><td>1.0</td><td> </td><td>37.6</td><td>1.0</td><td>1.0</td></tr><tr><td> Female</td><td>17.5</td><td>2.5(1.5-4.2)**</td><td>2.8(1.2-6.5)*</td><td>2.8</td><td>0.7(0.2-2.0)</td><td> </td><td>53.3</td><td>3.0(1.8-5.1)**</td><td>2.9(1.7-4.9)**</td></tr><tr><td>Education</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Middle school or lower</td><td>9.5</td><td>1.0</td><td> </td><td>2.9</td><td>1.0</td><td> </td><td>58.5</td><td>3.7(2.3-5.9)**</td><td>3.4(2.0-5.5)**</td></tr><tr><td> High school or higher</td><td>9.7</td><td>1.0(0.6-1.7)</td><td> </td><td>5.2</td><td>1.8(0.9-3.8)</td><td> </td><td>27.4</td><td>1.0</td><td>1.0</td></tr><tr><td colspan="2">Had ever injected</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Yes</td><td>8.7</td><td>0.9(0.4-1.9)</td><td> </td><td>9.8</td><td>3.6(1.6-8.1)**</td><td>2.7(1.1-6.5)*</td><td>44.0</td><td>0.8(0.4-1.7)</td><td> </td></tr><tr><td> No</td><td>9.7</td><td>1.0</td><td> </td><td>2.9</td><td>1.0</td><td>1.0</td><td>50.3</td><td>1.0</td><td> </td></tr><tr><td colspan="4">Had ever sex with regular sex partners in last year</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Yes</td><td>8.8</td><td>0.1(0.1-0.6)**</td><td>0.2(0.1-0.6)**</td><td>3.6</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> No</td><td>42.9</td><td>1.0</td><td> </td><td>0.0</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td colspan="6">Had ever sex with commercial sex partners in last year</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Yes</td><td>11.6</td><td>1.7(1.0-2.7)*</td><td>2.0(1.0-3.9)*</td><td>3.1</td><td>0.7 (0.5-1.2)</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> No</td><td>7.3</td><td>1.0</td><td>1.0</td><td>4.5</td><td>1.0</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td colspan="3">Ever received intervention</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Yes</td><td>10.8</td><td>1.0</td><td> </td><td>3.8</td><td>1.0</td><td> </td><td>34.1</td><td>1.0</td><td>1.0</td></tr><tr><td> No</td><td>9.3</td><td>0.9(0.5-1.6)</td><td> </td><td>3.7</td><td>1(0.4-2.6)</td><td> </td><td>53.8</td><td>2.3(1.4-3.7)**</td><td>2.1(1.2-3.6)*</td></tr><tr><td>HCV infection</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Yes</td><td>36.7</td><td>6.2(2.8-13.6)**</td><td>12.1(4.1-20.3)**</td><td> </td><td> </td><td> </td><td>42.9</td><td>0.9(0.4-1.9)</td><td> </td></tr><tr><td> No</td><td>8.5</td><td>1.0</td><td>1.0</td><td> </td><td> </td><td> </td><td>45.4</td><td>1.0</td><td> </td></tr><tr><td colspan="2">Syphilis</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Yes</td><td> </td><td> </td><td> </td><td>14.3</td><td>6.2(2.8-13.6)**</td><td>8.0(3.5-18.0)**</td><td>56.2</td><td>3.0(1.8-5.1)**</td><td>4.2(2.4-7.4)**</td></tr><tr><td> No</td><td> </td><td> </td><td> </td><td>2.6</td><td>1.0</td><td> </td><td>27.9</td><td>1.0</td><td>1.0</td></tr></table> |
f13ab445039a71c78fe8c01ea6f9f7362b3f728e4f1fe5249aa079944e409750.png | simple | <table><tr><td> </td><td>Avg Wait Time</td><td>Std. Dev</td><td>Avg % of</td><td>Std. Dev</td></tr><tr><td> </td><td>in Hours</td><td> </td><td>Patient center</td><td> </td></tr><tr><td>Monday</td><td>0.7609</td><td>0.0104</td><td>4.50 %</td><td>0.0029</td></tr><tr><td>Tuesday</td><td>0.7284</td><td>0.0109</td><td>5.13 %</td><td>0.0033</td></tr><tr><td>Wednesday</td><td>0.6218</td><td>0.0088</td><td>3.22 %</td><td>0.0026</td></tr><tr><td>Thursday</td><td>0.5672</td><td>0.0080</td><td>3.23 %</td><td>0.0026</td></tr><tr><td>Friday</td><td>0.5127</td><td>0.0073</td><td>3.38 %</td><td>0.0027</td></tr><tr><td>Saturday</td><td>0.3954</td><td>0.0057</td><td>2.12 %</td><td>0.0022</td></tr><tr><td>Sunday</td><td>0.3858</td><td>0.0050</td><td>1.84 %</td><td>0.0020</td></tr></table> |
ff1c421ca943423befde1b1f5098bf9d6fe6db4ed22d9ddb916113c85f1c56a1.png | simple | <table><tr><td>Outcome</td><td>Improved</td><td>Deteriorated</td><td>No change</td><td><i>N</i></td></tr><tr><td>Caregiver burden (ZBI)</td><td>0</td><td>4</td><td>13</td><td>17</td></tr><tr><td>Hopefulness (HHI)</td><td>3</td><td>8</td><td>6</td><td>17</td></tr><tr><td>Anxiety (HADS)</td><td>2</td><td>0</td><td>15</td><td>17</td></tr><tr><td>Depression (HADS)</td><td>1</td><td>1</td><td>15</td><td>17</td></tr></table> |
a4f39ba92b7031aa7ae630d2f4bce64f0cf20db5b8c74136275cfcbca7b18bb6.png | simple | <table><tr><td>Group</td><td>Gender (male/ female)</td><td>Age (year)</td><td>Disease course (year)</td><td>BMI (kg/m<sup>2</sup>)</td><td>FBG (mmol/l)</td><td>HbA1c (%)</td><td>TC (mmol/l)</td><td>LDL-C (mmol/l)</td><td>FPG (mmol/l)</td><td>TG (mmol/l)</td><td>BUN (mmol/l)</td><td>FINS (mIU/l)</td><td>Cr (μmol/l)</td><td>HOMA-IR</td></tr><tr><td>Control</td><td>60/55</td><td>48.53 ± 7.26</td><td>/</td><td>22.82 ± 2.33</td><td>4.74 ± 0.75</td><td>4.30 ± 0.42</td><td>4.13 ± 0.88</td><td>3.21 ± 0.55</td><td>5.02 ± 0.68</td><td>1.45 ± 0.44</td><td>4.89 ± 1.17</td><td>5.50 ± 0.88</td><td>58.82 ± 7.65</td><td>1.25 ± 0.37</td></tr><tr><td>NDR</td><td>34/31</td><td>47.76 ± 8.05</td><td>4.16 ± 1.21*</td><td>22.67 ± 1.98</td><td>7.12 ± 0.68*</td><td>6.25 ± 0.58*</td><td>4.25 ± 1.02</td><td>3.26 ± 0.61</td><td>5.31 ± 0.73</td><td>1.48 ± 0.32</td><td>5.26 ± 1.34</td><td>5.66 ± 1.02</td><td>59.07 ± 7.88</td><td>1.37 ± 0.43</td></tr><tr><td>BDR</td><td>32/41</td><td>48.83 ± 7.13</td><td>9.13 ± 2.54*<sup>†</sup></td><td>23.06 ± 1.85</td><td>7.25 ± 0.84*</td><td>7.02 ± 0.66*<sup>†</sup></td><td>4.32 ± 0.94</td><td>3.30 ± 0.63</td><td>6.17 ± 0.75*<sup>†</sup></td><td>1.51 ± 0.34</td><td>5.33 ± 1.38</td><td>5.71 ± 1.14</td><td>61.55 ± 8.39</td><td>1.60 ± 0.50*<sup>†</sup></td></tr><tr><td>PDR</td><td>28/23</td><td>50.75 ± 10.18</td><td>13.58 ± 3.82*<sup>†</sup><sup>‡</sup></td><td>23.13 ± 2.02</td><td>7.33 ± 1.05*</td><td>8.16 ± 0.79*<sup>†</sup><sup>‡</sup></td><td>4.43 ± 1.08</td><td>3.38 ± 0.72</td><td>6.86 ± 0.96*<sup>†</sup><sup>‡</sup></td><td>1.55 ± 0.45</td><td>5.41 ± 1.71</td><td>5.78 ± 1.21</td><td>62.43 ± 10.06</td><td>1.81 ± 0.62*<sup>†</sup></td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.